1
|
Vega JA, Álvarez-González JG, Arellano-Pérez S, Fernández C, Cuiñas P, Jiménez E, Fernández-Alonso JM, Fontúrbel T, Alonso-Rego C, Ruiz-González AD. Developing customized fuel models for shrub and bracken communities in Galicia (NW Spain). J Environ Manage 2024; 351:119831. [PMID: 38134501 DOI: 10.1016/j.jenvman.2023.119831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 11/29/2023] [Accepted: 12/03/2023] [Indexed: 12/24/2023]
Abstract
Geospatial fire behaviour and fire hazard simulators, fire effects models and smoke emission software commonly use standard fuel models in order to simplify data collection and the inclusion of complex fuel scenarios. These fuel models are often mapped using remotely sensed data. However, given the great complexity of fuelbeds, with properties that vary widely in both time and space, the use of these standard fuel models can greatly limit accurate fuel mapping. This affects fuel hazard assessment, fuel reduction treatment plans, fire management decision-making and evaluation of the environmental impact of wildfire. In this study, we developed unique customized fire behaviour fuel models for shrub and bracken communities, by using k-medoids clustering analysis based on both fuel structural characteristics and potential fire behaviour. We used an original database of 722 destructive sample plots in nine different shrub and bracken communities covering the entire distribution area in Galicia (NW Spain), one of the regions in Europe most affected by forest fires. Measurements of cover, height and fuel fractions loads differentiated by size and vegetative state (live or dead) were used to estimate the potential rate of fire spread with five different models including fireline intensity, heat per unit area and the flame length for each sampling site and considering extreme environmental conditions. The optimal number of clusters was established by combining practical knowledge about the shrubland communities under study and their associated fire behaviour, with maximization of the mean value of the silhouette variable and minimization of the within-cluster sum of squares. The structural characteristics of the medoids derived from the analysis were associated with each of the proposed customized fuel models. Finally, a simple dichotomous classification based only on shrub height was developed to enable construction of spatially explicit fuel model maps based on remotely sensed data. Thus, the methodology applied allows generation of a more realistic representation of fuel distribution in the landscape, based on fuel structure measurements of natural regional ecosystems rather than on the use of standard models. We believe that the proposed methodology is generally applicable to communities composed of other shrub and fern species in different biogeographical regions.
Collapse
Affiliation(s)
- José A Vega
- Centro de Investigación Forestal de Lourizán, PO Box 127. 36080, Pontevedra, Spain.
| | - Juan Gabriel Álvarez-González
- Unidad de Gestión Ambiental y Forestal Sostenible (UXAFORES). Departamento de Ingeniería Agroforestal, Campus Terra, Universidad de Santiago de Compostela, Campus Universitario S/n, 27002, Lugo, Spain.
| | - Stéfano Arellano-Pérez
- Unidad de Gestión Ambiental y Forestal Sostenible (UXAFORES). Departamento de Ingeniería Agroforestal, Campus Terra, Universidad de Santiago de Compostela, Campus Universitario S/n, 27002, Lugo, Spain; AGRESTA Sociedad Cooperativa, C/ Duque de Fernán Nuñez 2, 28012, Madrid, Spain.
| | - Cristina Fernández
- Centro de Investigación Forestal de Lourizán, PO Box 127. 36080, Pontevedra, Spain.
| | - Pedro Cuiñas
- Centro de Investigación Forestal de Lourizán, PO Box 127. 36080, Pontevedra, Spain.
| | - Enrique Jiménez
- Centro de Investigación Forestal de Lourizán, PO Box 127. 36080, Pontevedra, Spain.
| | | | - Teresa Fontúrbel
- Centro de Investigación Forestal de Lourizán, PO Box 127. 36080, Pontevedra, Spain.
| | - Cecilia Alonso-Rego
- Unidad de Gestión Ambiental y Forestal Sostenible (UXAFORES). Departamento de Ingeniería Agroforestal, Campus Terra, Universidad de Santiago de Compostela, Campus Universitario S/n, 27002, Lugo, Spain.
| | - Ana Daría Ruiz-González
- Unidad de Gestión Ambiental y Forestal Sostenible (UXAFORES). Departamento de Ingeniería Agroforestal, Campus Terra, Universidad de Santiago de Compostela, Campus Universitario S/n, 27002, Lugo, Spain.
| |
Collapse
|
2
|
Cuevas-Gómez I, de Andrés J, Cardenas N, Espinosa-Martos I, Jiménez E. Feed supplementation with Ligilactobacillus salivarius PS21603 optimises intestinal morphology and gut microbiota composition in weaned piglets. Benef Microbes 2024; 15:195-210. [PMID: 38350485 DOI: 10.1163/18762891-bja00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 12/17/2023] [Indexed: 02/15/2024]
Abstract
Post-weaning diarrhoea in piglets remains an important cause of economic losses for swine producers. Feed supplementation with probiotics is one of the alternatives to antibiotics used to reduce the impact of such gastrointestinal disease. The aim of the present study was to evaluate the effect of Ligilactobacillus salivarius PS21603 supplementation on the intestinal structure and the gut microbiota composition of weaned piglets. Safety and tolerance of L. salivarius PS21603 were previously evaluated in a 28-days study using 384 weaned piglets (28 ± 2 days old and 7.5 ± 1.5 kg) divided in three treatment groups: T1: Basal diet + L. salivarius PS21603 109 cfu/day, T2: Basal diet + L. salivarius PS21603 107 cfu/day, and T3: Basal diet (control group). For the present study, 16 piglets per treatment group were randomly selected and faecal samples were collected on day 0 (weaning) and 28 of study. At the end of study, three males and three females per treatment were euthanised. Intestinal morphometric values were measured after necropsy. Faecal counts of Escherichia coli were evaluated by culture techniques, and faecal microbiota composition was assessed by high-throughput sequencing. All data were analysed and compared between treatment groups. Supplementation with L. salivarius PS21603 caused an increase in the intestine length of piglets from T1 and in the villous height:crypt ratio of piglets from T2 (P < 0.05) compared to T3 on day 28. According to the Shannon Diversity Index, microbiota diversity increased on day 28 compared to day 0, with no significant differences observed between treatments. The main changes in the relative abundance of bacteria at the phylum, family, and genus levels were observed between different sampling time points. However, piglets from T1 and T2 had lower faecal E. coli counts than T3 on day 28 (P < 0.05). Moreover, supplementation with L. salivarius PS21603 modulated gut microbiota through a more optimal composition, reducing Escherichia and increasing Bifidobacterium relative abundance in piglets from T1 (P < 0.05) from the beginning to the end of the study. Therefore, the strain L. salivarius PS21603 has shown probiotic properties to be used as feed additive in the pig industry, along with good hygiene and farm management practices, for the prevention and/or treatment of post-weaning diarrhoea in piglets.
Collapse
Affiliation(s)
- I Cuevas-Gómez
- Probisearch S.L.U., C/Santiago Grisolı́a, 2, 28760 Tres Cantos, Spain
| | - J de Andrés
- Probisearch S.L.U., C/Santiago Grisolı́a, 2, 28760 Tres Cantos, Spain
| | - N Cardenas
- Probisearch S.L.U., C/Santiago Grisolı́a, 2, 28760 Tres Cantos, Spain
| | - I Espinosa-Martos
- Probisearch S.L.U., C/Santiago Grisolı́a, 2, 28760 Tres Cantos, Spain
| | - E Jiménez
- Probisearch S.L.U., C/Santiago Grisolı́a, 2, 28760 Tres Cantos, Spain
| |
Collapse
|
3
|
Fontúrbel MT, Jiménez E, Merino A, Vega JA. Contrasting immediate impact of prescribed fires and experimental summer fires on soil organic matter quality and microbial properties in the forest floor and mineral soil in Mediterranean black pine forest. Sci Total Environ 2024; 907:167669. [PMID: 37848140 DOI: 10.1016/j.scitotenv.2023.167669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/02/2023] [Accepted: 10/06/2023] [Indexed: 10/19/2023]
Abstract
Prescribed fire (PB) is used to achieve ecological objectives and to reduce fuel hazard thus limiting detrimental impacts of wildfire and appropriate selection of prescription window is critical for these goals. Operational use of PB in the Mediterranean forest is scarce and information about its effects on soil remains incomplete. This study for the first time i) compared the immediate impact of spring and autumn PB and experimental summer fire on key properties of forest floor and mineral topsoil in Mediterranean black pine forest, and ii) assessed the capacity of PB to reduce fuel, with limited immediate impacts on soil. PB significantly reduced the 32.5 % of pre-fire forest floor depth, while summer fire consumed 88.5 % and exposed about 30 % of the mineral soil surface. Mean maximum temperature during fire at the mineral soil surface was 23 °C in PB, in contrast to 128 °C in summer fire, while soil heating at 2 cm depth was negligible in both cases. PB did not cause immediate changes in OM quality parameters, and chemical (C and N concentrations, C/N and pH) and microbiological properties (Cmic, Cmic/C, and β-glucosidase, acid phosphatase and alkaline phosphatase activities) in forest floor or mineral topsoil (0-2 cm). By contrast, summer fire greatly increased OM recalcitrance and reduced Cmic, Cmic/C and enzyme activities in forest floor immediately after fire. In the mineral topsoil, only microbial properties were significantly reduced. The maximum temperature reached during fire in forest floor and topsoil was associated with most of the overall changes in properties in both layers. The findings suggest that prescribed fire can significantly reduce fuel with limited initial impacts on soil. Although these findings are encouraging for operational use of prescribed burning in the ecosystem under study, long-term monitoring of repeated application of the technique on soil properties and other ecosystem components is necessary.
Collapse
Affiliation(s)
- M Teresa Fontúrbel
- Centro de Investigación Forestal de Lourizán, Xunta de Galicia, PO Box 127, 36080 Pontevedra, Spain
| | - Enrique Jiménez
- Centro de Investigación Forestal de Lourizán, Xunta de Galicia, PO Box 127, 36080 Pontevedra, Spain
| | - Agustín Merino
- University of Santiago de Compostela, Escuela Politécnica Superior, Soil Science and Agricultural Chemistry, Lugo, Spain.
| | - José A Vega
- Centro de Investigación Forestal de Lourizán, Xunta de Galicia, PO Box 127, 36080 Pontevedra, Spain
| |
Collapse
|
4
|
Romero P, Huang R, Jiménez E, Palma-Hidalgo JM, Ungerfeld EM, Popova M, Morgavi DP, Belanche A, Yáñez-Ruiz DR. Evaluating the effect of phenolic compounds as hydrogen acceptors when ruminal methanogenesis is inhibited in vitro – Part 2. Dairy goats. Animal 2023; 17:100789. [PMID: 37087998 DOI: 10.1016/j.animal.2023.100789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 03/17/2023] [Accepted: 03/20/2023] [Indexed: 03/31/2023] Open
Abstract
Most mitigation strategies to reduce enteric methane (CH4) production in the rumen induce an excess of rumen dihydrogen (H2) that is expelled and consequently not redirected to the synthesis of metabolites that can be utilised by the ruminant. We hypothesised that phenolic compounds can be potential H2 acceptors when added to the diet, as they can be degraded to compounds that may be beneficial for the animal, using part of the H2 available when ruminal methanogenesis is inhibited. We performed four in vitro incubation experiments using rumen inoculum from Murciano-Granadina adult goats: Experiment 1 examined the inhibitory potential of Asparagopsis taxiformis (AT) at different concentrations (0, 1, 2, 3, 4 and 5% of the substrate on a DM basis) in 24 h incubations; Experiment 2 investigated the effect of a wide range of phenolic compounds (phenol, catechol, resorcinol, hydroquinone, pyrogallol, phloroglucinol, gallic acid and formic acid) at different doses (0, 2, 4, and 6 mM) on rumen fermentation for 24 h; Experiment 3 evaluated the combined effect of each phenolic compound at 6 mM with AT at 2% DM in sequential batch cultures for 5 days; and Experiment 4 examined the dose-response effect of phloroglucinol at different concentrations (0, 6, 16, 26 and 36 mM) combined with AT in sequential batch cultures for 5 days. Results from Experiment 1 confirmed that AT at 2% DM substantially inhibited CH4 production while significantly increasing H2 accumulation and decreasing the acetate:propionate ratio. Results from Experiment 2 showed that phenolic compounds did not negatively affect rumen fermentation at any dose. In Experiment 3, each phenolic compound at 6 mM combined with AT at 2% DM inhibited CH4 production. Phloroglucinol numerically decreased H2 accumulation and significantly increased total gas production (TGP), volatile fatty acid (VFA) production and the acetate:propionate ratio. In Experiment 4, phloroglucinol at increasing doses supplemented with AT at 2% DM significantly decreased H2 accumulation and the abundances of archaea, protozoa and fungi abundances, and increased TGP, total VFA production and the acetate:propionate ratio in a dose-dependent way. In conclusion, combined treatment with AT and phloroglucinol was successful to mitigate CH4 production while preventing the accumulation of H2, leading to an increase in acetate and total VFA production and therefore an improvement in rumen fermentation in goats.
Collapse
Affiliation(s)
- P Romero
- Estación Experimental del Zaidín (CSIC), Profesor Albareda, 1, 18008 Granada, Spain
| | - R Huang
- Université Clermont Auvergne, INRAE, VetAgro Sup, UMR Herbivores, F-63122 Saint-Genès Champanelle, France
| | - E Jiménez
- Estación Experimental del Zaidín (CSIC), Profesor Albareda, 1, 18008 Granada, Spain
| | - J M Palma-Hidalgo
- Estación Experimental del Zaidín (CSIC), Profesor Albareda, 1, 18008 Granada, Spain
| | - E M Ungerfeld
- Centro Regional de Investigación Carillanca, Instituto de Investigaciones Agropecuarias INIA, Temuco 4880000, Chile
| | - M Popova
- Université Clermont Auvergne, INRAE, VetAgro Sup, UMR Herbivores, F-63122 Saint-Genès Champanelle, France
| | - D P Morgavi
- Université Clermont Auvergne, INRAE, VetAgro Sup, UMR Herbivores, F-63122 Saint-Genès Champanelle, France
| | - A Belanche
- Estación Experimental del Zaidín (CSIC), Profesor Albareda, 1, 18008 Granada, Spain; Departamento de Producción Animal y Ciencia de los Alimentos, Universidad de Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain
| | - D R Yáñez-Ruiz
- Estación Experimental del Zaidín (CSIC), Profesor Albareda, 1, 18008 Granada, Spain.
| |
Collapse
|
5
|
Guijarro A, Castro A, Hernández V, de la Peña E, Sánchez-Rosendo L, Jiménez E, Pérez-Férnandez E, Llorente C. Population based study of morbidity and mortality rates associated to radical prostatectomy cases in Spain. Actas Urol Esp 2022; 46:619-628. [PMID: 36280035 DOI: 10.1016/j.acuroe.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 04/28/2022] [Indexed: 11/07/2022]
Abstract
INTRODUCTION There is no population-based study that accounts for the number of radical prostatectomies (RP) carried out in Spain, nor regarding the morbidity and mortality of this intervention. Our objective is to study the morbidity and mortality of RP in Spain from 2011 to 2015 and to evaluate the geographic variation. MATERIAL AND METHODS We designed a retrospective observational study of all patients submitted to RP in Spain during five consecutive years (2011-2015). The data was extracted from the «Conjunto Mínimo Básico de Datos» (CMBD). We have evaluated geographic variations in terms of morbidity and hospital stay, and the impact of the mean annual surgical volume for each center on these variables. RESULTS Between 2011-2015, a total of 37,725 RPs were performed in 221 Spanish public hospitals. The mean age of the series was 63.9±3.23 years. Of all RPs, 50% were performed through an open approach, and 43.4% have been operated on in hospitals with <500 beds. We observed an important variability in the distribution of the cases operated on in the different regions. The regions that perform more RPs are Andalusia, Catalonia, Galicia, and Madrid. Our study shows a complication rate of 8.6%, with hemorrhage and the need for transfusion being the most frequent (5.3 and 4%, respectively). There are significant differences in bleeding rates and hospital stay among regions, which are maintained after adjusting for patient characteristics and type of hospital. When studying the annual surgical volume of each hospital, we find that the impact on the rate of hemorrhage or transfusion is linear; however, hospital stay remains stable at around 5 days from 60 RPs/year. CONCLUSIONS In national terms, morbidity and mortality rates after RP are comparable to those described in the literature. This study reveals a clear dispersion in the hospitals that carry out this intervention, showing clear differences in terms of morbidity and hospital stay between the different regions.
Collapse
Affiliation(s)
- A Guijarro
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
| | - A Castro
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - V Hernández
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - E de la Peña
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - L Sánchez-Rosendo
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - E Jiménez
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - E Pérez-Férnandez
- Unidad de Investigación, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - C Llorente
- Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| |
Collapse
|
6
|
Cuevas-Gómez I, de Andrés J, Cardenas N, Espinosa-Martos I, Jiménez E. Safety assessment and characterisation of Ligilactobacillus salivarius PS21603 as potential feed additive for swine. Benef Microbes 2022; 13:397-406. [DOI: 10.3920/bm2022.0020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The present study aimed to characterise in vitro properties of the strain Ligilactobacillus salivarius PS21603 and evaluate in vivo piglets’ tolerance for its use as feed additive in swine. The ability of L. salivarius PS21603 of inhibiting enteropathogens’ growth in vitro was evaluated using a co-culture assay. Low pH tolerance, bile tolerance, and resistance to osmotic changes were evaluated. The antibiotic susceptibility profile of L. salivarius PS21603 was assessed through broth microdilution method. Whole genome sequencing (WGS) was performed to exclude the presence of antibiotic resistance genes. L. salivarius PS21603 showed a high antimicrobial activity in vitro, reducing in a mean of 6.16 log cfu/ml eight different enterotoxigenic Escherichia coli strains. Moreover, L. salivarius PS21603 showed resistance to osmotic changes and was able to survive to a pH above 3.5 during 24 h and up to pH 2 at least during 2 h. In addition, WGS revealed that L. salivarius PS21603 did not harbour any resistance genes and thus there was no risk of transmissibility. Finally, an in vivo 28-days safety and tolerance study was performed. For that, 384 healthy piglets (28±2 days old and 7.5±1.5 kg, at weaning) were divided into three treatment groups receiving a different dose of L. salivarius PS21603: T1, 109 cfu/day; T2, 107 cfu/day; T3, control. Piglet’s health status was daily controlled. Individual bodyweight and feed intake per pen were weekly recorded to determine performance parameters. Blood samples were collected in 16 piglets from each treatment group on days 0 and 28 for determination of cytokine profiles. L. salivarius PS21603 was safe and well tolerated by piglets, there were no differences in performance nor cytokine profile between treatment groups. In conclusion, L. salivarius PS21603 is a potential candidate for a probiotic prevention strategy against pig diarrhoea.
Collapse
Affiliation(s)
- I. Cuevas-Gómez
- Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - J. de Andrés
- Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - N. Cardenas
- Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | | | - E. Jiménez
- Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| |
Collapse
|
7
|
Jiménez E, Bonnín CDM, Solé B, Sánchez-Moreno J, Reinares M, Torrent C, Torres I, Salagre E, Varo C, Ruíz V, Giménez A, Benabarre A, Gutiérrez-Rojas L, Cervilla J, Sáiz PA, García-Portilla MP, Bobes J, Amann BL, Martínez-Arán A, Vieta E. Corrigendum to "Spanish validation of the Barcelona TEMPS-A questionnaire in patients with bipolar disorder and general population" [J. Affect. Disord. 249 (2019) 199-207 (Apr 15)]. J Affect Disord 2022; 316:280. [PMID: 35985967 DOI: 10.1016/j.jad.2022.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Affiliation(s)
- E Jiménez
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C D M Bonnín
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - J Sánchez-Moreno
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Reinares
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C Torrent
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - I Torres
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Salagre
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C Varo
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - V Ruíz
- Institut Clínic de Neurociències, Hospital Clinic, Barcelona, Catalonia, Spain
| | - A Giménez
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A Benabarre
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - L Gutiérrez-Rojas
- Psychiatry Service, Hospital Clínico San Cecilio, University of Granada, Granada, Spain
| | - J Cervilla
- Psychiatry Service, Hospital Clínico San Cecilio, University of Granada, Granada, Spain
| | - P A Sáiz
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - M P García-Portilla
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - J Bobes
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - B L Amann
- Department of Psychiatry, Institut de Neuropsiquiatria i Addiccions, Centre Fòrum Research Unit, Parc de Salut Mar Hospital del Mar, IMIM, Autonomous University of Barcelona, CIBERSAM, Barcelona, Spain
| | - A Martínez-Arán
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - E Vieta
- Bipolar and Depression Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| |
Collapse
|
8
|
Guijarro A, Castro A, Hernández V, de la Peña E, Sánchez-Rosendo L, Jiménez E, Pérez-Férnandez E, Llorente C. Estudio poblacional de casuística y morbimortalidad de la prostatectomía radical en España. Actas Urol Esp 2022. [DOI: 10.1016/j.acuro.2022.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Rodríguez Rey A, Piazza F, Montejo L, Jiménez E, Martínez-Arán A. Are there differences in affective temperaments between patients with Bipolar I and II disorder? Eur Psychiatry 2022. [PMCID: PMC9562955 DOI: 10.1192/j.eurpsy.2022.572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Bipolar Disorder (BD) is a severe mental disorder with a high genetic load, in which is relevant to identify potential differences in affective temperaments between both diagnostic subtypes. Objectives To find differences between BDI and BDII patients in affective temperaments evaluated by Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego TEMPS-A. Methods A sample of 407 euthymic patients with diagnosis of bipolar disorder type I (BDI= 307) or type II (BDII= 100) according to DSM-IV-TR criteria being age 18 or older was recruited from the Bipolar and Depressive Disorders Unit of the Hospital Clinic of Barcelona. Five affective temperaments were evaluated using the TEMPS-A. It was initially verified that the scores of these temperaments do not fulfil the assumption of normality by means of tests. Differences in means were estimated using Mann-Whitney U and Chi square tests (p <0.05) as appropriate, and ANCOVA controlling the effect of confounding variables. Results Data revealed that patients with BD II had significantly higher scores in four affective temperaments: dysthymic, cyclothymic, irritable and anxious compared to BDI. After controlling the most relevant moderating variables, BDII patients continued to show higher scores in irritable temperament . Conclusions BDII patients present a more irritable temperament than BDI (p=0,037), which can affect the course and management of the disease. It could be suggested that presenting higher scores of these temperaments could be associated with BDII and further studies are needed to replicate this finding since it might help the clinicians in early phases to guide in the diagnostic process. Disclosure No significant relationships.
Collapse
|
10
|
Garutti I, Cabañero A, Vicente R, Sánchez D, Granell M, Fraile CA, Real Navacerrada M, Novoa N, Sanchez-Pedrosa G, Congregado M, Gómez A, Miñana E, Piñeiro P, Cruz P, de la Gala F, Quero F, Huerta LJ, Rodríguez M, Jiménez E, Puente-Maestu L, Aragon S, Osorio-Salazar E, Sitges M, Lopez Maldonado MD, Rios FT, Morales JE, Callejas R, Gonzalez-Bardancas S, Botella S, Cortés M, Yepes MJ, Iranzo R, Sayas J. Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program. Rev Esp Anestesiol Reanim (Engl Ed) 2022; 69:208-241. [PMID: 35585017 DOI: 10.1016/j.redare.2021.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 02/04/2021] [Indexed: 06/15/2023]
Abstract
In recent years, multidisciplinary programs have been implemented that include different actions during the pre, intra and postoperative period, aimed at reducing perioperative stress and therefore improving the results of patients undergoing surgical interventions. Initially, these programs were developed for colorectal surgery and from there they have been extended to other surgeries. Thoracic surgery, considered highly complex, like other surgeries with a high postoperative morbidity and mortality rate, may be one of the specialties that most benefit from the implementation of these programs. This review presents the recommendations made by different specialties involved in the perioperative care of patients who require resection of a lung tumor. Meta-analyzes, systematic reviews, randomized and non-randomized controlled studies, and retrospective studies conducted in patients undergoing this type of intervention have been taken into account in preparing the recommendations presented in this guide. The GRADE scale has been used to classify the recommendations, assessing on the one hand the level of evidence published on each specific aspect and, on the other hand, the strength of the recommendation with which the authors propose its application. The recommendations considered most important for this type of surgery are those that refer to pre-habilitation, minimization of surgical aggression, excellence in the management of perioperative pain and postoperative care aimed at providing rapid postoperative rehabilitation.
Collapse
Affiliation(s)
- I Garutti
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
| | - A Cabañero
- Servicio de Cirugía Torácica, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - R Vicente
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - D Sánchez
- Servicio de Cirugía Torácica, Hospital Clínic, Barcelona, Spain
| | - M Granell
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, Spain
| | - C A Fraile
- Servicio de Cirugía Torácica, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - M Real Navacerrada
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - N Novoa
- Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca (CAUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - G Sanchez-Pedrosa
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Congregado
- Servicio de Cirugía Torácica, Hospital Virgen de la Macarena, Sevilla, Spain
| | - A Gómez
- Unitat de Rehabilitació Cardiorespiratòria, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - E Miñana
- Servicio de Anestesia y Reanimación, Hospital de la Ribera, Alzira, Valencia, Spain
| | - P Piñeiro
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - P Cruz
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - F de la Gala
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - F Quero
- Servicio de Cirugía Torácica, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - L J Huerta
- Servicio de Cirugía Torácica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Rodríguez
- Servicio de Cirugía Torácica, Clínica Universidad de Navarra, Madrid, Spain
| | - E Jiménez
- Fisioterapia Respiratoria, Hospital Universitario A Coruña, La Coruña, Spain
| | - L Puente-Maestu
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - S Aragon
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, Spain
| | - E Osorio-Salazar
- Servicio de Anestesia y Reanimación, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - M Sitges
- Bloc Quirúrgic i Esterilització, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | | | - F T Rios
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - J E Morales
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, Spain
| | - R Callejas
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, Spain
| | - S Gonzalez-Bardancas
- Servicio de Anestesia y Reanimación, Complejo Hospitalario Universitario A Coruña, La Coruña, Spain
| | - S Botella
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - M Cortés
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M J Yepes
- Servicio de Anestesia y Reanimación, Clínica Universidad de Navarra, Navarra, Pamplona, Spain
| | - R Iranzo
- Servicio de Anestesia y Reanimación, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - J Sayas
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
11
|
Suffo M, Sales D, Cortés-Triviño E, de la Mata M, Jiménez E. Characterization and production of agglomerated cork stoppers for spirits based on a factor analysis method. Food Packag Shelf Life 2022. [DOI: 10.1016/j.fpsl.2022.100815] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Varo C, Solé B, Jiménez E, Bonnín CM, Torrent C, Valls E, Lahera G, Martínez-Arán A, Carvalho AF, Miskowiak KW, Vieta E, Reinares M. Identifying social cognition subgroups in euthymic patients with bipolar disorder: a cluster analytical approach. Psychol Med 2022; 52:159-168. [PMID: 32546284 DOI: 10.1017/s0033291720001865] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Bipolar disorder (BD) is associated with social cognition (SC) impairments even during remission periods although a large heterogeneity has been described. Our aim was to explore the existence of different profiles on SC in euthymic patients with BD, and further explore the potential impact of distinct variables on SC. METHODS Hierarchical cluster analysis was conducted using three SC domains [Theory of Mind (ToM), Emotional Intelligence (EI) and Attributional Bias (AB)]. The sample comprised of 131 individuals, 71 patients with BD and 60 healthy control subjects who were compared in terms of SC performance, demographic, clinical, and neurocognitive variables. A logistic regression model was used to estimate the effect of SC-associated risk factors. RESULTS A two-cluster solution was identified with an adjusted-performance group (N = 48, 67.6%) and a low-performance group (N = 23, 32.4%) with mild deficits in ToM and AB domains and with moderate difficulties in EI. Patients with low SC performance were mostly males, showed lower estimated IQ, higher subthreshold depressive symptoms, longer illness duration, and poorer visual memory and attention. Low estimated IQ (OR 0.920, 95% CI 0.863-0.981), male gender (OR 5.661, 95% CI 1.473-21.762), and longer illness duration (OR 1.085, 95% CI 1.006-1.171) contributed the most to the patients clustering. The model explained up to 35% of the variance in SC performance. CONCLUSIONS Our results confirmed the existence of two discrete profiles of SC among BD. Nearly two-thirds of patients exhibited adjusted social cognitive abilities. Longer illness duration, male gender, and lower estimated IQ were associated with low SC performance.
Collapse
Affiliation(s)
- C Varo
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Jiménez
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C M Bonnín
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C Torrent
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Valls
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - G Lahera
- Faculty of Medicine, University of Alcalá, IRyCIS, CIBERSAM, Madrid, Spain
| | - A Martínez-Arán
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A F Carvalho
- Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - K W Miskowiak
- Mental Health Services, Capital Region of Denmark, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- Department of Psychology, University of Copenhagen, Copenhagen, Denmark
| | - E Vieta
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Reinares
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| |
Collapse
|
13
|
Cardona AF, Jaramillo-Velásquez D, Ruiz-Patiño A, Polo C, Jiménez E, Hakim F, Gómez D, Ramón JF, Cifuentes H, Mejía JA, Salguero F, Ordoñez C, Muñoz Á, Bermúdez S, Useche N, Pineda D, Ricaurte L, Zatarain-Barrón ZL, Rodríguez J, Avila J, Rojas L, Jaller E, Sotelo C, Garcia-Robledo JE, Santoyo N, Rolfo C, Rosell R, Arrieta O. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol 2021; 154:353-364. [PMID: 34498213 DOI: 10.1007/s11060-021-03834-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 08/19/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND Amplification of EGFR and its active mutant EGFRvIII are common in glioblastoma (GB). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors or antibodies has shown limited efficacy. To improve the likelihood of effectiveness, we targeted adult patients with recurrent GB enriched for simultaneous EGFR amplification and EGFRvIII mutation, with osimertinib/bevacizumab at doses described for non-small cell lung cancer. METHODS We retrospectively explored whether previously described EGFRvIII mutation in association with EGFR gene amplification could predict response to osimertinib/bevacizumab combination in a subset of 15 patients treated at recurrence. The resistance pattern in a subgroup of subjects is described using a commercial next-generation sequencing panel in liquid biopsy. RESULTS There were ten males (66.7%), and the median patient's age was 56 years (range 38-70 years). After their initial diagnosis, 12 patients underwent partial (26.7%) or total resection (53.3%). Subsequently, all cases received IMRT and concurrent and adjuvant temozolomide (TMZ; the median number of cycles 9, range 6-12). The median follow-up after recurrence was 17.1 months (95% CI 12.3-22.6). All patients received osimertinib/bevacizumab as a second-line intervention with a median progression-free survival (PFS) of 5.1 months (95% CI 2.8-7.3) and overall survival of 9.0 months (95% CI 3.9-14.0). The PFS6 was 46.7%, and the overall response rate was 13.3%. After exposure to the osimertinib/bevacizumab combination, the main secondary alterations were MET amplification, STAT3, IGF1R, PTEN, and PDGFR. CONCLUSIONS While the osimertinib/bevacizumab combination was marginally effective in most GB patients with simultaneous EGFR amplification plus EGFRvIII mutation, a subgroup experienced a long-lasting meaningful benefit. The findings of this brief cohort justify the continuation of the research in a clinical trial. The pattern of resistance after exposure to osimertinib/bevacizumab includes known mechanisms in the regulation of EGFR, findings that contribute to the understanding and targeting in a stepwise rational this pathway.
Collapse
Affiliation(s)
- Andrés F Cardona
- Clinical and Translational Oncology Group, Brain Tumor Unit, Clínica del Country, Calle 116 No. 9 - 72, c. 318, Bogotá, Colombia. .,Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia. .,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia. .,Thoracic Oncology Unit, Clínica del Country, Bogotá, Colombia.
| | | | - Alejandro Ruiz-Patiño
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Carolina Polo
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Enrique Jiménez
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Fernando Hakim
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Diego Gómez
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | | | | | | | - Fernando Salguero
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Camila Ordoñez
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Álvaro Muñoz
- Radio-Oncology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Sonia Bermúdez
- Neuroradiology Section, Radiology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Nicolas Useche
- Neuroradiology Section, Radiology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Diego Pineda
- Neuroradiology Section, Radiology Department, Clínica del Country, Bogotá, Colombia
| | | | | | - July Rodríguez
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Jenny Avila
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Leonardo Rojas
- Clinical and Translational Oncology Group, Brain Tumor Unit, Clínica del Country, Calle 116 No. 9 - 72, c. 318, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia.,Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia
| | - Elvira Jaller
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Carolina Sotelo
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | | | - Nicolas Santoyo
- Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.,Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia
| | - Christian Rolfo
- Center for Thoracic Oncology, Tisch Cáncer Center, Mount Sinai Hospital System & Icahn School of Medicine, Mount Sinai, New York, NY, USA
| | - Rafael Rosell
- Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Barcelona, Spain
| | - Oscar Arrieta
- Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
| |
Collapse
|
14
|
Neeman EM, González D, Blázquez S, Ballesteros B, Canosa A, Antiñolo M, Vereecken L, Albaladejo J, Jiménez E. The impact of water vapor on the OH reactivity toward CH 3CHO at ultra-low temperatures (21.7-135.0 K): Experiments and theory. J Chem Phys 2021; 155:034306. [PMID: 34293904 PMCID: PMC7611909 DOI: 10.1063/5.0054859] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The role of water vapor (H2O) and its hydrogen-bonded complexes in the gas-phase reactivity of organic compounds with hydroxyl (OH) radicals has been the subject of many recent studies. Contradictory effects have been reported at temperatures between 200 and 400 K. For the OH + acetaldehyde reaction, a slight catalytic effect of H2O was previously reported at temperatures between 60 and 118 K. In this work, we used Laval nozzle expansions to reinvestigate the impact of H2O on the OH-reactivity with acetaldehyde between 21.7 and 135.0 K. The results of this comprehensive study demonstrate that water, instead, slows down the reaction by factors of ∼3 (21.7 K) and ∼2 (36.2-89.5 K), and almost no effect of added H2O was observed at 135.0 K.
Collapse
Affiliation(s)
- E. M. Neeman
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
| | - D. González
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
| | - S. Blázquez
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
| | - B. Ballesteros
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - A. Canosa
- CNRS, IPR (Institut de Physique de Rennes) - UMR 6251, Université de Rennes, F-35000, Rennes, France
| | - M. Antiñolo
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - L. Vereecken
- Institute for energy and climate research, IEK-8: Troposphere. Forschungszentrum Jülich GmbH, Jülich, Germany
| | - J. Albaladejo
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - E. Jiménez
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| |
Collapse
|
15
|
Garutti I, Cabañero A, Vicente R, Sánchez D, Granell M, Fraile CA, Real Navacerrada M, Novoa N, Sanchez-Pedrosa G, Congregado M, Gómez A, Miñana E, Piñeiro P, Cruz P, de la Gala F, Quero F, Huerta LJ, Rodríguez M, Jiménez E, Puente-Maestu L, Aragon S, Osorio-Salazar E, Sitges M, Lopez Maldonado MD, Rios FT, Morales JE, Callejas R, Gonzalez-Bardancas S, Botella S, Cortés M, Yepes MJ, Iranzo R, Sayas J. Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program. Rev Esp Anestesiol Reanim (Engl Ed) 2021; 69:S0034-9356(21)00102-X. [PMID: 34294445 DOI: 10.1016/j.redar.2021.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 01/28/2021] [Accepted: 02/04/2021] [Indexed: 11/24/2022]
Abstract
In recent years, multidisciplinary programs have been implemented that include different actions during the pre, intra and postoperative period, aimed at reducing perioperative stress and therefore improving the results of patients undergoing surgical interventions. Initially, these programs were developed for colorectal surgery and from there they have been extended to other surgeries. Thoracic surgery, considered highly complex, like other surgeries with a high postoperative morbidity and mortality rate, may be one of the specialties that most benefit from the implementation of these programs. This review presents the recommendations made by different specialties involved in the perioperative care of patients who require resection of a lung tumor. Meta-analyses, systematic reviews, randomized and non-randomized controlled studies, and retrospective studies conducted in patients undergoing this type of intervention have been taken into account in preparing the recommendations presented in this guide. The GRADE scale has been used to classify the recommendations, assessing on the one hand the level of evidence published on each specific aspect and, on the other hand, the strength of the recommendation with which the authors propose its application. The recommendations considered most important for this type of surgery are those that refer to pre-habilitation, minimization of surgical aggression, excellence in the management of perioperative pain and postoperative care aimed at providing rapid postoperative rehabilitation.
Collapse
Affiliation(s)
- I Garutti
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España.
| | - A Cabañero
- Servicio de Cirugía Torácica, Hospital Universitario Ramón y Cajal, Madrid, España
| | - R Vicente
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - D Sánchez
- Servicio de Cirugía Torácica, Hospital Clínic, Barcelona, España
| | - M Granell
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, España
| | - C A Fraile
- Servicio de Cirugía Torácica, Hospital Universitari Arnau de Vilanova, Lleida, España
| | - M Real Navacerrada
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, España
| | - N Novoa
- Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca (CAUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - G Sanchez-Pedrosa
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - M Congregado
- Servicio de Cirugía Torácica, Hospital Virgen de la Macarena, Sevilla, España
| | - A Gómez
- Unitat de Rehabilitació Cardiorespiratòria, Hospital Universitari Vall d'Hebron, Barcelona, España
| | - E Miñana
- Servicio de Anestesia y Reanimación, Hospital de La Ribera, Alzira, Valencia, España
| | - P Piñeiro
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - P Cruz
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - F de la Gala
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - F Quero
- Servicio de Cirugía Torácica, Hospital Universitario Virgen de las Nieves, Granada, España
| | - L J Huerta
- Servicio de Cirugía Torácica, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - M Rodríguez
- Servicio de Cirugía Torácica, Clínica Universidad de Navarra, Madrid, España
| | - E Jiménez
- Fisioterapia Respiratoria, Hospital Universitario de A Coruña, La Coruña, España
| | - L Puente-Maestu
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| | - S Aragon
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, España
| | - E Osorio-Salazar
- Servicio de Anestesia y Reanimación, Hospital Universitari Arnau de Vilanova, Lleida, España
| | - M Sitges
- Bloc Quirúrgic i Esterilització, Hospital del Mar, Parc de Salut Mar, Barcelona, España
| | | | - F T Rios
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - J E Morales
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, España
| | - R Callejas
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, España
| | - S Gonzalez-Bardancas
- Servicio de Anestesia y Reanimación, Complejo Hospitalario Universitario A Coruña, La Coruña, España
| | - S Botella
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - M Cortés
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, España
| | - M J Yepes
- Servicio de Anestesia y Reanimación, Clínica Universidad de Navarra, Navarra, Pamplona, España
| | - R Iranzo
- Servicio de Anestesia y Reanimación, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
| | - J Sayas
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| |
Collapse
|
16
|
Ramirez Daffos P, Jiménez E, Bolaños Naranjo M, González-Astorga B, Rubiales S, Ceballos Barbancho E, Rodríguez J, Reina Zoilo J. P-60 Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
17
|
Palma-Hidalgo JM, Belanche A, Jiménez E, Martín-García AI, Newbold CJ, Yáñez-Ruiz DR. Short communication: Saliva and salivary components affect goat rumen fermentation in short-term batch incubations. Animal 2021; 15:100267. [PMID: 34102432 DOI: 10.1016/j.animal.2021.100267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 04/27/2021] [Accepted: 04/29/2021] [Indexed: 11/29/2022] Open
Abstract
The research about the role of saliva in ruminants has been mainly focused on its buffering capacity together with facilitation of the rumination process. However, the role of salivary bioactive components on modulating the activity of the rumen microbiota has been neglected until recently. This study developed an in vitro approach to assess the impact of different components in saliva on rumen microbial fermentation. Four different salivary fractions were prepared from four goats: (i) non-filtrated saliva (NFS), (ii) filtrated through 0.25 µm to remove microorganisms and large particles (FS1), (iii) centrifuged through a 30 kDa filter to remove large proteins, (FS2), and (iv) autoclaved saliva (AS) to keep only the minerals. Two experiments were conducted in 24 h batch culture incubations with 6 ml of total volume consisting of 2 ml of rumen fluid and 4 ml of saliva/buffer mix. In Experiment 1, the effect of increasing the proportion of saliva (either NFS or FS1) in the solution (0%, 16%, 33% and 50% of the total volume) was evaluated. Treatment FS1 promoted greater total volatile fatty acids (VFA) (+8.4%) and butyrate molar proportion (+2.8%) but lower NH3-N concentrations than NFS fraction. Replacing the bicarbonate buffer solution by increasing proportions of saliva resulted in higher NH3-N, total VFA (+8.0%) and propionate molar proportion (+11%). Experiment 2 addressed the effect of the different fractions of saliva (NFS, FS1, FS2 and AS). Saliva fractions led to higher total VFA and NH3-N concentrations than non-saliva incubations, which suggests that the presence of some salivary elements enhanced rumen microbial activity. Fraction FS1 promoted a higher concentration of total VFA (+7.8%) than the other three fractions, and higher propionate (+26%) than NFS and AS. This agrees with findings from Experiment 1 and supports that 'microbe-free saliva', in which large salivary proteins are maintained, boosts rumen fermentation. Our results show the usefulness of this in vitro approach and suggest that different salivary components can modulate rumen microbial fermentation, although the specific metabolites and effects they cause need further research.
Collapse
Affiliation(s)
- J M Palma-Hidalgo
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - A Belanche
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - E Jiménez
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - A I Martín-García
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - C J Newbold
- Scotland's Rural College (SRUC), Peter Wilson Building King's Buildings, W Mains Rd, Edinburgh EH9 3JG, United Kingdom
| | - D R Yáñez-Ruiz
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain.
| |
Collapse
|
18
|
Jiménez E, Pimentel E, Cruces MP, Amaya-Chávez A. Radioprotective effect of chloropyllin, protoporphyrin-IX and bilirubin compared with amifostine® in Drosophila melanogaster. Environ Toxicol Pharmacol 2020; 80:103464. [PMID: 32750419 DOI: 10.1016/j.etap.2020.103464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 07/29/2020] [Accepted: 07/30/2020] [Indexed: 06/11/2023]
Abstract
The identification of substances that prevent or minimize the detrimental effects of ionizing radiation is an essential undertaking. The aim of this paper was to evaluate and compare the radioprotective potential of chlorophyllin, protoporphyrin and bilirubin, with amifostine®, an US Food & Drug Administration approved radioprotector Using the somatic mutation and recombination assay in the Drosophila melanogaster wing, it was found that pretreatment (1-9 h) with any of the porphyrins or amifostine® alone, did not affect the larva-adult viability or the basal frequency of mutation. However, they were associated with significant reductions in frequency of somatic mutation and recombination compared with the gamma-irradiated (20 Gy) control as follows: bilirubin (69.3 %)> chlorophyllin (40.0 %)> protoporphyrin (39.0 %)> amifostine® (19.7 %). Bilirubin also caused a 16 % increase in larva-adult viability with 3 h of pretreatment respect to percentage induced in 20 Gy control group. Whilst amifostine® was associated with lower genetic damage after pre-treatment of 1 and 3 h, this did not attain significance. These findings suggest that the tested porphyrins may have some potential as radioprotectant agents.
Collapse
Affiliation(s)
- E Jiménez
- Instituto Nacional de Investigaciones Nucleares, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Edo. de México, C.P. 52750, Mexico
| | - E Pimentel
- Instituto Nacional de Investigaciones Nucleares, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Edo. de México, C.P. 52750, Mexico.
| | - M P Cruces
- Instituto Nacional de Investigaciones Nucleares, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Edo. de México, C.P. 52750, Mexico
| | - A Amaya-Chávez
- Facultad de Química, Universidad Autónoma del Estado de México, Toluca, Mexico
| |
Collapse
|
19
|
Gordin S, Gutherz G, Elazary A, Romach A, Jiménez E, Berant J, Cohen Y. Reading Akkadian cuneiform using natural language processing. PLoS One 2020; 15:e0240511. [PMID: 33112872 PMCID: PMC7592802 DOI: 10.1371/journal.pone.0240511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 09/29/2020] [Indexed: 11/18/2022] Open
Abstract
In this paper we present a new method for automatic transliteration and segmentation of Unicode cuneiform glyphs using Natural Language Processing (NLP) techniques. Cuneiform is one of the earliest known writing system in the world, which documents millennia of human civilizations in the ancient Near East. Hundreds of thousands of cuneiform texts were found in the nineteenth and twentieth centuries CE, most of which are written in Akkadian. However, there are still tens of thousands of texts to be published. We use models based on machine learning algorithms such as recurrent neural networks (RNN) with an accuracy reaching up to 97% for automatically transliterating and segmenting standard Unicode cuneiform glyphs into words. Therefore, our method and results form a major step towards creating a human-machine interface for creating digitized editions. Our code, Akkademia, is made publicly available for use via a web application, a python package, and a github repository.
Collapse
Affiliation(s)
- Shai Gordin
- Faculty of Social Sciences and Humanities, Digital Humanities Ariel Lab, Ariel University, Ariel, Israel
- * E-mail:
| | - Gai Gutherz
- School of Computer Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Ariel Elazary
- School of Computer Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Avital Romach
- Jacob M. Alkow Department of Archaeology and Ancient Near Eastern Civilizations, Tel Aviv University, Tel Aviv, Israel
| | - Enrique Jiménez
- Institute for Assyriology and Hittitology, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Jonathan Berant
- School of Computer Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Yoram Cohen
- Jacob M. Alkow Department of Archaeology and Ancient Near Eastern Civilizations, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
20
|
Gómez-Amarillo DF, Pulido LF, Mejía I, García-Baena C, Cárdenas MF, Gómez LM, Fuentes YV, Volcinschi-Moros D, Jaramillo-Velásquez D, Ramón JF, Mejía JA, Jiménez E, Hakim F. Cerebrospinal fluid closing pressure-guided tap test for the diagnosis of idiopathic normal pressure hydrocephalus: A descriptive cross-sectional study. Surg Neurol Int 2020; 11:315. [PMID: 33093992 PMCID: PMC7568097 DOI: 10.25259/sni_380_2020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 08/03/2020] [Indexed: 01/22/2023] Open
Abstract
Background: Tap test improves symptoms of idiopathic normal pressure hydrocephalus (iNPH); hence, it is widely used as a diagnostic procedure. However, it has a low sensitivity and there is no consensus on the parameters that should be used nor the volume to be extracted. We propose draining cerebrospinal fluid (CSF) during tap test until a closing pressure of 0 cm H2O is reached as a standard practice. We use this method with all our patients at our clinic. Methods: This is a descriptive cross-sectional study where all patients with presumptive diagnosis of iNPH from January 2014 to December 2019 were included in the study. We used a univariate descriptive analysis and stratified analysis to compare the opening pressure and the volume of CSF extracted during the lumbar puncture, between patients in whom a diagnosis of iNPH was confirmed and those in which it was discarded. Results: A total of 92 patients were included in the study. The mean age at the time of presentation was 79.4 years and 63 patients were male. The diagnosis of iNPH was confirmed in 73.9% patients. The mean opening pressure was 14.4 cm H2O mean volume of CSF extracted was 43.4 mL. Conclusion: CSF extraction guided by a closing pressure of 0 cm H2O instead of tap test with a fixed volume of CSF alone may be an effective method of optimizing iNPH symptomatic improvement and diagnosis.
Collapse
|
21
|
Arnaez J, Herranz-Rubia N, Garcia-Alix A, Diez-Delgado J, Benavente-Fernández I, Tofé I, Jerez A, Hurtado J, Ceballos J, Millán M, Esquivel M, Ruiz C, Baca M, Tapia E, Losada M, Torres E, Pavón A, Jiménez P, Jiménez F, Ventura M, Rite S, González T, Arias R, Balliu P, Lloreda-García J, Alcaráz J, Tapia C, de la Morena A, Centelles I, Güemes I, Estañ J, Alberola A, Aparici S, López R, Beceiro J, García B, Martínez L, González E, Arruza L, Blanco M, Moral M, Arias B, Mar F, Jiménez J, Romera G, Cuñarro A, Muñóz C, Cabañas F, Valverde E, Montero R, Tejedor J, Santana C, Reyes B, Romero S, Orizaola A, Baquero M, Hernández D, Pantoja A, Vega-del-Val C, Castañón L, Gutiérrez E, Benito M, Caserío S, Arca G, García M, López-Vílchez M, Castells L, Domingo M, Coroleu W, Boix H, Porta R, García-Alix A, Martínez-Nadal S, Jiménez E, Sole E, Albújar M, Fernández E, Barrio A, Piñán E, Avila-Alvarez A, Vázquez M, Balado N, Crespo P, Couce M, Concheiro-Guisán A, Esteban I, Lavilla A, Alzina V, Aguirre A, Loureiro B, Echániz I, Elorza M, Euba A. Atención integral del neonato con encefalopatía hipóxico-isquémica en España. An Pediatr (Barc) 2020; 92:286-296. [DOI: 10.1016/j.anpedi.2019.05.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 05/22/2019] [Accepted: 05/24/2019] [Indexed: 10/26/2022] Open
|
22
|
Belanche A, Palma-Hidalgo JM, Nejjam I, Jiménez E, Martín-García AI, Yáñez-Ruiz DR. Inoculation with rumen fluid in early life as a strategy to optimize the weaning process in intensive dairy goat systems. J Dairy Sci 2020; 103:5047-5060. [PMID: 32278566 DOI: 10.3168/jds.2019-18002] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 02/07/2020] [Indexed: 12/16/2022]
Abstract
Ruminants are born with an undeveloped physical, metabolic, and microbial rumen. Rumen development is limited under artificial rearing systems when newborn animals are separated from the dam, fed on milk replacer, and weaned at an early age. This study aims to evaluate the effects of early-life inoculation of young ruminants with rumen fluid from adult animals. Eighty newborn goat kids were randomly allocated to 1 of 4 experimental treatments and inoculated daily from d 1 to wk 11 with autoclaved rumen fluid (AUT), fresh rumen fluid obtained from adult goats fed either a forage diet (RFF) or concentrate-rich diet (RFC), or absence of inoculation (CTL). Goat kids were artificially reared with ad libitum access to milk replacer, starter concentrate, and forage hay. Blood was sampled weekly and rumen microbial fermentation was monitored at 5 (preweaning), 7 (weaning), and 9 wk of age (postweaning). Results indicated that inoculation with fresh rumen fluid accelerated the rumen microbial and fermentative development before weaning. As a result, RFC and RFF animals had higher solid feed intake (+73%), rumen concentrations of ammonia-N (+26%), total volatile fatty acids (+46%), butyrate (+50%), and plasma β-hydroxybutyrate (+48%), and lower milk intake (-6%) than CTL and AUT animals at wk 5. Inoculation with fresh inoculum also promoted early rumen colonization by a complex and abundant protozoal community, whereas CTL animals remained protozoa free. Although all kids experienced moderate growth retardation during 1 wk after weaning, inoculation with fresh rumen fluid favored the weaning process, leading to 2.2 times higher weight gain than CTL and AUT animals during wk 8. Some of these advantages were retained during the postweaning period and RFF and RFC animals showed higher forage intake (up to +44%) than CTL and AUT animals with no detrimental effects on feed digestibility or stress levels. The superior microbial load of RFC compared with RFF inoculum tended to provide further improvements in terms of forage intake, plasma β-hydroxybutyrate, and rumen protozoa, whereas AUT inoculation provided minor (if any) advantages with respect to CTL animals. Although no differences were noted on animal growth, this study suggests that early life inoculation of goat kids with rumen microbiota can represent an effective strategy to accelerate the rumen development, facilitating a smooth transition from milk to solid feed and to the potential implementation of early weaning strategies.
Collapse
Affiliation(s)
- A Belanche
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain.
| | - J M Palma-Hidalgo
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - I Nejjam
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - E Jiménez
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - A I Martín-García
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - D R Yáñez-Ruiz
- Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| |
Collapse
|
23
|
Albalate M, Arribas P, Torres E, Cintra M, Alcázar R, Puerta M, Ortega M, Procaccini F, Martin J, Jiménez E, Fernandez I, de Sequera P. High prevalence of asymptomatic COVID-19 in hemodialysis. Daily learning during first month of COVID-19 pandemic ☆. Nefrología (English Edition) 2020; 40. [PMCID: PMC7309939 DOI: 10.1016/j.nefroe.2020.06.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Dialysis patients are a risk group for SARS-CoV2 infection and possibly further complications, but we have little information. The aim of this paper is to describe the experience of the first month of the SARS-Cov2 pandemic in a hospital haemodialysis (HD) unit serving the district of Madrid with the second highest incidence of COVID19 (almost 1000 patients in 100,000 h). In the form of a diary, we present the actions undertaken, the incidence of COVID19 in patients and health staff, some clinical characteristics and the results of screening all the patients in the unit. We started with 90 patients on HD: 37 (41.1%) had COVID19, of whom 17 (45.9%) were diagnosed through symptoms detected in triage or during the session, and 15 (40.5%) through subsequent screening of those who, until that time, had not undergone SARS-CoV2 PCR testing. Fever was the most frequent symptom, 50% had lymphopenia and 18.4% <95% O2 saturation. Sixteen (43.2%) patients required hospital admission and 6 (16.2%) died. We found a cluster of infection per shift and also among those using public transport. In terms of staff, of the 44 people involved, 15 (34%) had compatible symptoms, 4 (9%) were confirmed as SARS-Cov2 PCR cases by occupational health, 9 (20%) required some period of sick leave, temporary disability to work (ILT), and 5 were considered likely cases. Conclusions We detected a high prevalence of COVID19 with a high percentage detected by screening; hence the need for proactive diagnosis to stop the pandemic. Most cases are managed as outpatients, however severe symptoms are also appearing and mortality to date is 16.2%. In terms of staff, 20% have required sick leave in relation to COVID19.
Collapse
Affiliation(s)
- M. Albalate
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
- Corresponding author.
| | - P. Arribas
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - E. Torres
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - M. Cintra
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - R. Alcázar
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - M. Puerta
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - M. Ortega
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - F. Procaccini
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - J. Martin
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - E. Jiménez
- Medicina Preventiva y Salud Pública, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - I. Fernandez
- Medicina Preventiva y Salud Pública, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | - P. de Sequera
- Servicio de Nefrología, Hospital Universitario Infanta Leonor (HUIL). Madrid, Spain
| | | |
Collapse
|
24
|
Segura AG, Mitjans M, Jiménez E, Fatjó-Vilas M, Ruiz V, Saiz PA, García-Portilla MP, González-Blanco L, Bobes J, Vieta E, Benabarre A, Arias B. Association of childhood trauma and genetic variability of CRH-BP and FKBP5 genes with suicidal behavior in bipolar patients. J Affect Disord 2019; 255:15-22. [PMID: 31195252 DOI: 10.1016/j.jad.2019.05.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 05/03/2019] [Accepted: 05/07/2019] [Indexed: 11/26/2022]
Abstract
BACKGROUND Around 8% of bipolar disorder (BD) patients die by suicide every year, accounting for the highest rate among the psychiatric population. Suicidal behavior (SB) is mediated by an intertwining system of extrinsic and intrinsic factors. Childhood trauma (CT) and gene variants of the stress-management hypothalamic-pituitary-adrenal (HPA) axis have been reported as risk factors for SB. The aim of this study was to elucidate the association of CT and HPA axis genetic variants with SB. METHODS 135 BD patients were recruited for clinical assessment of CT and SB by means of the Childhood Trauma Questionnaire (CTQ) and the Columbia Suicide Severity Rating Scale (C-SSRS), respectively. A total of 28 single nucleotide polymorphisms (SNPs) from 8 HPA axis genes (POMC, NR3C2, CRH-BP, NR3C1, FKBP5, CRHR2, CRHR1, and MC2R) were genotyped. RESULTS The analyses showed an association of total CTQ score (p = 0.003), emotional abuse (p = 0.001), sexual abuse (p = 0.005) and emotional neglect (p = 0.005) with SB. CRH-BP rs7728378-C carriers (p = 0.004; OR = 3.05), FKBP5 rs3777747-AA (p = 0.039; OR = 0.34) and FKBP5 rs2766533-GG genotypes (p = 0.001; OR = 2.93) were associated with SB although only rs2766533 survived multiple test correction. No gene-environment interaction was found. LIMITATIONS The relatively small sample size limits the statistical power to detect smaller environmental and genetic effects. Cross-sectional data collection in psychometric assessments can yield biased data. CONCLUSIONS The present study characterizes novel SB risk factors and replicates previous findings in BD patients. CT and variability in CRH-BP and FKBP5 genes should be further studied for a better understanding of SB and ultimately help in suicide prevention.
Collapse
Affiliation(s)
- A G Segura
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, IBUB, University of Barcelona, CIBERSAM, Barcelona, Spain
| | - M Mitjans
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, IBUB, University of Barcelona, CIBERSAM, Barcelona, Spain
| | - E Jiménez
- Bipolar Disorder Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Fatjó-Vilas
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, IBUB, University of Barcelona, CIBERSAM, Barcelona, Spain; FIDMAG Germanes Hospitalaries Research Foundation, CIBERSAM, Barcelona, Spain
| | - V Ruiz
- Institut Clínic de Neurociencies, Hospital Clínic, Barcelona, Spain
| | - P A Saiz
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - M P García-Portilla
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - L González-Blanco
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - J Bobes
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - E Vieta
- Bipolar Disorder Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A Benabarre
- Bipolar Disorder Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Arias
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, IBUB, University of Barcelona, CIBERSAM, Barcelona, Spain.
| |
Collapse
|
25
|
Ramirez Daffos P, González-Astorga B, Jiménez E, Rubiales S, Bolaños M, Ceballos E, Rodríguez J, Reina J. Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, Ramón JF, Useche N, Bermúdez S, Pineda D, Cifuentes H, Rojas L, Ricaurte L, Pino LE, Balaña C, Arrieta O. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS One 2019; 14:e0217340. [PMID: 31220093 PMCID: PMC6586269 DOI: 10.1371/journal.pone.0217340] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 05/10/2019] [Indexed: 11/29/2022] Open
Abstract
Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.
Collapse
Affiliation(s)
- Andrés F. Cardona
- Brain Tumor Section, Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Foundation for Clinical and Applied Cancer Research–FICMAC, Bogotá, Colombia
- Molecular Oncology and Biology Systems Group (G-FOX), Universidad El Bosque, Bogotá, Colombia
- * E-mail: ,
| | | | | | - Fernando Hakim
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
| | - Enrique Jiménez
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
| | - Juan Armando Mejía
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
| | - Juan Fernando Ramón
- Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
| | - Nicolás Useche
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
- Neuroradiology Section, Radiology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Sonia Bermúdez
- Neuroscience Department, Universidad El Bosque, Bogotá, Colombia
- Neuroradiology Section, Radiology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Diego Pineda
- Brain Tumor Section, Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Neuroradiology Section, Clínica del Country, Bogotá, Colombia
| | | | - Leonardo Rojas
- Brain Tumor Section, Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Foundation for Clinical and Applied Cancer Research–FICMAC, Bogotá, Colombia
- Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia
| | - Luisa Ricaurte
- Foundation for Clinical and Applied Cancer Research–FICMAC, Bogotá, Colombia
| | - Luis Eduardo Pino
- Clinical Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Carmen Balaña
- Neuro-Oncology Section, Oncology Department, Hospital Germans Trias I Pujol, Catalan Institute of Oncology–ICO, Barcelona, Spain
| | - Oscar Arrieta
- Laboratory of Experimental Oncology, Instituto Nacional de Cancerología (INCaN), México City, México
| |
Collapse
|
27
|
Pardo J, Mena A, Jiménez E, Aymar N, Ortiz I, Roncero R, Mestre F, Vidal M. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. Clin Transl Oncol 2019; 21:1568-1572. [PMID: 31093890 DOI: 10.1007/s12094-019-02125-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Accepted: 04/19/2019] [Indexed: 11/28/2022]
Abstract
PURPOSE The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy. MATERIALS AND METHODS This study involved 62 advanced cancer patients, with well-controlled background pain, who presented BTCP associated to routine radiotherapy procedures, treated with FPNS according to our protocol of administration. The BPE intensity was measured using a visual analog scale (VAS). RESULTS The BTCP was triggered during the computed tomography simulation (79.3%) or treatment delivery (20.7%). Patients indicated a mean VAS of 8.8 (range 7-10) when attempting the procedure. After 4.5 min (range 2-10) of the first FPNS dose, the majority of patients (85.5%) indicated a VAS of 4.3 (range 2-6). 15.5% of the patients did not respond after 15 min; requiring a second dose. All these patients responded, reporting a mean VAS of 4.2 (range 4-6) after 3.0 min (range 2-5) of the second dose. None of the patients required a third dose, nor reported an AE after the administration of FPNS. CONCLUSIONS In our knowledge, our study is the one of highest recruitment, and with the fastest response of BTCP treated with FPNS reported in advanced cancer patients undergoing radiotherapy. FPNS has proven to be highly effective in reducing the intensity of procedural BTCP in a very short period of time.
Collapse
Affiliation(s)
- J Pardo
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain. .,Institut d'Investigació Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain. .,Hospital Universitari General de Catalunya, Quirónsalud, Barcelona, Spain.
| | - A Mena
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain.,Institut d'Investigació Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
| | - E Jiménez
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain.,Institut d'Investigació Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
| | - N Aymar
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain
| | - I Ortiz
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain
| | - R Roncero
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain
| | - F Mestre
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain
| | - M Vidal
- Radiation Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa 79, 07010, Palma de Mallorca, Spain
| |
Collapse
|
28
|
Varo C, Jiménez E, Solé B, Bonnín CM, Torrent C, Lahera G, Benabarre A, Saiz PA, de la Fuente L, Martínez-Arán A, Vieta E, Reinares M. Social cognition in bipolar disorder: the role of sociodemographic, clinical, and neurocognitive variables in emotional intelligence. Acta Psychiatr Scand 2019; 139:369-380. [PMID: 30786002 DOI: 10.1111/acps.13014] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/11/2019] [Indexed: 12/20/2022]
Abstract
OBJECTIVE The main aims of this study were to examine the differences in the Emotional Intelligence (EI), the emotional domain of social cognition (SC), between euthymic patients with bipolar disorder (BD) and healthy controls (HC) and to evaluate the contribution of sociodemographic, clinical, and neuropsychological variables to EI. METHODS We recruited 202 patients with BD and 50 HC. EI was evaluated using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). The sociodemographic, clinical, and neurocognitive variables that showed a significant association with EI were entered into hierarchical multiple regression analysis. RESULTS BD patients obtained significantly lower scores compared to HC in the Emotional Intelligence Quotient (EIQ) and in the Understanding Emotions branch score. The best fitting model for the variables associated with EI in the patients group was a linear combination of gender, estimated IQ, family history of affective diagnosis, and executive function. The model, including these previous variables, explained up to 27.6% of the observed variance (R2 = 0.276, F = 16.406, P < 0.001). CONCLUSIONS The identification of variables associated with deficit in EI, such as male gender, lower estimated IQ, family history of affective diagnosis. and lower executive function performance, may help in selecting treatment targets to improve SC, and especially EI, in patients with BD.
Collapse
Affiliation(s)
- C Varo
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Jiménez
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C M Bonnín
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C Torrent
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - G Lahera
- Faculty of Medicine, University of Alcalá, IRyCIS, CIBERSAM, Madrid, Spain
| | - A Benabarre
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - P A Saiz
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.,Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - L de la Fuente
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.,Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - A Martínez-Arán
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Vieta
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Reinares
- Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| |
Collapse
|
29
|
Merino A, Jiménez E, Fernández C, Fontúrbel MT, Campo J, Vega JA. Soil organic matter and phosphorus dynamics after low intensity prescribed burning in forests and shrubland. J Environ Manage 2019; 234:214-225. [PMID: 30622019 DOI: 10.1016/j.jenvman.2018.12.055] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 12/14/2018] [Accepted: 12/18/2018] [Indexed: 06/09/2023]
Abstract
Various different factors have led to the accumulation of biomass in forest soils in the Mediterranean-climate region in the last few decades, thus exacerbating the effects of wildfires. Although prescribed burning is used to decrease the fuel load and reduce the currency of mega-wildfires, the impacts on soil organic matter (SOM) and nutrient cycling, and therefore on forest ecosystem sustainability, are uncertain. The present study was designed to cover a range of conditions and therefore to assess the variability in the responses in similar geographical areas. Three prescribed burning treatments producing different levels of soil burn severity were conducted in two different types of forests (Pinus nigra and Pinus pinaster) and one (previously treated by prescribed burning) shrubland ecosystem (Cytisus oromediterraneus), all characterized by different fuel loads and depths of soil organic layer, in Central Spain. After the treatments, the SOM content, its thermal properties, and the distribution of Phosphorus (P) forms (31P NMR spectroscopy) were measured in the soil organic layer and mineral soils (0-2 cm depth), and the results were related to the temperatures reached. The prescribed burning les to low-moderate perturbations in SOM quality and Carbon (C) and P dynamics. The organic P, which in the unburnt plots represented 70% of the extractable P, was greatly depleted (by 56 and 95% with respect the initials values). This effect was concurrent with decreases in the most thermolabile SOM fractions, suggesting that organic P is readily mineralized, even at relatively low temperatures. Release of large amounts of soluble orthophosphate may occur when the prescribed burning leads to a high level of soil burn severity. The findings show that prescribed burning treatments should be planned carefully in order to prevent long-term perturbation of C and P cycling.
Collapse
Affiliation(s)
- Agustín Merino
- University of Santiago de Compostela, Escuela Politécnica Superior, Soil Science and Agricultural Chemistry, Lugo, Spain.
| | - Enrique Jiménez
- Centro de Investigación Forestal, Lourizán, Consellería de Medio Rural, Xunta de Galicia, P.O.Box 127, 36080 Pontevedra, Spain
| | - Cristina Fernández
- Centro de Investigación Forestal, Lourizán, Consellería de Medio Rural, Xunta de Galicia, P.O.Box 127, 36080 Pontevedra, Spain
| | - Maria T Fontúrbel
- Centro de Investigación Forestal, Lourizán, Consellería de Medio Rural, Xunta de Galicia, P.O.Box 127, 36080 Pontevedra, Spain
| | - Julio Campo
- Instituto de Ecología, Universidad Nacional Autónoma de México, P.O.Box 70-275, 04510 Mexico City, Mexico
| | - Jose A Vega
- Centro de Investigación Forestal, Lourizán, Consellería de Medio Rural, Xunta de Galicia, P.O.Box 127, 36080 Pontevedra, Spain
| |
Collapse
|
30
|
Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma. Clin Transl Oncol 2019; 21:1364-1373. [DOI: 10.1007/s12094-019-02066-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 02/15/2019] [Indexed: 11/30/2022]
|
31
|
Varo C, Murru A, Salagre E, Jiménez E, Solé B, Montejo L, Carvalho AF, Stubbs B, Grande I, Martínez-Arán A, Vieta E, Reinares M. Behavioral addictions in bipolar disorders: A systematic review. Eur Neuropsychopharmacol 2019; 29:76-97. [PMID: 30420190 DOI: 10.1016/j.euroneuro.2018.10.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 09/18/2018] [Accepted: 10/23/2018] [Indexed: 12/16/2022]
Abstract
Clinical and epidemiological research suggests that behavioral addictions (BA) are associated with a wide range of psychiatric disorders. However, the relationship between BA and bipolar disorders (BD) has not been thoroughly explored. The aim of this systematic review was to critically summarize and evaluate the current available evidence regarding a possible association between BA and BD. A systematic review of major electronic databases according to PRISMA guidelines was conducted from inception to 31st December 2017. We sought quantitative studies data concerning prevalence of comorbidity, features and treatment related to BA-BD comorbidity. Data were narratively synthesized. Of the 1250 studies returned from the search, a total of 28 articles were included in this review. BA may be overrepresented in BD samples, and the other way around. Pathological gambling and kleptomania were the most prevalent conditions followed by compulsive buying, compulsive sexual behavior and internet addiction. BA was also associated with other mood disorders, anxiety disorders and substance use disorder. BD-BA comorbidity was related with more severe course of illness. Studies on treatment strategies for BD-BA comorbidity are rather limited; only one randomized controlled trial that fulfilled inclusion criteria was identified. Methodological heterogeneity in terms of design and results among studies was found. BD-BA commonly co-occurs although there is a need for rigorous studies. Routine screening and adequate assessment may be helpful in BD patients to identify individuals at risk for BA and to effectively manage the complex consequences associated with BA-BD comorbidity.
Collapse
Affiliation(s)
- C Varo
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A Murru
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - E Salagre
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Jiménez
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - L Montejo
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A F Carvalho
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - B Stubbs
- Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, Box SE5 8AF, United Kingdom
| | - I Grande
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A Martínez-Arán
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Vieta
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - M Reinares
- Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| |
Collapse
|
32
|
Bonnín CM, Martínez-Arán A, Reinares M, Valentí M, Solé B, Jiménez E, Montejo L, Vieta E, Rosa AR. Thresholds for severity, remission and recovery using the functioning assessment short test (FAST) in bipolar disorder. J Affect Disord 2018; 240:57-62. [PMID: 30053684 DOI: 10.1016/j.jad.2018.07.045] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 06/07/2018] [Accepted: 07/15/2018] [Indexed: 01/18/2023]
Abstract
BACKGROUND Despite its importance, no distinction between none, mild, moderate and severe functional impairment is available. Categorization of functional impairment could help to better assess randomized controlled trials (RCT) and to study the correlates of functional impairment according to severity. The Functional Assessment Short Test (FAST) is one of the most widely used measures of functional impairment in bipolar disorder and related conditions, but to date no severity cut-offs have been determined for their use in clinical research and practice. METHOD FAST and Global Functioning Assessment (GAF) ratings from 65 euthymic outpatients with bipolar disorder at the Hospital Clínic in Barcelona were analyzed. A linear regression was computed using the FAST as the independent variable and the GAF as the dependent variable. Cut-offs scores for the FAST were estimated taking into account the GAF scores as a reference. RESULTS Linear regression analysis with GAF scores as the dependent variable yielded the following equation: GAF score = 91,41-1,031 * FAST score. The cut-off scores for the FAST scale derived from this equation were as follows: scores from 0 to 11 included patients with no impairment. Scores from 12 to 20, represented the category of mild impairment. Moderate impairment comprised scores from 21 to 40. Finally, scores above 40 represent severe functional impairment. Further, the 4 × 4 cross-tabulation resulted in a significant association of FAST and GAF severity gradation: (Chi2 = 95,095; df = 9; p < 0,001). Chance-corrected agreement was κ = 0,65 (p < 0.001). LIMITATIONS In the absence of a better alternative, the GAF, a broad clinical measure, was used as gold standard for establishing FAST categories according to severity. CONCLUSION The categorization of functional impairment in four categories based on empirical data shows that 12, 20 and 40 represent clinically meaningful cut-offs of the FAST for mild, moderate, and severe functional impairment and for functional recovery, remission, and improvement. The proposed categories are suitable to be further implemented in clinical studies and RCTs.
Collapse
Affiliation(s)
- C M Bonnín
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - A Martínez-Arán
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - M Reinares
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Valentí
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Jiménez
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - L Montejo
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Vieta
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - A R Rosa
- Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Pharmacology, Postgraduate Program in Pharmacology and Therapeutics and Postgraduate Program in Psychiatry and Behavior Science, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| |
Collapse
|
33
|
Arnaez J, Garcia-Alix A, Calvo S, Lubián-López S, Diez-Delgado J, Benavente I, Tofé I, Jerez A, Hurtado J, Ceballos J, Millán M, Esquivel M, Ruiz C, Baca M, Tapia E, Losada M, Torres E, Pavón A, Jiménez P, Jiménez F, Ventura M, Rite S, González T, Arias R, Balliu P, Lloreda-García J, Alcaráz J, Tapia C, de la Morena A, Centelles I, Güemes I, Estañ J, Alberola A, Aparici S, López R, Beceiro J, García B, Martínez L, González E, Arruza L, Blanco M, Moral M, Arias B, Mar F, Jiménez J, Romera G, Cuñarro A, Muñóz C, Cabañas F, Valverde E, Montero R, Tejedor J, Santana C, Reyes B, Romero S, Orizaola A, Baquero M, Hernández D, Pantoja A, Vega C, Castañón L, Gutiérrez E, Benito M, Caserío S, Arca G, García M, López-Vílchez M, Castells L, Domingo M, Coroleu W, Boix H, Porta R, García-Alix A, Martínez-Nadal S, Jiménez E, Sole E, Albújar M, Fernández E, Barrio A, Piñán E, Avila-Alvarez A, Vázquez M, Balado N, Crespo P, Couce M, Concheiro-Guisán A, Esteban I, Lavilla A, Alzina V, Aguirre A, Loureiro B, Echániz I, Euba MEA. Care of the newborn with perinatal asphyxia candidate for therapeutic hypothermia during the first six hours of life in Spain. Anales de Pediatría (English Edition) 2018. [DOI: 10.1016/j.anpede.2017.11.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
|
34
|
Sanchez-Moreno J, Bonnin CM, González-Pinto A, Amann BL, Solé B, Balanzá-Martinez V, Arango C, Jiménez E, Tabarés-Seisdedos R, Garcia-Portilla MP, Ibáñez A, Crespo JM, Ayuso-Mateos JL, Martinez-Aran A, Torrent C, Vieta E. Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. Acta Psychiatr Scand 2018; 138:145-154. [PMID: 29726004 DOI: 10.1111/acps.12894] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/10/2018] [Indexed: 02/06/2023]
Abstract
OBJECTIVE The current investigation aimed at studying the sociodemographic, clinical, and neuropsychological variables related to functional outcome in a sample of euthymic patients with bipolar disorder(BD) presenting moderate-severe levels of functional impairment. METHODS Two-hundred and thirty-nine participants with BD disorders and with Functioning Assessment Short Test(FAST) scores equal or above 18 were administered a clinical and diagnostic interview, and the administration of mood measure scales and a comprehensive neuropsychological battery. Analyses involved preliminary Pearson bivariate correlations to identify sociodemographic and clinical variables associated with the FAST total score. Regarding neuropsychological variables, a principal component analysis (PCA) was performed to group the variables in orthogonal factors. Finally, a hierarchical multiple regression was run. RESULTS The best fitting model for the variables associated with functioning was a linear combination of gender, age, estimated IQ, Hamilton Depression Rating Scale (HAM-D), number of previous manic episodes, Factor 1 and Factor 2 extracted from the PCA. The model, including all these previous variables, explained up to 29.4% of the observed variance. CONCLUSIONS Male gender, older age, lower premorbid IQ, subdepressive symptoms, higher number of manic episodes, and lower performance in verbal memory, working memory, verbal fluency, and processing speed were associated with lower functioning in patients with BD.
Collapse
Affiliation(s)
- J Sanchez-Moreno
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - C M Bonnin
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - A González-Pinto
- Álava University Hospital, CIBERSAM, BIOARABA, University of the Basque Country, Vitoria, Spain
| | - B L Amann
- Centre Fòrum Research Unit, Institute of Neuropsychiatry and Addictions, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.,Department of Psychiatry, Parc de Salut Mar, CIBERSAM, Autonomous University of Barcelona, Barcelona, Spain
| | - B Solé
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - V Balanzá-Martinez
- Department of Medicine, CIBERSAM, INCLIVA, University of Valencia, Valencia, Spain.,Department of Psychiatry, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - C Arango
- Child and Adolescent Psychiatry Department, Hospital Universitario Gregorio Marañón School of Medicine, IiSGM, CIBERSAM, Universidad Complutense, Madrid, Spain
| | - E Jiménez
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - R Tabarés-Seisdedos
- Department of Medicine, CIBERSAM, INCLIVA, University of Valencia, Valencia, Spain
| | - M P Garcia-Portilla
- Department of Psychiatry, School of Medicine, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Servicio de Salud del Principado de Asturias (SESPA), University of Oviedo, Oviedo, Spain
| | - A Ibáñez
- Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERSAM, Universidad de Alcalá, Madrid, Spain
| | - J M Crespo
- Department of Psychiatry, Bellvitge Biomedical Research Institute (IDIBELL), CIBERSAM, University Hospital of Bellvitge, Barcelona, Spain
| | - J L Ayuso-Mateos
- Department of Psychiatry, IIS-IP, CIBERSAM, Universidad Autónoma de Madrid, Madrid, Spain
| | - A Martinez-Aran
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - C Torrent
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | - E Vieta
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain
| | | |
Collapse
|
35
|
Jiménez E, Solé B, Arias B, Mitjans M, Varo C, Reinares M, Bonnín CM, Salagre E, Ruíz V, Torres I, Tomioka Y, Sáiz PA, García-Portilla MP, Burón P, Bobes J, Martínez-Arán A, Torrent C, Vieta E, Benabarre A. Characterizing decision-making and reward processing in bipolar disorder: A cluster analysis. Eur Neuropsychopharmacol 2018; 28:863-874. [PMID: 29807846 DOI: 10.1016/j.euroneuro.2018.04.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Revised: 03/22/2018] [Accepted: 04/30/2018] [Indexed: 11/25/2022]
Abstract
The presence of abnormalities in emotional decision-making and reward processing among bipolar patients (BP) has been well rehearsed. These disturbances are not limited to acute phases and are common even during remission. In recent years, the existence of discrete cognitive profiles in this psychiatric population has been replicated. However, emotional decision making and reward processing domains have barely been studied. Therefore, our aim was to explore the existence of different profiles on the aforementioned cognitive dimensions in BP. The sample consisted of 126 euthymic BP. Main sociodemographic, clinical, functioning, and neurocognitive variables were gathered. A hierarchical-clustering technique was used to identify discrete neurocognitive profiles based on the performance in the Iowa Gambling Task. Afterward, the resulting clusters were compared using ANOVA or Chi-squared Test, as appropriate. Evidence for the existence of three different profiles was provided. Cluster 1 was mainly characterized by poor decision ability. Cluster 2 presented the lowest sensitivity to punishment. Finally, cluster 3 presented the best decision-making ability and the highest levels of punishment sensitivity. Comparison between the three clusters indicated that cluster 2 was the most functionally impaired group. The poorest outcomes in attention, executive function domains, and social cognition were also observed within the same group. In conclusion, similarly to that observed in "cold cognitive" domains, our results suggest the existence of three discrete cognitive profiles concerning emotional decision making and reward processing. Amongst all the indexes explored, low punishment sensitivity emerge as a potential correlate of poorer cognitive and functional outcomes in bipolar disorder.
Collapse
Affiliation(s)
- E Jiménez
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Solé
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - B Arias
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, CIBERSAM, Barcelona, Spain
| | - M Mitjans
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, CIBERSAM, Barcelona, Spain; Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany
| | - C Varo
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - M Reinares
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C M Bonnín
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - E Salagre
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - V Ruíz
- Institut Clinic de Neurociencies, Hospital Clinic, Barcelona, Catalonia, Spain
| | - I Torres
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - Y Tomioka
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - P A Sáiz
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - M P García-Portilla
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - P Burón
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain
| | - J Bobes
- Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - A Martínez-Arán
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - C Torrent
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - E Vieta
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
| | - A Benabarre
- Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| |
Collapse
|
36
|
Solé B, Bonnin CM, Jiménez E, Torrent C, Torres I, Varo C, Valls E, Montejo L, Gómez-Ocaña C, Tomioka Y, Vieta E, Martinez-Aran A, Reinares M. Heterogeneity of functional outcomes in patients with bipolar disorder: a cluster-analytic approach. Acta Psychiatr Scand 2018; 137:516-527. [PMID: 29508379 DOI: 10.1111/acps.12871] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/09/2018] [Indexed: 01/21/2023]
Abstract
OBJECTIVE The aim was to examine the heterogeneity of psychosocial outcomes in euthymic bipolar disorder (BD) patients and analyse the potential influence of distinct variables on functioning. METHOD Using a hierarchical cluster exploratory analysis, 143 euthymic patients with diagnosis of BD were grouped according to their functional performance based on domains scores of the Functioning Assessment Short Test (FAST). The resulting groups were compared on sociodemographic, clinical and neurocognitive variables to find factors associated with each functional cluster. RESULTS Patients were grouped in three functional profiles: patients with good functioning in all the FAST areas, patients with an intermediate profile showing great difficulties in the occupational domain and milder difficulties in most of the rest domains, and a third group with serious difficulties in almost all functional areas. Both functionally impaired groups were characterized by higher subthreshold symptoms (depressive and manic) and higher unemployment rates. The most functionally impaired group also showed lower scores on some measures of processing speed. CONCLUSION Two of three functional profiles showed some kind of impairment which was associated with subsyndromal symptoms and cognitive performance. These patterns should be taken into consideration to develop more individualized interventions to restore, or improve, psychosocial outcomes.
Collapse
Affiliation(s)
- B Solé
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - C M Bonnin
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - E Jiménez
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - C Torrent
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - I Torres
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - C Varo
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - E Valls
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - L Montejo
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - C Gómez-Ocaña
- Institute of Neuroscience, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Y Tomioka
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - E Vieta
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - A Martinez-Aran
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - M Reinares
- Barcelona Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain
| |
Collapse
|
37
|
De Andrés J, Manzano S, García C, Rodríguez JM, Espinosa-Martos I, Jiménez E. Modulatory effect of three probiotic strains on infants' gut microbial composition and immunological parameters on a placebo-controlled, double-blind, randomised study. Benef Microbes 2018; 9:573-584. [PMID: 29726280 DOI: 10.3920/bm2017.0132] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The gut microbiota plays a crucial role in gastrointestinal health. Current use of probiotics is aimed at modulating the bacterial gut composition to alleviate specific diseases. The safety and tolerance of three probiotic strains (Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052 and Bifidobacterium bifidum R0071) has recently been described. The objective of the present study was to analyse the microbiological composition and immunological parameters of faecal samples obtained from healthy infants from 3 to 12 months of age after receiving either one of the three probiotic strains or placebo for 8 weeks. 16S ribosomal RNA gene sequencing and multiplexing technology was used for analysis. Faecal sample analysis showed that the most abundant genus in all four groups of infants pre- and post-intervention was Bifidobacterium, representing approximately 50% of the sequences. After the intervention period the microbial composition of faecal samples in the probiotic groups did not display notable changes. In contrast, a decrease in different Bifidobacterium species, such as B. bifidum and Bifidobacterium breve and an increase in Bacteroides, Blautia, Clostridium, Coprococcus and Faecalibacterium genera was observed in the placebo group. The analysis of a wide range of immune factors in faecal samples suggests a modulatory effect by these three probiotic strains during the intervention period. The anti-inflammatory ratio interleukin (IL)-10/IL-12 increased at the end of the intervention period in the B. infantis R0033 group while the TNF-α/IL-10 ratio increased in the L. helveticus R0052 group. The decrease of the IL-10/IL-12 ratio together with the increase of the tumour necrosis factor alpha (TNF-α)/IL-10 ratio demonstrated a pro-inflammatory profile in the placebo group. In conclusion, the species profile of the microbiome observed in all three probiotic groups resembled that of a younger infant, similar to an unweaned infant, when compared to the placebo group which may also be related with an anti-inflammatory effect.
Collapse
Affiliation(s)
- J De Andrés
- 1 Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040Madrid, Spain
| | - S Manzano
- 1 Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040Madrid, Spain.,2 Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - C García
- 2 Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - J M Rodríguez
- 1 Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040Madrid, Spain
| | - I Espinosa-Martos
- 2 Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - E Jiménez
- 1 Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040Madrid, Spain.,2 Probisearch S.L.U., C/Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| |
Collapse
|
38
|
Ocaña AJ, Blázquez S, Ballesteros B, Canosa A, Antiñolo M, Albaladejo J, Jiménez E. Gas phase kinetics of the OH + CH 3CH 2OH reaction at temperatures of the interstellar medium (T = 21-107 K). Phys Chem Chem Phys 2018; 20:5865-5873. [PMID: 29417104 PMCID: PMC5975950 DOI: 10.1039/c7cp07868d] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Ethanol, CH3CH2OH, has been unveiled in the interstellar medium (ISM) by radioastronomy and it is thought to be released into the gas phase after the warm-up phase of the grain surface, where it is formed. Once in the gas phase, it can be destroyed by different reactions with atomic and radical species, such as hydroxyl (OH) radicals. The knowledge of the rate coefficients of all these processes at temperatures of the ISM is essential in the accurate interpretation of the observed abundances. In this work, we have determined the rate coefficient for the reaction of OH with CH3CH2OH (k(T)) between 21 and 107 K by employing the pulsed and continuous CRESU (Cinétique de Réaction en Ecoulement Supersonique Uniforme, which means Reaction Kinetics in a Uniform Supersonic Flow) technique. The pulsed laser photolysis technique was used for generating OH radicals, whose time evolution was monitored by laser induced fluorescence. An increase of approximately 4 times was observed for k(21 K) with respect to k(107 K). With respect to k(300 K), the OH-reactivity at 21 K is enhanced by two orders of magnitude. The obtained T-expression in the investigated temperature range is k(T) = (2.1 ± 0.5) × 10-11 (T/300 K)-(0.71±0.10) cm3 molecule-1 s-1. In addition, the pressure dependence of k(T) has been investigated at several temperatures between 21 K and 90 K. No pressure dependence of k(T) was observed in the investigated ranges. This may imply that this reaction is purely bimolecular or that the high-pressure limit is reached at the lowest total pressure experimentally accessible in our system. From our results, k(T) at usual IS temperatures (∼10-100 K) is confirmed to be very fast. Typical rate coefficients can be considered to range within about 4 × 10-11 cm3 molecule-1 s-1 at 100 K and around 1 × 10-10 cm3 molecule-1 s-1 at 20 K. The extrapolation of k at the lowest temperatures of the dense molecular clouds of ISM is also discussed in this paper.
Collapse
Affiliation(s)
- A J Ocaña
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha, Avda. Camilo José Cela, 1B, 13071 Ciudad Real, Spain.
| | | | | | | | | | | | | |
Collapse
|
39
|
Shannon RJ, Gómez Martín JC, Caravan RL, Blitz MA, Plane JMC, Heard DE, Antiñolo M, Agúndez M, Jiménez E, Ballesteros B, Canosa A, El Dib G, Albaladejo J, Cernicharo J. Comment on “Methanol dimer formation drastically enhances hydrogen abstraction from methanol by OH at low temperature” by W. Siebrand, Z. Smedarchina, E. Martínez-Núñez and A. Fernández-Ramos, Phys. Chem. Chem. Phys., 2016, 18, 22712. Phys Chem Chem Phys 2018; 20:8349-8354. [DOI: 10.1039/c7cp04561a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A low fraction of methanol dimers is formed in the Laval nozzle used for kinetics studies at very low temperatures.
Collapse
|
40
|
Tanarro I, Alemán B, de Vicente P, Gallego JD, Pardo JR, Santoro G, Lauwaet K, Tercero F, Díaz-Pulido A, Moreno E, Agúndez M, Goicoechea JR, Sobrado JM, López JA, Martínez L, Doménech JL, Herrero VJ, Hernández JM, Peláez RJ, López-Pérez JA, Gómez-González J, Alonso JL, Jiménez E, Teyssier D, Makasheva K, Castellanos M, Joblin C, Martín-Gago JA, Cernicharo J. Using radio astronomical receivers for molecular spectroscopic characterization in astrochemical laboratory simulations: A proof of concept. Astron Astrophys 2018; 609:A15. [PMID: 29277841 PMCID: PMC5741178 DOI: 10.1051/0004-6361/201730969] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We present a proof of concept on the coupling of radio astronomical receivers and spectrometers with chemical reactors and the performances of the resulting setup for spectroscopy and chemical simulations in laboratory astrophysics. Several experiments including cold plasma generation and UV photochemistry were performed in a 40 cm long gas cell placed in the beam path of the Aries 40 m radio telescope receivers operating in the 41-49 GHz frequency range interfaced with fast Fourier transform spectrometers providing 2 GHz bandwidth and 38 kHz resolution. The impedance matching of the cell windows has been studied using different materials. The choice of the material and its thickness was critical to obtain a sensitivity identical to that of standard radio astronomical observations. Spectroscopic signals arising from very low partial pressures of CH3OH, CH3CH2OH, HCOOH, OCS, CS, SO2 (<10-3 mbar) were detected in a few seconds. Fast data acquisition was achieved allowing for kinetic measurements in fragmentation experiments using electron impact or UV irradiation. Time evolution of chemical reactions involving OCS, O2 and CS2 was also observed demonstrating that reactive species, such as CS, can be maintained with high abundance in the gas phase during these experiments.
Collapse
Affiliation(s)
- I Tanarro
- IEM. CSIC. Instituto de Estructura de la Materia. Molecular Physics Department. C/Serrano 123, 28006 Madrid, Spain
| | - B Alemán
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - P de Vicente
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - J D Gallego
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - J R Pardo
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - G Santoro
- ICMM. CSIC. Materials Science Factory. Structure of Nanoscopic Systems Group, ESISNA. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - K Lauwaet
- ICMM. CSIC. Materials Science Factory. Structure of Nanoscopic Systems Group, ESISNA. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - F Tercero
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - A Díaz-Pulido
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - E Moreno
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - M Agúndez
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - J R Goicoechea
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - J M Sobrado
- Centro de Astrobiología, (CAB-CSIC/INTA). Carretera Torrejón a Ajalvir km 4, Torrejón de Ardoz 28850 (Madrid), Spain
| | - J A López
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - L Martínez
- ICMM. CSIC. Materials Science Factory. Structure of Nanoscopic Systems Group, ESISNA. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - J L Doménech
- IEM. CSIC. Instituto de Estructura de la Materia. Molecular Physics Department. C/Serrano 123, 28006 Madrid, Spain
| | - V J Herrero
- IEM. CSIC. Instituto de Estructura de la Materia. Molecular Physics Department. C/Serrano 123, 28006 Madrid, Spain
| | - J M Hernández
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - R J Peláez
- IEM. CSIC. Instituto de Estructura de la Materia. Molecular Physics Department. C/Serrano 123, 28006 Madrid, Spain
| | - J A López-Pérez
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - J Gómez-González
- Centro Nacional de Tecnologías Radioastronómicas y Aplicaciones Geoespaciales (CNTRAG), Observatorio de Yebes (IGN), Spain
| | - J L Alonso
- Grupo de Espectroscopía Molecular (GEM), Edificio Quifima, Área de Química-Física, Laboratorios de Espectroscopía y Bioespectroscopía, Parque Científico UVa, Unidad Asociada CSIC, Universidad de Valladolid, 47011 Valladolid, Spain
| | - E Jiménez
- Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Avda. Camilo José Cela 1B, E-13071, Ciudad Real, Spain
| | - D Teyssier
- European Space Astronomy Centre, ESA, PO Box 78, 28691 Villanueva de la Cañada, Madrid, Spain
| | - K Makasheva
- LAPLACE (Laboratoire Plasma et Conversion dÉnergie); Université de Toulouse; CNRS, UPS, INPT; 118 route de Narbonne, F-31062 Toulouse cedex 9, France
| | - M Castellanos
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - C Joblin
- Université de Toulouse, UPS-OMS, IRAP, 31000 Toulouse, France
- CNRS, IRAP, 9 Av. Colonel Roche, BP 44346, 31028 Toulouse Cedex 4, France
| | - J A Martín-Gago
- ICMM. CSIC. Materials Science Factory. Structure of Nanoscopic Systems Group, ESISNA. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| | - J Cernicharo
- ICMM. CSIC. Molecular Astrophysics Group. C/ Sor Juana Inés de la Cruz 3. Cantoblanco, 28049 Madrid. Spain
| |
Collapse
|
41
|
Natera-de Benito D, Töpf A, Vilchez JJ, González-Quereda L, Domínguez-Carral J, Díaz-Manera J, Ortez C, Bestué M, Gallano P, Dusl M, Abicht A, Müller JS, Senderek J, García-Ribes A, Muelas N, Evangelista T, Azuma Y, McMacken G, Paipa Merchan A, Rodríguez Cruz PM, Camacho A, Jiménez E, Miranda-Herrero MC, Santana-Artiles A, García-Campos O, Dominguez-Rubio R, Olivé M, Colomer J, Beeson D, Lochmüller H, Nascimento A. Molecular characterization of congenital myasthenic syndromes in Spain. Neuromuscul Disord 2017; 27:1087-1098. [PMID: 29054425 DOI: 10.1016/j.nmd.2017.08.003] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 08/08/2017] [Accepted: 08/10/2017] [Indexed: 10/19/2022]
Abstract
Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders, all of which impair neuromuscular transmission. Epidemiological data and frequencies of gene mutations are scarce in the literature. Here we describe the molecular genetic and clinical findings of sixty-four genetically confirmed CMS patients from Spain. Thirty-six mutations in the CHRNE, RAPSN, COLQ, GFPT1, DOK7, CHRNG, GMPPB, CHAT, CHRNA1, and CHRNB1 genes were identified in our patients, with five of them not reported so far. These data provide an overview on the relative frequencies of the different CMS subtypes in a large Spanish population. CHRNE mutations are the most common cause of CMS in Spain, accounting for 27% of the total. The second most common are RAPSN mutations. We found a higher rate of GFPT1 mutations in comparison with other populations. Remarkably, several founder mutations made a large contribution to CMS in Spain: RAPSN c.264C > A (p.Asn88Lys), CHRNE c.130insG (Glu44Glyfs*3), CHRNE c.1353insG (p.Asn542Gluf*4), DOK7 c.1124_1127dup (p.Ala378Serfs*30), and particularly frequent in Spain in comparison with other populations, COLQ c.1289A > C (p.Tyr430Ser). Furthermore, we describe phenotypes and distinguishing clinical signs associated with the various CMS genes which might help to identify specific CMS subtypes to guide diagnosis and management.
Collapse
Affiliation(s)
- D Natera-de Benito
- Department of Neuromuscular Diseases, Hospital Sant Joan de Déu, CIBERER U703, Barcelona, Spain.
| | - A Töpf
- John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
| | - J J Vilchez
- Department of Neurology, Hospital Universitari La Fe, Universitat de Valencia, CIBERER U763, Valencia, Spain
| | - L González-Quereda
- Department of Genetics, Hospital de la Santa Creu i Sant Pau and CIBERER U705, Barcelona, Spain
| | - J Domínguez-Carral
- Department of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - J Díaz-Manera
- Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and Centre for Biomedical Network Research on Rare Diseases (CIBERER), Barcelona, Spain
| | - C Ortez
- Department of Neuromuscular Diseases, Hospital Sant Joan de Déu, CIBERER U703, Barcelona, Spain
| | - M Bestué
- Department of Neurology, Hospital General San Jorge, Huesca, Spain
| | - P Gallano
- Department of Genetics, Hospital de la Santa Creu i Sant Pau and CIBERER U705, Barcelona, Spain
| | - M Dusl
- Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, 80336 Munich, Germany
| | - A Abicht
- Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, 80336 Munich, Germany; Medical Genetics Center, Munich, Germany
| | - J S Müller
- Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - J Senderek
- Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, 80336 Munich, Germany
| | - A García-Ribes
- Department of Pediatrics, Hospital Universitario Cruces, Bilbao, Spain
| | - N Muelas
- Department of Neurology, Hospital Universitari La Fe, Universitat de Valencia, CIBERER U763, Valencia, Spain
| | - T Evangelista
- John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
| | - Y Azuma
- John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
| | - G McMacken
- John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
| | - A Paipa Merchan
- Neuropathology Unit, Department of Pathology and Neuromuscular Unit, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain
| | - P M Rodríguez Cruz
- Neurosciences Group, Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
| | - A Camacho
- Department of Pediatric Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E Jiménez
- Department of Pediatrics, Hospital Universitario Rey Juan Carlos, Madrid, Spain
| | - M C Miranda-Herrero
- Department of Neuropediatrics, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - A Santana-Artiles
- Department of Neuropediatrics, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
| | - O García-Campos
- Department of Neuropediatrics, Hospital Virgen de la Salud, Toledo, Spain
| | - R Dominguez-Rubio
- Neuropathology Unit, Department of Pathology and Neuromuscular Unit, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain
| | - M Olivé
- Neuropathology Unit, Department of Pathology and Neuromuscular Unit, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain
| | - J Colomer
- Department of Neuromuscular Diseases, Hospital Sant Joan de Déu, CIBERER U703, Barcelona, Spain
| | - D Beeson
- Neurosciences Group, Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
| | - H Lochmüller
- John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
| | - A Nascimento
- Department of Neuromuscular Diseases, Hospital Sant Joan de Déu, CIBERER U703, Barcelona, Spain
| |
Collapse
|
42
|
Ocaña AJ, Jiménez E, Ballesteros B, Canosa A, Antiñolo M, Albaladejo J, Agúndez M, Cernicharo J, Zanchet A, del Mazo P, Roncero O, Aguado A. Is the gas-phase OH+H 2CO reaction a source of HCO in interstellar cold dark clouds? A kinetic, dynamic and modelling study. Astrophys J 2017; 850:28. [PMID: 29880977 PMCID: PMC5988043 DOI: 10.3847/1538-4357/aa93d9] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Chemical kinetics of neutral-neutral gas-phase reactions at ultralow temperatures is a fascinating research subject with important implications on the chemistry of complex organic molecules in the interstellar medium (T∼10-100K). Scarce kinetic information is currently available for this kind of reactions at T<200 K. In this work we use the CRESU (Cinétique de Réaction en Ecoulement Supersonique Uniforme, which means Reaction Kinetics in a Uniform Supersonic Flow) technique to measure for the first time the rate coefficients (k) of the gas-phase OH+H2CO reaction between 22 and 107 K. k values greatly increase from 2.1×10-11 cm3 s-1 at 107 K to 1.2×10-10 cm3 s-1 at 22 K. This is also confirmed by quasi-classical trajectories (QCT) at collision energies down to 0.1 meV performed using a new full dimension and ab initio potential energy surface, recently developed which generates highly accurate potential and includes long range dipole-dipole interactions. QCT calculations indicate that at low temperatures HCO is the exclusive product for the OH+H2CO reaction. In order to revisit the chemistry of HCO in cold dense clouds, k is reasonably extrapolated from the experimental results at 10K (2.6×10-10 cm3 s-1). The modeled abundances of HCO are in agreement with the observations in cold dark clouds for an evolving time of 105-106 yrs. The different sources of production of HCO are presented and the uncertainties in the chemical networks discussed. This reaction can be expected to be a competitive process in the chemistry of prestellar cores. The present reaction is shown to account for a few percent of the total HCO production rate. Extensions to photodissociation regions and diffuse clouds environments are also commented.
Collapse
Affiliation(s)
- A. J. Ocaña
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
| | - E. Jiménez
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - B. Ballesteros
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - A. Canosa
- Institut de Physique de Rennes, UMR 6251 CNRS-Université de Rennes 1. Campus de Beaulieu, Bât 11C, 263 Av. Général Leclerc, 35042, Rennes, France
| | - M. Antiñolo
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - J. Albaladejo
- Departamento de Química Física. Facultad de Ciencias y Tecnologías Químicas. Universidad de Castilla-La Mancha. Avda. Camilo José Cela 1B. 13071, Ciudad Real, Spain
- Instituto de Investigación en Combustión y Contaminación Atmosférica. Universidad de Castilla-La Mancha. Camino de Moledores s/n. 13071, Ciudad Real, Spain
| | - M. Agúndez
- Instituto de Ciencia de Materiales de Madrid. Consejo Superior de Investigaciones Científicas. C/ Sor Juana Inés de la Cruz, 3. 28049, Cantoblanco, Madrid, Spain
| | - J. Cernicharo
- Instituto de Ciencia de Materiales de Madrid. Consejo Superior de Investigaciones Científicas. C/ Sor Juana Inés de la Cruz, 3. 28049, Cantoblanco, Madrid, Spain
| | - A. Zanchet
- Instituto de Física Fundamental, CSIC, C/ Serrano, 123, 28006 Madrid, Spain
| | - P. del Mazo
- Instituto de Física Fundamental, CSIC, C/ Serrano, 123, 28006 Madrid, Spain
| | - O. Roncero
- Instituto de Física Fundamental, CSIC, C/ Serrano, 123, 28006 Madrid, Spain
| | - A. Aguado
- Departamento de Química Física Aplicada (UAM), Unidad Asociada IFF-CSIC, Facultad de Ciencias C-XIV, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| |
Collapse
|
43
|
Manzano S, De Andrés J, Castro I, Rodríguez J, Jiménez E, Espinosa-Martos I. Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial. Benef Microbes 2017; 8:569-578. [DOI: 10.3920/bm2017.0009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Some strains of species belonging to the genera Bifidobacterium and Lactobacillus are used in order to maintain health. Although these organisms have a long record of safe use, it is important to assess their safety and tolerance in potentially vulnerable populations, such as infants. The objective of this study was to evaluate the safety and tolerance of three probiotic strains (Bifidobacterium longum subsp. infantis R0033, Bifidobacterium bifidum R0071 and Lactobacillus helveticus R0052) in healthy infants aged 3 to 12 months. A multi-centre randomized, double-blind, placebo-controlled intervention study with 221 healthy full-term infants was conducted. Infants received either a placebo or one of the 3 probiotic strains (3×109 cfu) daily during an 8 week intervention period. Growth (weight, height and head circumference), adverse events (AEs)/serious adverse events (SAEs), concentrations of D-lactic acid in urine samples, characteristics of the stools and use of medication were collected for safety evaluation. All 4 groups were homogeneous with respect to age, gender, feeding type, ethnicity, height, weight and head circumference at the start of the study. The results showed that changes in growth (weight, height and head circumference) were equivalent in all 4 groups. No SAEs were reported. Total number of AEs recorded was equivalent in all groups. Thus, the use of B. infantis R0033, L. helveticus R0052 and B. bifidum R0071 in infancy is safe, and well tolerated.
Collapse
Affiliation(s)
- S. Manzano
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
- Probisearch S.L.U., C/ Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - J. De Andrés
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
| | - I. Castro
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
| | - J.M. Rodríguez
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
- Probisearch S.L.U., C/ Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - E. Jiménez
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
- Probisearch S.L.U., C/ Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| | - I. Espinosa-Martos
- Dpto. Nutrición, Bromatología y Tecnología de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de hierro s/n, 28040 Madrid, Spain
- Probisearch S.L.U., C/ Santiago Grisolía, 2, 28760 Tres Cantos, Spain
| |
Collapse
|
44
|
Antiñolo M, Ocaña AJ, Aranguren JP, Lane SI, Albaladejo J, Jiménez E. Atmospheric degradation of 2-chloroethyl vinyl ether, allyl ether and allyl ethyl ether: Kinetics with OH radicals and UV photochemistry. Chemosphere 2017; 181:232-240. [PMID: 28441613 DOI: 10.1016/j.chemosphere.2017.04.053] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 04/11/2017] [Accepted: 04/12/2017] [Indexed: 06/07/2023]
Abstract
Unsaturated ethers are oxygenated volatile organic compounds (OVOCs) emitted by anthropogenic sources. Potential removal processes in the troposphere are initiated by hydroxyl (OH) radicals and photochemistry. In this work, we report for the first time the rate coefficients of the gas-phase reaction with OH radicals (kOH) of 2-chloroethyl vinyl ether (2ClEVE), allyl ether (AE), and allyl ethyl ether (AEE) as a function of temperature in the 263-358 K range, measured by the pulsed laser photolysis-laser induced fluorescence technique. No pressure dependence of kOH was observed in the 50-500 Torr range in He as bath gas, while a slightly negative T-dependence was observed. The temperature dependent expressions for the rate coefficients determined in this work are: The estimated atmospheric lifetimes (τOH) assuming kOH at 288 K were 3, 2, and 4 h for 2ClEVE, AE and AEE, respectively. The kinetic results are discussed in terms of the chemical structure of the unsaturated ethers by comparison with similar compounds. We also report ultraviolet (UV) and infrared (IR) absorption cross sections (σλ and σ(ν˜), respectively). We estimate the photolysis rate coefficients in the solar UV actinic region to be less than 10-7 s-1, implying that these compounds are not removed from the atmosphere by this process. In addition, from σ(ν˜) and τOH, the global warming potential of each unsaturated ether was calculated to be almost zero. A discussion on the atmospheric implications of the titled compounds is presented.
Collapse
Affiliation(s)
- M Antiñolo
- Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Avda. Camilo José Cela, 1B, Ciudad Real, 13071, Spain; Instituto de Investigación en Combustión y Contaminación Atmosférica, Universidad de Castilla-La Mancha, Camino de Moledores s/n, Ciudad Real, 13071, Spain
| | - A J Ocaña
- Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Avda. Camilo José Cela, 1B, Ciudad Real, 13071, Spain
| | - J P Aranguren
- Instituto de Investigaciones en Fisicoquímica de Córdoba, Departamento de Fisicoquímica, Facultad de Ciencias Químicas, Centro Láser de Ciencias Moleculares, Universidad Nacional de Córdoba, Ciudad Universitaria, Pabellón Argentina, Ala 1, Córdoba, 5000, Argentina
| | - S I Lane
- Instituto de Investigaciones en Fisicoquímica de Córdoba, Departamento de Fisicoquímica, Facultad de Ciencias Químicas, Centro Láser de Ciencias Moleculares, Universidad Nacional de Córdoba, Ciudad Universitaria, Pabellón Argentina, Ala 1, Córdoba, 5000, Argentina
| | - J Albaladejo
- Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Avda. Camilo José Cela, 1B, Ciudad Real, 13071, Spain; Instituto de Investigación en Combustión y Contaminación Atmosférica, Universidad de Castilla-La Mancha, Camino de Moledores s/n, Ciudad Real, 13071, Spain
| | - E Jiménez
- Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Avda. Camilo José Cela, 1B, Ciudad Real, 13071, Spain; Instituto de Investigación en Combustión y Contaminación Atmosférica, Universidad de Castilla-La Mancha, Camino de Moledores s/n, Ciudad Real, 13071, Spain.
| |
Collapse
|
45
|
Moñino P, Aguado D, Barat R, Jiménez E, Giménez JB, Seco A, Ferrer J. A new strategy to maximize organic matter valorization in municipalities: Combination of urban wastewater with kitchen food waste and its treatment with AnMBR technology. Waste Manag 2017; 62:274-289. [PMID: 28237363 DOI: 10.1016/j.wasman.2017.02.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 01/25/2017] [Accepted: 02/04/2017] [Indexed: 06/06/2023]
Abstract
The aim of this study was to evaluate the feasibility of treating the kitchen food waste (FW) jointly with urban wastewater (WW) in a wastewater treatment plant (WWTP) by anaerobic membrane technology (AnMBR). The experience was carried out in six different periods in an AnMBR pilot-plant for a total of 536days, varying the SRT, HRT and the food waste penetration factor (PF) of food waste disposers. The results showed increased methane production of up to 190% at 70days SRT, 24h HRT and 80% PF, compared with WW treatment only. FW COD and biodegradability were higher than in WW, so that the incorporation of FW into the treatment increases the organic load and the methane production and reduces sludge production (0.142 vs 0.614kgVSSkgremovedCOD-1, at 70days SRT, 24h HRT and 80% PF, as compared to WW treatment only).
Collapse
Affiliation(s)
- P Moñino
- CALAGUA - Unidad Mixta UV-UPV, Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient - IIAMA, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain.
| | - D Aguado
- CALAGUA - Unidad Mixta UV-UPV, Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient - IIAMA, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain.
| | - R Barat
- CALAGUA - Unidad Mixta UV-UPV, Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient - IIAMA, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain.
| | - E Jiménez
- FCC Aqualia S.A., Avda. del Camino de Santiago, 40, Edificio 3, 4ª planta, 28050 Madrid, Spain.
| | - J B Giménez
- CALAGUA - Unidad Mixta UV-UPV, Departament d'Enginyeria Química, Universitat de València, Avinguda de la Universitat s/n, 46100 Burjassot, València, Spain.
| | - A Seco
- CALAGUA - Unidad Mixta UV-UPV, Departament d'Enginyeria Química, Universitat de València, Avinguda de la Universitat s/n, 46100 Burjassot, València, Spain.
| | - J Ferrer
- CALAGUA - Unidad Mixta UV-UPV, Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient - IIAMA, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain.
| |
Collapse
|
46
|
Raimondi N, Vial MR, Calleja J, Quintero A, Cortés Alban A, Celis E, Pacheco C, Ugarte S, Añón JM, Hernández G, Vidal E, Chiappero G, Ríos F, Castilleja F, Matos A, Rodriguez E, Antoniazzi P, Teles JM, Dueñas C, Sinclair J, Martínez L, Von der Osten I, Vergara J, Jiménez E, Arroyo M, Rodriguez C, Torres J, Fernandez-Bussy S, Nates JL. Evidence-based guides in tracheostomy use in critical patients. Med Intensiva 2017; 41:94-115. [PMID: 28188061 DOI: 10.1016/j.medin.2016.12.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 11/20/2016] [Accepted: 12/02/2016] [Indexed: 10/20/2022]
Abstract
OBJECTIVES Provide evidence based guidelines for tracheostomy in critically ill adult patients and identify areas needing further research. METHODS A task force composed of representatives of 10 member countries of the Pan-American and Iberic Federation of Societies of Critical and Intensive Therapy Medicine and of the Latin American Critical Care Trial Investigators Network developed recommendations based on the Grading of Recommendations Assessment, Development and Evaluation system. RESULTS The group identified 23 relevant questions among 87 issues that were initially identified. In the initial search, 333 relevant publications were identified of which 226 publications were chosen. The task force generated a total of 19 recommendations: 10 positive (1B=3, 2C=3, 2D=4) and 9 negative (1B=8, 2C=1). A recommendation was not possible in six questions. CONCLUSION Percutaneous techniques are associated with a lower risk of infections compared to surgical tracheostomy. Early tracheostomy only seems to reduce the duration of ventilator use but not the incidence of pneumonia, the length of stay, or the long-term mortality rate. The evidence does not support the use of routine bronchoscopy guidance or laryngeal masks during the procedure. Finally, proper prior training is as important or even a more significant factor in reducing complications than the technique used.
Collapse
Affiliation(s)
- N Raimondi
- Hospital Municipal Juan A. Fernández, Universidad de Buenos Aires, Argentina
| | - M R Vial
- MD Anderson Cancer Center, The University of Texas, Texas, United States; Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile
| | - J Calleja
- Hospital Zambrano Hellion, Instituto Tecnológico de Monterrey, Monterrey, Nuevo León, México
| | - A Quintero
- Instituto Medico de Alta Tecnología, Universidad del Sinú, Montería, Colombia
| | - A Cortés Alban
- Clínica Mayor de Temuco, Hospital de Nueva Imperial, Universidad Mayor de Temuco, Temuco, Chile
| | - E Celis
- Hospital Universitario Fundación Santa Fé de Bogotá, Bogotá, Colombia
| | - C Pacheco
- Hospital Universitario de Caracas, Caracas, Venezuela
| | - S Ugarte
- Hospital del Salvador, Clínica Indisa, Universidad de Chile, Santiago, Chile
| | - J M Añón
- Hospital Universitario la Paz -Carlos III. IdiPaz, Madrid, España
| | - G Hernández
- Complejo Hospitalario de Toledo, Toledo, España
| | - E Vidal
- Hospital Ángeles Lomas, Hospital Español de México, Ciudad de México, México
| | - G Chiappero
- Hospital Juan A. Fernández CABA, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - F Ríos
- Hospital Nacional Alejandro Posadas, Sanatorio Las Lomas, San Isidro, Buenos Aires, Argentina
| | - F Castilleja
- Hospital Zambrano Hellion, Instituto Tecnológico de Monterrey, Monterrey, Nuevo León, México
| | - A Matos
- Complejo Hospitalario Caja de Seguro Social, Panamá
| | - E Rodriguez
- Complejo Hospitalario Caja de Seguro Social, Panamá
| | - P Antoniazzi
- Hospital Santa Casa, Ribeirao Preto, Sao Paulo, Brazil
| | - J M Teles
- Hospital de Urgências de Goiânia, Goiás, Brazil
| | - C Dueñas
- Gestión Salud, Santa Cruz de Bocagrande, Universidad de Cartagena, Cartagena, Colombia
| | - J Sinclair
- Hospital Punta Pacífica, Johns Hopkins Medicine, Universidad de Panamá, Ciudad de Panamá, Panamá
| | - L Martínez
- Hospital Policlínica Metropolitana, Caracas, Venezuela
| | - I Von der Osten
- Hospital Central "Miguel Pérez Carreño" IVSS, Universidad Central de Venezuela, Caracas, Venezuela
| | - J Vergara
- Hospital Luis Vernaza, Universidad de Especialidades Espíritu Santo "UEES", Guayaquil, Ecuador
| | - E Jiménez
- Baylor Scott & White Health, Texas A&M Health Science Center College of Medicine, Temple, Texas, Estados Unidos
| | - M Arroyo
- Clínica Santa Sofía, Caracas, Venezuela
| | - C Rodriguez
- Instituto Medico de Alta Tecnología, Universidad del Sinú, Montería, Colombia
| | - J Torres
- Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile
| | - S Fernandez-Bussy
- Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile; Division of Pulmonary, Critical Care & Sleep Medicine, University of Florida, Gainesville, Florida, Estados Unidos
| | - J L Nates
- MD Anderson Cancer Center, The University of Texas, Texas, United States.
| |
Collapse
|
47
|
Sánchez-Morla EM, Mateo J, Aparicio A, García-Jiménez MÁ, Jiménez E, Santos JL. Prepulse inhibition in euthymic bipolar disorder patients in comparison with control subjects. Acta Psychiatr Scand 2016; 134:350-9. [PMID: 27294331 DOI: 10.1111/acps.12604] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/23/2016] [Indexed: 01/17/2023]
Abstract
OBJECTIVE Deficient prepulse inhibition (PPI) of the startle response, indicating sensorimotor gating deficits, has been reported in schizophrenia and other neuropsychiatric disorders. This study aimed to assess sensorimotor gating deficits in patients with euthymic bipolar. Furthermore, we analysed the relationships between PPI and clinical and cognitive measures. METHOD Prepulse inhibition was measured in 64 patients with euthymic bipolar and in 64 control subjects matched for age, gender, education level and smoking status. Clinical characteristics and level of functioning were assessed in all participants using Hamilton Depression Rating Scale (HDRS), Young Mania Rating Scale (YMRS) and Functioning Assessment Short Test (FAST). Cognition was evaluated using the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) and the Stroop test as an additional measure of executive function. RESULTS Compared with controls, patients with bipolar disorder exhibited PPI deficits at 60- and 120-millisecond prepulse-pulse intervals. Among patients with bipolar disorder, PPI was correlated with the social cognition domain of the MCCB. PPI was not significantly correlated with other clinical, functional and neurocognitive variables in either group. CONCLUSIONS Our data suggest that PPI deficit is a neurobiological marker in euthymic bipolar disorder, which is associated with social cognition but not with other clinical, functional or cognitive measures.
Collapse
Affiliation(s)
- E M Sánchez-Morla
- Department of Psychiatry, Hospital Virgen de la Luz, Cuenca, Spain. .,Department of Psychiatry, Hospital Universitario de Guadalajara, Guadalajara, Spain. .,Department of Medicine, School of Medicine, University of Alcalá, Madrid, Spain.
| | - J Mateo
- Innovation in Bioengineering Research Group, University of Castilla La Mancha, Cuenca, Spain
| | - A Aparicio
- Department of Psychiatry, Hospital Virgen de la Luz, Cuenca, Spain
| | | | - E Jiménez
- Department of Psychiatry, Hospital Virgen de la Luz, Cuenca, Spain
| | - J L Santos
- Department of Psychiatry, Hospital Virgen de la Luz, Cuenca, Spain
| |
Collapse
|
48
|
Moñino P, Jiménez E, Barat R, Aguado D, Seco A, Ferrer J. Potential use of the organic fraction of municipal solid waste in anaerobic co-digestion with wastewater in submerged anaerobic membrane technology. Waste Manag 2016; 56:158-165. [PMID: 27436236 DOI: 10.1016/j.wasman.2016.07.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Revised: 07/12/2016] [Accepted: 07/13/2016] [Indexed: 06/06/2023]
Abstract
Food waste was characterized for its potential use as substrate for anaerobic co-digestion in a submerged anaerobic membrane bioreactor pilot plant that treats urban wastewater (WW). 90% of the particles had sizes under 0.5mm after grinding the food waste in a commercial food waste disposer. COD, nitrogen and phosphorus concentrations were 100, 2 and 20 times higher in food waste than their average concentrations in WW, but the relative flow contribution of both streams made COD the only pollutant that increased significantly when both substrates were mixed. As sulphate concentration in food waste was in the same range as WW, co-digestion of both substrates would increase the COD/SO4-S ratio and favour methanogenic activity in anaerobic treatments. The average methane potential of the food waste was 421±15mLCH4g(-1)VS, achieving 73% anaerobic biodegradability. The anaerobic co-digestion of food waste with WW is expected to increase methane production 2.9-fold. The settleable solids tests and the particle size distribution analyses confirmed that both treatment lines of a conventional WWTP (water and sludge lines) would be clearly impacted by the incorporation of food waste into its influent. Anaerobic processes are therefore preferred over their aerobic counterparts due to their ability to valorise the high COD content to produce biogas (a renewable energy) instead of increasing the energetic costs associated with the aeration process for aerobic COD oxidation.
Collapse
Affiliation(s)
- P Moñino
- Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient, IIAMA, Universitat Politècnica de València, Camí de Vera, s/n, 46022 València, Spain.
| | - E Jiménez
- Departament d'Enginyeria Química, Escola Tècnica Superior d'Enginyeria, Universitat de València, Doctor Moliner 50, 46100 Burjassot, València, Spain.
| | - R Barat
- Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient, IIAMA, Universitat Politècnica de València, Camí de Vera, s/n, 46022 València, Spain.
| | - D Aguado
- Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient, IIAMA, Universitat Politècnica de València, Camí de Vera, s/n, 46022 València, Spain.
| | - A Seco
- Departament d'Enginyeria Química, Escola Tècnica Superior d'Enginyeria, Universitat de València, Doctor Moliner 50, 46100 Burjassot, València, Spain.
| | - J Ferrer
- Institut Universitari d'Investigació d'Enginyeria de l'Aigua i Medi Ambient, IIAMA, Universitat Politècnica de València, Camí de Vera, s/n, 46022 València, Spain.
| |
Collapse
|
49
|
Cardona AF, Rojas L, Wills B, Behaine J, Jiménez E, Hakim F, Useche N, Bermúdez S, Arrieta O, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, González D, Rodríguez J, Ortiz LD, Cifuentes H, Balaña C. Genotyping low-grade gliomas among Hispanics. Neurooncol Pract 2016; 3:164-172. [PMID: 31386063 DOI: 10.1093/nop/npv061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Indexed: 11/12/2022] Open
Abstract
Background Low-grade gliomas (LGGs) are classified by the World Health Organization as astrocytoma (DA), oligodendroglioma (OD), and mixed oligoastrocytoma (OA). TP53 mutation and 1p19q codeletion are the most-commonly documented molecular abnormalities. Isocitrate dehydrogenase (IDH) 1/2 mutations are frequent in LGGs; however, IDH-negative gliomas can also occur. Recent research suggests that ATRX plays a significant role in gliomagenesis. Methods We investigated p53 and Olig2 protein expression, and MGMT promoter methylation, 1p19q codeletion, IDH, and ATRX status in 63 Colombian patients with LGG. The overall survival (OS) rate was estimated and compared according to genotype. Results The most common histology was DA, followed by OD and OA. IDH1/2 mutations were found in 57.1% and MGMT+ (positive status of MGMT promoter methylation methyl-guanyl-methyl-transferase gene) in 65.1% of patients, while overexpression of p53 and Olig2 was present in 30.2% and 44.4%, respectively, and 1p19q codeletion in 34.9% of the patients. Overexpression of ATRX was analyzed in 25 patients, 16% tested positive and were also mutations in isocitrate dehydrogenase and negative 1p19q-codelition. The median follow-up was 15.8 months (95% CI, 7.6-42.0) and OS was 39.2 months (95% CI, 1.3-114). OS was positively and significantly affected by MGMT+, 1p19q codeletion, surgical intervention extent, and number of lobes involved. Multivariate analysis confirmed that MGMT methylation status and 1p19q codeletion affected OS. Conclusions This is the first study evaluating the molecular profile of Hispanic LGG patients. Findings confirmed the prognostic relevance of MGMT methylation and 1p19q codeletion, but do not support IDH1/2 mutation as a relevant marker. The latter may be explained by sample size and selection bias. ATRX alterations were limited to patients with DA and were mutations in isocitrate dehydrogenase and negative 1p19q-codelition.
Collapse
Affiliation(s)
- Andrés Felipe Cardona
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Leonardo Rojas
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Beatriz Wills
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - José Behaine
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Enrique Jiménez
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Fernando Hakim
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Nicolás Useche
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Sonia Bermúdez
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Oscar Arrieta
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Juan Armando Mejía
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Juan Fernando Ramón
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Hernán Carranza
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Carlos Vargas
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Jorge Otero
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Diego González
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - July Rodríguez
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - León Darío Ortiz
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Hernando Cifuentes
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| | - Carmen Balaña
- Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia (A.F.C., H.C., C.V., J.O.); Foundation for Clinical and Applied Cancer Research- FICMAC, Bogotá, Colombia (A.F.C., B.W., H.C., C.V., J.O., J.R.); Institute of Neuroscience, Universidad El Bosque, Bogotá, Colombia (A.F.C., J.B., E.J., F.H., N.U., S.B., D.G.); Internal Medicicine Depatment, Universidad del Bosque-Fundación Santa Fe de Bogotá, Bogotá, Colombia (B.W.); Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia (L.R.); Neurosurgery Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia (F.H., J.A.M., J.F.R., E.J.); Radiology Department, Division of Neuro-radiology, Fundación Santa Fe de Bogotá, Bogotá, Colombia (N.U., S.B.); Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), México City, México (O.A.); Clinical Oncology Department, Division of Neuro-Oncology, Clínica de Las Américas, Medellín, Colombia (L.D.O.); Neurosurgery Department, Clínica del Country, Bogotá, Colombia (H.C.); Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain (C.B.)
| |
Collapse
|
50
|
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, Wood T, Luo F, Stevenson R, Polimanti R, Gelernter J, Lin X, Lim IY, Wu Y, Teh AL, Chen L, Aris IM, Soh SE, Tint MT, MacIsaac JL, Yap F, Kwek K, Saw SM, Kobor MS, Meaney MJ, Godfrey KM, Chong YS, Holbrook JD, Lee YS, Gluckman PD, Karnani N, Kapoor A, Lee D, Chakravarti A, Maercker C, Graf F, Boutros M, Stamoulis G, Santoni F, Makrythanasis P, Letourneau A, Guipponi M, Panousis N, Garieri M, Ribaux P, Falconnet E, Borel C, Antonarakis SE, Kumar S, Curran J, Blangero J, Chatterjee S, Kapoor A, Akiyama J, Auer D, Berrios C, Pennacchio L, Chakravarti A, Donti TR, Cappuccio G, Miller M, Atwal P, Kennedy A, Cardon A, Bacino C, Emrick L, Hertecant J, Baumer F, Porter B, Bainbridge M, Bonnen P, Graham B, Sutton R, Sun Q, Elsea S, Hu Z, Wang P, Zhu Y, Zhao J, Xiong M, Bennett DA, Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D’Ippolito E, Baroni S, Kaczkowski B, Tanaka Y, Kawaji H, Sandelin A, Andersson R, Itoh M, Lassmann T, Hayashizaki Y, Carninci P, Forrest ARR, Semple CA, Rosenthal EA, Shirts B, Amendola L, Gallego C, Horike-Pyne M, Burt A, Robertson P, Beyers P, Nefcy C, Veenstra D, Hisama F, Bennett R, Dorschner M, Nickerson D, Smith J, Patterson K, Crosslin D, Nassir R, Zubair N, Harrison T, Peters U, Jarvik G, Menghi F, Inaki K, Woo X, Kumar P, Grzeda K, Malhotra A, Kim H, Ucar D, Shreckengast P, Karuturi K, Keck J, Chuang J, Liu ET, Ji B, Tyler A, Ananda G, Carter G, Nikbakht H, Montagne M, Zeinieh M, Harutyunyan A, Mcconechy M, Jabado N, Lavigne P, Majewski J, Goldstein JB, Overman M, Varadhachary G, Shroff R, Wolff R, Javle M, Futreal A, Fogelman D, Bravo L, Fajardo W, Gomez H, Castaneda C, Rolfo C, Pinto JA, Akdemir KC, Chin L, Futreal A, Patterson S, Statz C, Mockus S, Nikolaev SN, Bonilla XI, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy V, Sharpe H, McKee T, Letourneau A, Ribaux P, Popadin K, Basset-Seguin N, Chaabene RB, Santoni F, Andrianova M, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage F, Antonarakis S, Likhitrattanapisal S, Lincoln S, Kurian A, Desmond A, Yang S, Kobayashi Y, Ford J, Ellisen L, Peters TL, Alvarez KR, Hollingsworth EF, Lopez-Terrada DH, Hastie A, Dzakula Z, Pang AW, Lam ET, Anantharaman T, Saghbini M, Cao H, Gonzaga-Jauregui C, Ma L, King A, Rosenzweig EB, Krishnan U, Reid JG, Overton JD, Dewey F, Chung WK, Small K, DeLuca A, Cremers F, Lewis RA, Puech V, Bakall B, Silva-Garcia R, Rohrschneider K, Leys M, Shaya FS, Stone E, Sobreira NL, Schiettecatte F, Ling H, Pugh E, Witmer D, Hetrick K, Zhang P, Doheny K, Valle D, Hamosh A, Jhangiani SN, Akdemir ZC, Bainbridge MN, Charng W, Wiszniewski W, Gambin T, Karaca E, Bayram Y, Eldomery MK, Posey J, Doddapaneni H, Hu J, Sutton VR, Muzny DM, Boerwinkle EA, Valle D, Lupski JR, Gibbs RA, Shekar S, Salerno W, English A, Mangubat A, Bruestle J, Thorogood A, Knoppers BM, Takahashi H, Nitta KR, Kozhuharova A, Suzuki AM, Sharma H, Cotella D, Santoro C, Zucchelli S, Gustincich S, Carninci P, Mulvihill JJ, Baynam G, Gahl W, Groft SC, Kosaki K, Lasko P, Melegh B, Taruscio D, Ghosh R, Plon S, Scherer S, Qin X, Sanghvi R, Walker K, Chiang T, Muzny D, Wang L, Black J, Boerwinkle E, Weinshilboum R, Gibbs R, Karpinets T, Calderone T, Wani K, Yu X, Creasy C, Haymaker C, Forget M, Nanda V, Roszik J, Wargo J, Haydu L, Song X, Lazar A, Gershenwald J, Davies M, Bernatchez C, Zhang J, Futreal A, Woodman S, Chesler EJ, Reynolds T, Bubier JA, Phillips C, Langston MA, Baker EJ, Xiong M, Ma L, Lin N, Amos C, Lin N, Wang P, Zhu Y, Zhao J, Calhoun V, Xiong M, Dobretsberger O, Egger M, Leimgruber F, Sadedin S, Oshlack A, Antonio VAA, Ono N, Ahmed Z, Bolisetty M, Zeeshan S, Anguiano E, Ucar D, Sarkar A, Nandineni MR, Zeng C, Shao J, Cao H, Hastie A, Pang AW, Lam ET, Liang T, Pham K, Saghbini M, Dzakula Z, Chee-Wei Y, Dongsheng L, Lai-Ping W, Lian D, Hee ROT, Yunus Y, Aghakhanian F, Mokhtar SS, Lok-Yung CV, Bhak J, Phipps M, Shuhua X, Yik-Ying T, Kumar V, Boon-Peng H, Campbell I, Young MA, James P, Rain M, Mohammad G, Kukreti R, Pasha Q, Akilzhanova AR, Guelly C, Abilova Z, Rakhimova S, Akhmetova A, Kairov U, Trajanoski S, Zhumadilov Z, Bekbossynova M, Schumacher C, Sandhu S, Harkins T, Makarov V, Doddapaneni H, Glenn R, Momin Z, Dilrukshi B, Chao H, Meng Q, Gudenkauf B, Kshitij R, Jayaseelan J, Nessner C, Lee S, Blankenberg K, Lewis L, Hu J, Han Y, Dinh H, Jireh S, Walker K, Boerwinkle E, Muzny D, Gibbs R, Hu J, Walker K, Buhay C, Liu X, Wang Q, Sanghvi R, Doddapaneni H, Ding Y, Veeraraghavan N, Yang Y, Boerwinkle E, Beaudet AL, Eng CM, Muzny DM, Gibbs RA, Worley KCC, Liu Y, Hughes DST, Murali SC, Harris RA, English AC, Qin X, Hampton OA, Larsen P, Beck C, Han Y, Wang M, Doddapaneni H, Kovar CL, Salerno WJ, Yoder A, Richards S, Rogers J, Lupski JR, Muzny DM, Gibbs RA, Meng Q, Bainbridge M, Wang M, Doddapaneni H, Han Y, Muzny D, Gibbs R, Harris RA, Raveenedran M, Xue C, Dahdouli M, Cox L, Fan G, Ferguson B, Hovarth J, Johnson Z, Kanthaswamy S, Kubisch M, Platt M, Smith D, Vallender E, Wiseman R, Liu X, Below J, Muzny D, Gibbs R, Yu F, Rogers J, Lin J, Zhang Y, Ouyang Z, Moore A, Wang Z, Hofmann J, Purdue M, Stolzenberg-Solomon R, Weinstein S, Albanes D, Liu CS, Cheng WL, Lin TT, Lan Q, Rothman N, Berndt S, Chen ES, Bahrami H, Khoshzaban A, Keshal SH, Bahrami H, Khoshzaban A, Keshal SH, Alharbi KKR, Zhalbinova M, Akilzhanova A, Rakhimova S, Bekbosynova M, Myrzakhmetova S, Matar M, Mili N, Molinari R, Ma Y, Guerrier S, Elhawary N, Tayeb M, Bogari N, Qotb N, McClymont SA, Hook PW, Goff LA, McCallion A, Kong Y, Charette JR, Hicks WL, Naggert JK, Zhao L, Nishina PM, Edrees BM, Athar M, Al-Allaf FA, Taher MM, Khan W, Bouazzaoui A, Harbi NA, Safar R, Al-Edressi H, Anazi A, Altayeb N, Ahmed MA, Alansary K, Abduljaleel Z, Kratz A, Beguin P, Poulain S, Kaneko M, Takahiko C, Matsunaga A, Kato S, Suzuki AM, Bertin N, Lassmann T, Vigot R, Carninci P, Plessy C, Launey T, Graur D, Lee D, Kapoor A, Chakravarti A, Friis-Nielsen J, Izarzugaza JM, Brunak S, Chakraborty A, Basak J, Mukhopadhyay A, Soibam BS, Das D, Biswas N, Das S, Sarkar S, Maitra A, Panda C, Majumder P, Morsy H, Gaballah A, Samir M, Shamseya M, Mahrous H, Ghazal A, Arafat W, Hashish M, Gruber JJ, Jaeger N, Snyder M, Patel K, Bowman S, Davis T, Kraushaar D, Emerman A, Russello S, Henig N, Hendrickson C, Zhang K, Rodriguez-Dorantes M, Cruz-Hernandez CD, Garcia-Tobilla CDP, Solorzano-Rosales S, Jäger N, Chen J, Haile R, Hitchins M, Brooks JD, Snyder M, Jiménez-Morales S, Ramírez M, Nuñez J, Bekker V, Leal Y, Jiménez E, Medina A, Hidalgo A, Mejía J, Halytskiy V, Naggert J, Collin GB, DeMauro K, Hanusek R, Nishina PM, Belhassa K, Belhassan K, Bouguenouch L, Samri I, Sayel H, moufid FZ, El Bouchikhi I, Trhanint S, Hamdaoui H, Elotmani I, Khtiri I, Kettani O, Quibibo L, Ahagoud M, Abbassi M, Ouldim K, Marusin AV, Kornetov AN, Swarovskaya M, Vagaiceva K, Stepanov V, De La Paz EMC, Sy R, Nevado J, Reganit P, Santos L, Magno JD, Punzalan FE, Ona D, Llanes E, Santos-Cortes RL, Tiongco R, Aherrera J, Abrahan L, Pagauitan-Alan P, Morelli KH, Domire JS, Pyne N, Harper S, Burgess R, Zhalbinova M, Akilzhanova A, Rakhimova S, Bekbosynova M, Myrzakhmetova S, Gari MA, Dallol A, Alsehli H, Gari A, Gari M, Abuzenadah A, Thomas M, Sukhai M, Garg S, Misyura M, Zhang T, Schuh A, Stockley T, Kamel-Reid S, Sherry S, Xiao C, Slotta D, Rodarmer K, Feolo M, Kimelman M, Godynskiy G, O’Sullivan C, Yaschenko E, Xiao C, Yaschenko E, Sherry S, Rangel-Escareño C, Rueda-Zarate H, Tayubi IA, Mohammed R, Ahmed I, Ahmed T, Seth S, Amin S, Song X, Mao X, Sun H, Verhaak RG, Futreal A, Zhang J, Whiite SJ, Chiang T, English A, Farek J, Kahn Z, Salerno W, Veeraraghavan N, Boerwinkle E, Gibbs R, Kasukawa T, Lizio M, Harshbarger J, Hisashi S, Severin J, Imad A, Sahin S, Freeman TC, Baillie K, Sandelin A, Carninci P, Forrest ARR, Kawaji H, Salerno W, English A, Shekar SN, Mangubat A, Bruestle J, Boerwinkle E, Gibbs RA, Salem AH, Ali M, Ibrahim A, Ibrahim M, Barrera HA, Garza L, Torres JA, Barajas V, Ulloa-Aguirre A, Kershenobich D, Mortaji S, Guizar P, Loera E, Moreno K, De León A, Monsiváis D, Gómez J, Cardiel R, Fernandez-Lopez JC, Bonifaz-Peña V, Rangel-Escareño C, Hidalgo-Miranda A, Contreras AV, Polfus L, Wang X, Philip V, Carter G, Abuzenadah AA, Gari M, Turki R, Dallol A, Uyar A, Kaygun A, Zaman S, Marquez E, George J, Ucar D, Hendrickson CL, Emerman A, Kraushaar D, Bowman S, Henig N, Davis T, Russello S, Patel K, Starr DB, Baird M, Kirkpatrick B, Sheets K, Nitsche R, Prieto-Lafuente L, Landrum M, Lee J, Rubinstein W, Maglott D, Thavanati PKR, de Dios AE, Hernandez REN, Aldrate MEA, Mejia MRR, Kanala KRR, Abduljaleel Z, Khan W, Al-Allaf FA, Athar M, Taher MM, Shahzad N, Bouazzaoui A, Huber E, Dan A, Al-Allaf FA, Herr W, Sprotte G, Köstler J, Hiergeist A, Gessner A, Andreesen R, Holler E, Al-Allaf F, Alashwal A, Abduljaleel Z, Taher M, Bouazzaoui A, Abalkhail H, Al-Allaf A, Bamardadh R, Athar M, Filiptsova O, Kobets M, Kobets Y, Burlaka I, Timoshyna I, Filiptsova O, Kobets MN, Kobets Y, Burlaka I, Timoshyna I, Filiptsova O, Kobets MN, Kobets Y, Burlaka I, Timoshyna I, Al-allaf FA, Mohiuddin MT, Zainularifeen A, Mohammed A, Abalkhail H, Owaidah T, Bouazzaoui A. Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016. Hum Genomics 2016; 10 Suppl 1:12. [PMID: 27294413 PMCID: PMC4896275 DOI: 10.1186/s40246-016-0063-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
O1 The metabolomics approach to autism: identification of biomarkers for early detection of autism spectrum disorder A. K. Srivastava, Y. Wang, R. Huang, C. Skinner, T. Thompson, L. Pollard, T. Wood, F. Luo, R. Stevenson O2 Phenome-wide association study for smoking- and drinking-associated genes in 26,394 American women with African, Asian, European, and Hispanic descents R. Polimanti, J. Gelernter O3 Effects of prenatal environment, genotype and DNA methylation on birth weight and subsequent postnatal outcomes: findings from GUSTO, an Asian birth cohort X. Lin, I. Y. Lim, Y. Wu, A. L. Teh, L. Chen, I. M. Aris, S. E. Soh, M. T. Tint, J. L. MacIsaac, F. Yap, K. Kwek, S. M. Saw, M. S. Kobor, M. J. Meaney, K. M. Godfrey, Y. S. Chong, J. D. Holbrook, Y. S. Lee, P. D. Gluckman, N. Karnani, GUSTO study group O4 High-throughput identification of specific qt interval modulating enhancers at the SCN5A locus A. Kapoor, D. Lee, A. Chakravarti O5 Identification of extracellular matrix components inducing cancer cell migration in the supernatant of cultivated mesenchymal stem cells C. Maercker, F. Graf, M. Boutros O6 Single cell allele specific expression (ASE) IN T21 and common trisomies: a novel approach to understand DOWN syndrome and other aneuploidies G. Stamoulis, F. Santoni, P. Makrythanasis, A. Letourneau, M. Guipponi, N. Panousis, M. Garieri, P. Ribaux, E. Falconnet, C. Borel, S. E. Antonarakis O7 Role of microRNA in LCL to IPSC reprogramming S. Kumar, J. Curran, J. Blangero O8 Multiple enhancer variants disrupt gene regulatory network in Hirschsprung disease S. Chatterjee, A. Kapoor, J. Akiyama, D. Auer, C. Berrios, L. Pennacchio, A. Chakravarti O9 Metabolomic profiling for the diagnosis of neurometabolic disorders T. R. Donti, G. Cappuccio, M. Miller, P. Atwal, A. Kennedy, A. Cardon, C. Bacino, L. Emrick, J. Hertecant, F. Baumer, B. Porter, M. Bainbridge, P. Bonnen, B. Graham, R. Sutton, Q. Sun, S. Elsea O10 A novel causal methylation network approach to Alzheimer’s disease Z. Hu, P. Wang, Y. Zhu, J. Zhao, M. Xiong, David A Bennett O11 A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway A. Hidalgo-Miranda, S. Romero-Cordoba, S. Rodriguez-Cuevas, R. Rebollar-Vega, E. Tagliabue, M. Iorio, E. D’Ippolito, S. Baroni O12 Transcriptome analysis identifies genes, enhancer RNAs and repetitive elements that are recurrently deregulated across multiple cancer types B. Kaczkowski, Y. Tanaka, H. Kawaji, A. Sandelin, R. Andersson, M. Itoh, T. Lassmann, the FANTOM5 consortium, Y. Hayashizaki, P. Carninci, A. R. R. Forrest O13 Elevated mutation and widespread loss of constraint at regulatory and architectural binding sites across 11 tumour types C. A. Semple O14 Exome sequencing provides evidence of pathogenicity for genes implicated in colorectal cancer E. A. Rosenthal, B. Shirts, L. Amendola, C. Gallego, M. Horike-Pyne, A. Burt, P. Robertson, P. Beyers, C. Nefcy, D. Veenstra, F. Hisama, R. Bennett, M. Dorschner, D. Nickerson, J. Smith, K. Patterson, D. Crosslin, R. Nassir, N. Zubair, T. Harrison, U. Peters, G. Jarvik, NHLBI GO Exome Sequencing Project O15 The tandem duplicator phenotype as a distinct genomic configuration in cancer F. Menghi, K. Inaki, X. Woo, P. Kumar, K. Grzeda, A. Malhotra, H. Kim, D. Ucar, P. Shreckengast, K. Karuturi, J. Keck, J. Chuang, E. T. Liu O16 Modeling genetic interactions associated with molecular subtypes of breast cancer B. Ji, A. Tyler, G. Ananda, G. Carter O17 Recurrent somatic mutation in the MYC associated factor X in brain tumors H. Nikbakht, M. Montagne, M. Zeinieh, A. Harutyunyan, M. Mcconechy, N. Jabado, P. Lavigne, J. Majewski O18 Predictive biomarkers to metastatic pancreatic cancer treatment J. B. Goldstein, M. Overman, G. Varadhachary, R. Shroff, R. Wolff, M. Javle, A. Futreal, D. Fogelman O19 DDIT4 gene expression as a prognostic marker in several malignant tumors L. Bravo, W. Fajardo, H. Gomez, C. Castaneda, C. Rolfo, J. A. Pinto O20 Spatial organization of the genome and genomic alterations in human cancers K. C. Akdemir, L. Chin, A. Futreal, ICGC PCAWG Structural Alterations Group O21 Landscape of targeted therapies in solid tumors S. Patterson, C. Statz, S. Mockus O22 Genomic analysis reveals novel drivers and progression pathways in skin basal cell carcinoma S. N. Nikolaev, X. I. Bonilla, L. Parmentier, B. King, F. Bezrukov, G. Kaya, V. Zoete, V. Seplyarskiy, H. Sharpe, T. McKee, A. Letourneau, P. Ribaux, K. Popadin, N. Basset-Seguin, R. Ben Chaabene, F. Santoni, M. Andrianova, M. Guipponi, M. Garieri, C. Verdan, K. Grosdemange, O. Sumara, M. Eilers, I. Aifantis, O. Michielin, F. de Sauvage, S. Antonarakis O23 Identification of differential biomarkers of hepatocellular carcinoma and cholangiocarcinoma via transcriptome microarray meta-analysis S. Likhitrattanapisal O24 Clinical validity and actionability of multigene tests for hereditary cancers in a large multi-center study S. Lincoln, A. Kurian, A. Desmond, S. Yang, Y. Kobayashi, J. Ford, L. Ellisen O25 Correlation with tumor ploidy status is essential for correct determination of genome-wide copy number changes by SNP array T. L. Peters, K. R. Alvarez, E. F. Hollingsworth, D. H. Lopez-Terrada O26 Nanochannel based next-generation mapping for interrogation of clinically relevant structural variation A. Hastie, Z. Dzakula, A. W. Pang, E. T. Lam, T. Anantharaman, M. Saghbini, H. Cao, BioNano Genomics O27 Mutation spectrum in a pulmonary arterial hypertension (PAH) cohort and identification of associated truncating mutations in TBX4 C. Gonzaga-Jauregui, L. Ma, A. King, E. Berman Rosenzweig, U. Krishnan, J. G. Reid, J. D. Overton, F. Dewey, W. K. Chung O28 NORTH CAROLINA macular dystrophy (MCDR1): mutations found affecting PRDM13 K. Small, A. DeLuca, F. Cremers, R. A. Lewis, V. Puech, B. Bakall, R. Silva-Garcia, K. Rohrschneider, M. Leys, F. S. Shaya, E. Stone O29 PhenoDB and genematcher, solving unsolved whole exome sequencing data N. L. Sobreira, F. Schiettecatte, H. Ling, E. Pugh, D. Witmer, K. Hetrick, P. Zhang, K. Doheny, D. Valle, A. Hamosh O30 Baylor-Johns Hopkins Center for Mendelian genomics: a four year review S. N. Jhangiani, Z. Coban Akdemir, M. N. Bainbridge, W. Charng, W. Wiszniewski, T. Gambin, E. Karaca, Y. Bayram, M. K. Eldomery, J. Posey, H. Doddapaneni, J. Hu, V. R. Sutton, D. M. Muzny, E. A. Boerwinkle, D. Valle, J. R. Lupski, R. A. Gibbs O31 Using read overlap assembly to accurately identify structural genetic differences in an ashkenazi jewish trio S. Shekar, W. Salerno, A. English, A. Mangubat, J. Bruestle O32 Legal interoperability: a sine qua non for international data sharing A. Thorogood, B. M. Knoppers, Global Alliance for Genomics and Health - Regulatory and Ethics Working Group O33 High throughput screening platform of competent sineups: that can enhance translation activities of therapeutic target H. Takahashi, K. R. Nitta, A. Kozhuharova, A. M. Suzuki, H. Sharma, D. Cotella, C. Santoro, S. Zucchelli, S. Gustincich, P. Carninci O34 The undiagnosed diseases network international (UDNI): clinical and laboratory research to meet patient needs J. J. Mulvihill, G. Baynam, W. Gahl, S. C. Groft, K. Kosaki, P. Lasko, B. Melegh, D. Taruscio O36 Performance of computational algorithms in pathogenicity predictions for activating variants in oncogenes versus loss of function mutations in tumor suppressor genes R. Ghosh, S. Plon O37 Identification and electronic health record incorporation of clinically actionable pharmacogenomic variants using prospective targeted sequencing S. Scherer, X. Qin, R. Sanghvi, K. Walker, T. Chiang, D. Muzny, L. Wang, J. Black, E. Boerwinkle, R. Weinshilboum, R. Gibbs O38 Melanoma reprogramming state correlates with response to CTLA-4 blockade in metastatic melanoma T. Karpinets, T. Calderone, K. Wani, X. Yu, C. Creasy, C. Haymaker, M. Forget, V. Nanda, J. Roszik, J. Wargo, L. Haydu, X. Song, A. Lazar, J. Gershenwald, M. Davies, C. Bernatchez, J. Zhang, A. Futreal, S. Woodman O39 Data-driven refinement of complex disease classification from integration of heterogeneous functional genomics data in GeneWeaver E. J. Chesler, T. Reynolds, J. A. Bubier, C. Phillips, M. A. Langston, E. J. Baker O40 A general statistic framework for genome-based disease risk prediction M. Xiong, L. Ma, N. Lin, C. Amos O41 Integrative large-scale causal network analysis of imaging and genomic data and its application in schizophrenia studies N. Lin, P. Wang, Y. Zhu, J. Zhao, V. Calhoun, M. Xiong O42 Big data and NGS data analysis: the cloud to the rescue O. Dobretsberger, M. Egger, F. Leimgruber O43 Cpipe: a convergent clinical exome pipeline specialised for targeted sequencing S. Sadedin, A. Oshlack, Melbourne Genomics Health Alliance O44 A Bayesian classification of biomedical images using feature extraction from deep neural networks implemented on lung cancer data V. A. A. Antonio, N. Ono, Clark Kendrick C. Go O45 MAV-SEQ: an interactive platform for the Management, Analysis, and Visualization of sequence data Z. Ahmed, M. Bolisetty, S. Zeeshan, E. Anguiano, D. Ucar O47 Allele specific enhancer in EPAS1 intronic regions may contribute to high altitude adaptation of Tibetans C. Zeng, J. Shao O48 Nanochannel based next-generation mapping for structural variation detection and comparison in trios and populations H. Cao, A. Hastie, A. W. Pang, E. T. Lam, T. Liang, K. Pham, M. Saghbini, Z. Dzakula O49 Archaic introgression in indigenous populations of Malaysia revealed by whole genome sequencing Y. Chee-Wei, L. Dongsheng, W. Lai-Ping, D. Lian, R. O. Twee Hee, Y. Yunus, F. Aghakhanian, S. S. Mokhtar, C. V. Lok-Yung, J. Bhak, M. Phipps, X. Shuhua, T. Yik-Ying, V. Kumar, H. Boon-Peng O50 Breast and ovarian cancer prevention: is it time for population-based mutation screening of high risk genes? I. Campbell, M.-A. Young, P. James, Lifepool O53 Comprehensive coverage from low DNA input using novel NGS library preparation methods for WGS and WGBS C. Schumacher, S. Sandhu, T. Harkins, V. Makarov O54 Methods for large scale construction of robust PCR-free libraries for sequencing on Illumina HiSeqX platform H. DoddapaneniR. Glenn, Z. Momin, B. Dilrukshi, H. Chao, Q. Meng, B. Gudenkauf, R. Kshitij, J. Jayaseelan, C. Nessner, S. Lee, K. Blankenberg, L. Lewis, J. Hu, Y. Han, H. Dinh, S. Jireh, K. Walker, E. Boerwinkle, D. Muzny, R. Gibbs O55 Rapid capture methods for clinical sequencing J. Hu, K. Walker, C. Buhay, X. Liu, Q. Wang, R. Sanghvi, H. Doddapaneni, Y. Ding, N. Veeraraghavan, Y. Yang, E. Boerwinkle, A. L. Beaudet, C. M. Eng, D. M. Muzny, R. A. Gibbs O56 A diploid personal human genome model for better genomes from diverse sequence data K. C. C. Worley, Y. Liu, D. S. T. Hughes, S. C. Murali, R. A. Harris, A. C. English, X. Qin, O. A. Hampton, P. Larsen, C. Beck, Y. Han, M. Wang, H. Doddapaneni, C. L. Kovar, W. J. Salerno, A. Yoder, S. Richards, J. Rogers, J. R. Lupski, D. M. Muzny, R. A. Gibbs O57 Development of PacBio long range capture for detection of pathogenic structural variants Q. Meng, M. Bainbridge, M. Wang, H. Doddapaneni, Y. Han, D. Muzny, R. Gibbs O58 Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans R. A. Harris, M. Raveenedran, C. Xue, M. Dahdouli, L. Cox, G. Fan, B. Ferguson, J. Hovarth, Z. Johnson, S. Kanthaswamy, M. Kubisch, M. Platt, D. Smith, E. Vallender, R. Wiseman, X. Liu, J. Below, D. Muzny, R. Gibbs, F. Yu, J. Rogers O59 Assessing RNA structure disruption induced by single-nucleotide variation J. Lin, Y. Zhang, Z. Ouyang P1 A meta-analysis of genome-wide association studies of mitochondrial dna copy number A. Moore, Z. Wang, J. Hofmann, M. Purdue, R. Stolzenberg-Solomon, S. Weinstein, D. Albanes, C.-S. Liu, W.-L. Cheng, T.-T. Lin, Q. Lan, N. Rothman, S. Berndt P2 Missense polymorphic genetic combinations underlying down syndrome susceptibility E. S. Chen P4 The evaluation of alteration of ELAM-1 expression in the endometriosis patients H. Bahrami, A. Khoshzaban, S. Heidari Keshal P5 Obesity and the incidence of apolipoprotein E polymorphisms in an assorted population from Saudi Arabia population K. K. R. Alharbi P6 Genome-associated personalized antithrombotical therapy for patients with high risk of thrombosis and bleeding M. Zhalbinova, A. Akilzhanova, S. Rakhimova, M. Bekbosynova, S. Myrzakhmetova P7 Frequency of Xmn1 polymorphism among sickle cell carrier cases in UAE population M. Matar P8 Differentiating inflammatory bowel diseases by using genomic data: dimension of the problem and network organization N. Mili, R. Molinari, Y. Ma, S. Guerrier P9 Vulnerability of genetic variants to the risk of autism among Saudi children N. Elhawary, M. Tayeb, N. Bogari, N. Qotb P10 Chromatin profiles from ex vivo purified dopaminergic neurons establish a promising model to support studies of neurological function and dysfunction S. A. McClymont, P. W. Hook, L. A. Goff, A. McCallion P11 Utilization of a sensitized chemical mutagenesis screen to identify genetic modifiers of retinal dysplasia in homozygous Nr2e3rd7 mice Y. Kong, J. R. Charette, W. L. Hicks, J. K. Naggert, L. Zhao, P. M. Nishina P12 Ion torrent next generation sequencing of recessive polycystic kidney disease in Saudi patients B. M. Edrees, M. Athar, F. A. Al-Allaf, M. M. Taher, W. Khan, A. Bouazzaoui, N. A. Harbi, R. Safar, H. Al-Edressi, A. Anazi, N. Altayeb, M. A. Ahmed, K. Alansary, Z. Abduljaleel P13 Digital expression profiling of Purkinje neurons and dendrites in different subcellular compartments A. Kratz, P. Beguin, S. Poulain, M. Kaneko, C. Takahiko, A. Matsunaga, S. Kato, A. M. Suzuki, N. Bertin, T. Lassmann, R. Vigot, P. Carninci, C. Plessy, T. Launey P14 The evolution of imperfection and imperfection of evolution: the functional and functionless fractions of the human genome D. Graur P16 Species-independent identification of known and novel recurrent genomic entities in multiple cancer patients J. Friis-Nielsen, J. M. Izarzugaza, S. Brunak P18 Discovery of active gene modules which are densely conserved across multiple cancer types reveal their prognostic power and mutually exclusive mutation patterns B. S. Soibam P19 Whole exome sequencing of dysplastic leukoplakia tissue indicates sequential accumulation of somatic mutations from oral precancer to cancer D. Das, N. Biswas, S. Das, S. Sarkar, A. Maitra, C. Panda, P. Majumder P21 Epigenetic mechanisms of carcinogensis by hereditary breast cancer genes J. J. Gruber, N. Jaeger, M. Snyder P22 RNA direct: a novel RNA enrichment strategy applied to transcripts associated with solid tumors K. Patel, S. Bowman, T. Davis, D. Kraushaar, A. Emerman, S. Russello, N. Henig, C. Hendrickson P23 RNA sequencing identifies gene mutations for neuroblastoma K. Zhang P24 Participation of SFRP1 in the modulation of TMPRSS2-ERG fusion gene in prostate cancer cell lines M. Rodriguez-Dorantes, C. D. Cruz-Hernandez, C. D. P. Garcia-Tobilla, S. Solorzano-Rosales P25 Targeted Methylation Sequencing of Prostate Cancer N. Jäger, J. Chen, R. Haile, M. Hitchins, J. D. Brooks, M. Snyder P26 Mutant TPMT alleles in children with acute lymphoblastic leukemia from México City and Yucatán, Mexico S. Jiménez-Morales, M. Ramírez, J. Nuñez, V. Bekker, Y. Leal, E. Jiménez, A. Medina, A. Hidalgo, J. Mejía P28 Genetic modifiers of Alström syndrome J. Naggert, G. B. Collin, K. DeMauro, R. Hanusek, P. M. Nishina P31 Association of genomic variants with the occurrence of angiotensin-converting-enzyme inhibitor (ACEI)-induced coughing among Filipinos E. M. Cutiongco De La Paz, R. Sy, J. Nevado, P. Reganit, L. Santos, J. D. Magno, F. E. Punzalan , D. Ona , E. Llanes, R. L. Santos-Cortes , R. Tiongco, J. Aherrera, L. Abrahan, P. Pagauitan-Alan; Philippine Cardiogenomics Study Group P32 The use of “humanized” mouse models to validate disease association of a de novo GARS variant and to test a novel gene therapy strategy for Charcot-Marie-Tooth disease type 2D K. H. Morelli, J. S. Domire, N. Pyne, S. Harper, R. Burgess P34 Molecular regulation of chondrogenic human induced pluripotent stem cells M. A. Gari, A. Dallol, H. Alsehli, A. Gari, M. Gari, A. Abuzenadah P35 Molecular profiling of hematologic malignancies: implementation of a variant assessment algorithm for next generation sequencing data analysis and clinical reporting M. Thomas, M. Sukhai, S. Garg, M. Misyura, T. Zhang, A. Schuh, T. Stockley, S. Kamel-Reid P36 Accessing genomic evidence for clinical variants at NCBI S. Sherry, C. Xiao, D. Slotta, K. Rodarmer, M. Feolo, M. Kimelman, G. Godynskiy, C. O’Sullivan, E. Yaschenko P37 NGS-SWIFT: a cloud-based variant analysis framework using control-accessed sequencing data from DBGAP/SRA C. Xiao, E. Yaschenko, S. Sherry P38 Computational assessment of drug induced hepatotoxicity through gene expression profiling C. Rangel-Escareño, H. Rueda-Zarate P40 Flowr: robust and efficient pipelines using a simple language-agnostic approach;ultraseq; fast modular pipeline for somatic variation calling using flowr S. Seth, S. Amin, X. Song, X. Mao, H. Sun, R. G. Verhaak, A. Futreal, J. Zhang P41 Applying “Big data” technologies to the rapid analysis of heterogenous large cohort data S. J. Whiite, T. Chiang, A. English, J. Farek, Z. Kahn, W. Salerno, N. Veeraraghavan, E. Boerwinkle, R. Gibbs P42 FANTOM5 web resource for the large-scale genome-wide transcription start site activity profiles of wide-range of mammalian cells T. Kasukawa, M. Lizio, J. Harshbarger, S. Hisashi, J. Severin, A. Imad, S. Sahin, T. C. Freeman, K. Baillie, A. Sandelin, P. Carninci, A. R. R. Forrest, H. Kawaji, The FANTOM Consortium P43 Rapid and scalable typing of structural variants for disease cohorts W. Salerno, A. English, S. N. Shekar, A. Mangubat, J. Bruestle, E. Boerwinkle, R. A. Gibbs P44 Polymorphism of glutathione S-transferases and sulphotransferases genes in an Arab population A. H. Salem, M. Ali, A. Ibrahim, M. Ibrahim P46 Genetic divergence of CYP3A5*3 pharmacogenomic marker for native and admixed Mexican populations J. C. Fernandez-Lopez, V. Bonifaz-Peña, C. Rangel-Escareño, A. Hidalgo-Miranda, A. V. Contreras P47 Whole exome sequence meta-analysis of 13 white blood cell, red blood cell, and platelet traits L. Polfus, CHARGE and NHLBI Exome Sequence Project Working Groups P48 Association of adipoq gene with type 2 diabetes and related phenotypes in african american men and women: The jackson heart study S. Davis, R. Xu, S. Gebeab, P Riestra, A Gaye, R. Khan, J. Wilson, A. Bidulescu P49 Common variants in casr gene are associated with serum calcium levels in koreans S. H. Jung, N. Vinayagamoorthy, S. H. Yim, Y. J. Chung P50 Inference of multiple-wave population admixture by modeling decay of linkage disequilibrium with multiple exponential functions Y. Zhou, S. Xu P51 A Bayesian framework for generalized linear mixed models in genome-wide association studies X. Wang, V. Philip, G. Carter P52 Targeted sequencing approach for the identification of the genetic causes of hereditary hearing impairment A. A. Abuzenadah, M. Gari, R. Turki, A. Dallol P53 Identification of enhancer sequences by ATAC-seq open chromatin profiling A. Uyar, A. Kaygun, S. Zaman, E. Marquez, J. George, D. Ucar P54 Direct enrichment for the rapid preparation of targeted NGS libraries C. L. Hendrickson, A. Emerman, D. Kraushaar, S. Bowman, N. Henig, T. Davis, S. Russello, K. Patel P56 Performance of the Agilent D5000 and High Sensitivity D5000 ScreenTape assays for the Agilent 4200 Tapestation System R. Nitsche, L. Prieto-Lafuente P57 ClinVar: a multi-source archive for variant interpretation M. Landrum, J. Lee, W. Rubinstein, D. Maglott P59 Association of functional variants and protein physical interactions of human MUTY homolog linked with familial adenomatous polyposis and colorectal cancer syndrome Z. Abduljaleel, W. Khan, F. A. Al-Allaf, M. Athar , M. M. Taher, N. Shahzad P60 Modification of the microbiom constitution in the gut using chicken IgY antibodies resulted in a reduction of acute graft-versus-host disease after experimental bone marrow transplantation A. Bouazzaoui, E. Huber, A. Dan, F. A. Al-Allaf, W. Herr, G. Sprotte, J. Köstler, A. Hiergeist, A. Gessner, R. Andreesen, E. Holler P61 Compound heterozygous mutation in the LDLR gene in Saudi patients suffering severe hypercholesterolemia F. Al-Allaf, A. Alashwal, Z. Abduljaleel, M. Taher, A. Bouazzaoui, H. Abalkhail, A. Al-Allaf, R. Bamardadh, M. Athar
Collapse
Affiliation(s)
| | - Y. Wang
- School of Computing, Clemson University, Clemson, SC USA
| | - R. Huang
- Biochemical Genetics Laboratory, Greenwood Genetic Center, Greenwood, SC USA
| | - C. Skinner
- JCSRI, Greenwood Genetic Center, Greenwood, SC USA
| | - T. Thompson
- Biochemical Genetics Laboratory, Greenwood Genetic Center, Greenwood, SC USA
| | - L. Pollard
- Biochemical Genetics Laboratory, Greenwood Genetic Center, Greenwood, SC USA
| | - T. Wood
- Biochemical Genetics Laboratory, Greenwood Genetic Center, Greenwood, SC USA
| | - F. Luo
- School of Computing, Clemson University, Clemson, SC USA
| | - R. Stevenson
- JCSRI, Greenwood Genetic Center, Greenwood, SC USA
| | - R. Polimanti
- Department Psychiatry, Yale Sch Med and VA CT Healthcare Center, West Haven, CT USA
| | - J. Gelernter
- Department Psychiatry, Yale Sch Med and VA CT Healthcare Center, West Haven, CT USA
- Department Genetics, Yale Sch Med and VA CT Healthcare Center, West Haven, CT USA
- Department Neurobiology, Yale Sch Med and VA CT Healthcare Center, West Haven, CT USA
| | - X. Lin
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - I. Y. Lim
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - Y. Wu
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - A. L. Teh
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - L. Chen
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - I. M. Aris
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - S. E. Soh
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - M. T. Tint
- National University of Singapore, Singapore, Singapore
| | - J. L. MacIsaac
- University of British Columbia, Vancouver, British Columbia Canada
| | - F. Yap
- KK Women’s and Children’s Hospital, Singapore, Singapore
| | - K. Kwek
- KK Women’s and Children’s Hospital, Singapore, Singapore
| | - S. M. Saw
- National University of Singapore, Singapore, Singapore
| | - M. S. Kobor
- University of British Columbia, Vancouver, British Columbia Canada
| | - M. J. Meaney
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - K. M. Godfrey
- University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Y. S. Chong
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - J. D. Holbrook
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - Y. S. Lee
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | - P. D. Gluckman
- Singapore Institute for Clinical Sciences, Singapore, Singapore
- University of Auckland, Auckland, New Zealand
| | - N. Karnani
- Singapore Institute for Clinical Sciences, Singapore, Singapore
| | | | - A. Kapoor
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - D. Lee
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - A. Chakravarti
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - C. Maercker
- Esslingen University of Applied Sciences, Esslingen, Germany
| | - F. Graf
- German Cancer Research Center, Heidelberg, Germany
| | - M. Boutros
- German Cancer Research Center, Heidelberg, Germany
| | - G. Stamoulis
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - F. Santoni
- Geneva University Hospitals-HUG, Service of Genetic Medicine, Geneva, Switzerland
| | - P. Makrythanasis
- Geneva University Hospitals-HUG, Service of Genetic Medicine, Geneva, Switzerland
| | - A. Letourneau
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - M. Guipponi
- Geneva University Hospitals-HUG, Service of Genetic Medicine, Geneva, Switzerland
| | - N. Panousis
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - M. Garieri
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - P. Ribaux
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - E. Falconnet
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - C. Borel
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - S. E. Antonarakis
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
- Geneva University Hospitals-HUG, Service of Genetic Medicine, Geneva, Switzerland
- iGE3 Institute of Genetics and Genomics of Geneva, University of Geneva Medical School, Geneva, Switzerland
| | - S. Kumar
- South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio-Grande Valley, Edinburg, TX USA
| | - J. Curran
- South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio-Grande Valley, Brownsville, TX USA
| | - J. Blangero
- South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio-Grande Valley, Brownsville, TX USA
| | - S. Chatterjee
- Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD USA
| | - A. Kapoor
- Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD USA
| | - J. Akiyama
- Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, CA USA
| | - D. Auer
- Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD USA
| | - C. Berrios
- Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD USA
| | - L. Pennacchio
- Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, CA USA
| | - A. Chakravarti
- Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD USA
| | - T. R. Donti
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - G. Cappuccio
- Department of Translational Medical Sciences, Federico II University, Naples, Italy
| | - M. Miller
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - P. Atwal
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | | | - A. Cardon
- Section of Pediatric Neurology and Neuroscience, Baylor College of Medicine, Houston, TX USA
| | - C. Bacino
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - L. Emrick
- Section of Pediatric Neurology and Neuroscience, Baylor College of Medicine, Houston, TX USA
| | | | - F. Baumer
- Stanford Medical School, Stanford, CA USA
| | - B. Porter
- Stanford Medical School, Stanford, CA USA
| | - M. Bainbridge
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - P. Bonnen
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - B. Graham
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - R. Sutton
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Q. Sun
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - S. Elsea
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Z. Hu
- School of Public Health, Houston Health Science Center, Houston, TX USA
| | - P. Wang
- University of Texas, Houston Health Science Center, Houston, TX USA
| | - Y. Zhu
- Tulane University, New Orleans, LO USA
| | - J. Zhao
- Tulane University, New Orleans, LO USA
| | - M. Xiong
- University of Texas, Houston Health Science Center, Houston, TX USA
| | - David A. Bennett
- Rush Alzheimer’s Disease Center, Rush University, Chicago, IL USA
| | - A. Hidalgo-Miranda
- Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico
| | - S. Romero-Cordoba
- Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico
| | | | - R. Rebollar-Vega
- Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico
| | | | - M. Iorio
- National Tumor Institute, Milan, Italy
| | | | - S. Baroni
- National Tumor Institute, Milan, Italy
| | - B. Kaczkowski
- Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan
| | - Y. Tanaka
- Preventive Medicine and Applied Genomics unit, RIKEN Advanced Center for Computing and Communication, Yokohama, Japan
| | - H. Kawaji
- Preventive Medicine and Applied Genomics unit, RIKEN Advanced Center for Computing and Communication, Yokohama, Japan
| | - A. Sandelin
- Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - R. Andersson
- Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - M. Itoh
- Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan
| | - T. Lassmann
- Telethon Kids Institute, The University of Western Australia, Perth, Australia
| | | | - Y. Hayashizaki
- RIKEN Preventive Medicine & Diagnosis Innovation Program, Wako, Japan
| | - P. Carninci
- Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan
| | - A. R. R. Forrest
- Harry Perkins Institute of Medical Research, The University of Western Australia, Nedlands, Australia
| | - C. A. Semple
- MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK
| | | | | | | | - C. Gallego
- University of Michigan, Ann Arbor, MI USA
| | | | - A. Burt
- Univ of Washington, Seattle, WA USA
| | | | | | - C. Nefcy
- Univ of Washington, Seattle, WA USA
| | | | | | | | | | | | - J. Smith
- Univ of Washington, Seattle, WA USA
| | | | | | - R. Nassir
- University California, Davis, CA USA
| | | | | | - U. Peters
- Univ of Washington, Seattle, WA USA
- Fred Hutch, Seattle, WA USA
| | | | | | - F. Menghi
- The Jackson Laboratory, Farmington, CT USA
| | - K. Inaki
- The Jackson Laboratory, Farmington, CT USA
| | - X. Woo
- The Jackson Laboratory, Farmington, CT USA
| | - P. Kumar
- The Jackson Laboratory, Farmington, CT USA
| | - K. Grzeda
- The Jackson Laboratory, Farmington, CT USA
| | | | - H. Kim
- The Jackson Laboratory, Farmington, CT USA
| | - D. Ucar
- The Jackson Laboratory, Farmington, CT USA
| | | | | | - J. Keck
- The Jackson Laboratory, Sacramento, CA USA
| | - J. Chuang
- The Jackson Laboratory, Farmington, CT USA
| | - E. T. Liu
- The Jackson Laboratory, Farmington, CT USA
| | - B. Ji
- The Jackson Laboratory, Bar Harbor, ME USA
| | - A. Tyler
- The Jackson Laboratory, Bar Harbor, ME USA
| | - G. Ananda
- The Jackson Laboratory, Bar Harbor, ME USA
| | - G. Carter
- The Jackson Laboratory, Bar Harbor, ME USA
| | - H. Nikbakht
- Human Genetics, McGill University, Montreal, Quebec Canada
| | - M. Montagne
- Biochemistry, Sherbrooke University, Sherbrooke, Quebec Canada
| | - M. Zeinieh
- Human Genetics, McGill University, Montreal, Quebec Canada
| | - A. Harutyunyan
- Human Genetics, McGill University, Montreal, Quebec Canada
| | - M. Mcconechy
- Human Genetics, McGill University, Montreal, Quebec Canada
| | - N. Jabado
- Pediatrics, McGill University, Montreal, Quebec Canada
| | - P. Lavigne
- Biochemistry, Sherbrooke University, Sherbrooke, Quebec Canada
| | - J. Majewski
- Human Genetics, McGill University, Montreal, Quebec Canada
| | - J. B. Goldstein
- Genomic Medicine, MD Anderson Cancer Center, Houston, TX USA
| | - M. Overman
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - G. Varadhachary
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - R. Shroff
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - R. Wolff
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - M. Javle
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - A. Futreal
- Genomic Medicine, MD Anderson Cancer Center, Houston, TX USA
| | - D. Fogelman
- Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX USA
| | - L. Bravo
- Escuela de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Peru
| | - W. Fajardo
- Escuela de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Peru
| | - H. Gomez
- Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru
| | - C. Castaneda
- Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru
| | - C. Rolfo
- Oncology Department, University Hospital Antwerp, Antwerp, Belgium
| | - J. A. Pinto
- Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru
| | - K. C. Akdemir
- Genomic Medicine, MD Anderson Cancer Center, Houston, TX USA
| | - L. Chin
- University of Texas System, Houston, TX USA
| | - A. Futreal
- Genomic Medicine, MD Anderson Cancer Center, Houston, TX USA
| | | | - S. Patterson
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - C. Statz
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - S. Mockus
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - S. N. Nikolaev
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - X. I. Bonilla
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | - L. Parmentier
- Department of Dermatology, Hospital of Valais, Sion, Switzerland
| | - B. King
- Department of Pathology, NYU School of Medicine, New York, NY USA
| | - F. Bezrukov
- Department of Physics, University of Connecticut, Connecticut, USA
| | - G. Kaya
- Department of Dermatology, University Hospitals of Geneva, Geneva, Switzerland
| | - V. Zoete
- Swiss Institute of Bioinformatics, Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - V. Seplyarskiy
- Institute of Information Transmission Problems, Russian Academy of Sciences, Moscow, Russian Federation
| | - H. Sharpe
- Department of Molecular Oncology, Genentech Inc, San Francisco, CA USA
| | - T. McKee
- Service of Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland
| | - A. Letourneau
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - P. Ribaux
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - K. Popadin
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | | | - R. Ben Chaabene
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - F. Santoni
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - M. Andrianova
- Institute of Information Transmission Problems, Russian Academy of Sciences, Moscow, Russian Federation
| | - M. Guipponi
- Service of Genetic Medicine, University Hospitals of Geneva, Geneva, Switzerland
| | - M. Garieri
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - C. Verdan
- Service of Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland
| | - K. Grosdemange
- Department of Dermatology, University Hospitals of Geneva, Geneva, Switzerland
| | - O. Sumara
- Department of Biochemistry and Molecular Biology, University of Würzburg, Würzburg, Germany
| | - M. Eilers
- Department of Biochemistry and Molecular Biology, University of Würzburg, Würzburg, Germany
| | - I. Aifantis
- Department of Pathology, NYU School of Medicine, New York, NY USA
| | - O. Michielin
- Swiss Institute of Bioinformatics, Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - F. de Sauvage
- Department of Molecular Oncology, Genentech Inc, San Francisco, CA USA
| | - S. Antonarakis
- Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
| | | | | | - A. Kurian
- Stanford Medical Center, Palo Alto, CA USA
| | - A. Desmond
- Massachusetts General Hospital, Boston, MA USA
| | - S. Yang
- Invitae, San Francisco, CA USA
| | | | - J. Ford
- Stanford Medical Center, San Francisco, CA USA
| | - L. Ellisen
- Massachusetts General Hospital, Boston, MA USA
| | - T. L. Peters
- Pathology & Immunology, Baylor College of Medicine, Houston, TX USA
| | - K. R. Alvarez
- Pathology, Texas Children’s Hospital, Houston, TX USA
| | | | - D. H. Lopez-Terrada
- Pathology & Immunology, Baylor College of Medicine, Houston, TX USA
- Pathology, Texas Children’s Hospital, Houston, TX USA
| | - A. Hastie
- BioNano Genomics, Inc, San Diego, CA USA
| | - Z. Dzakula
- BioNano Genomics, Inc, San Diego, CA USA
| | - A. W. Pang
- BioNano Genomics, Inc, San Diego, CA USA
| | - E. T. Lam
- BioNano Genomics, Inc, San Diego, CA USA
| | | | | | - H. Cao
- BioNano Genomics, Inc, San Diego, CA USA
| | | | - C. Gonzaga-Jauregui
- Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, NY USA
| | - L. Ma
- Department of Pediatrics, New York, NY USA
| | - A. King
- Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, NY USA
| | - E. Berman Rosenzweig
- Department of Pediatrics, New York, NY USA
- Department of Medicine, Columbia University Medical Center, New York, NY USA
| | | | - J. G. Reid
- Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, NY USA
| | - J. D. Overton
- Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, NY USA
| | - F. Dewey
- Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, NY USA
| | - W. K. Chung
- Department of Pediatrics, New York, NY USA
- Department of Medicine, Columbia University Medical Center, New York, NY USA
| | - K. Small
- Molecular Insight Research Foundation, Glendale, ᅟ
| | - A. DeLuca
- Ophthalmology, University of Iowa, Iowa City, IA USA
| | - F. Cremers
- Biology, Raboud University Medical Center, Nijmegen, Netherlands
| | - R. A. Lewis
- Ophthalmology, Baylor College of Medicine, Houston, TX USA
| | - V. Puech
- Service d’Exploration de la vision et Neuro-ophtalmologie CHRU, Service d’Exploration de la vision et Neuro-ophtalmologie CHRU, Lille, France
| | - B. Bakall
- Associated Retina Consultants, University of Arizona College of Medicine, Phoenix, TX USA
| | | | | | - M. Leys
- WVU Eye Institute, Morgantown, WV USA
| | - F. S. Shaya
- Molecular Insight Research Foundation, Glendale, ᅟ
| | - E. Stone
- University of Iowa, Iowa City, IA USA
| | - N. L. Sobreira
- Johns Hopkins University School of Medicine, Baltimore, MD USA
| | | | - H. Ling
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - E. Pugh
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - D. Witmer
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - K. Hetrick
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - P. Zhang
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - K. Doheny
- Center for Inherited Disease Research, JHUSOM, Baltimore, MD USA
| | - D. Valle
- Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - A. Hamosh
- Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - S. N. Jhangiani
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Z. Coban Akdemir
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - M. N. Bainbridge
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - W. Charng
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - W. Wiszniewski
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - T. Gambin
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - E. Karaca
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Y. Bayram
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - M. K. Eldomery
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - J. Posey
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - H. Doddapaneni
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Hu
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - V. R. Sutton
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - D. M. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - E. A. Boerwinkle
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - D. Valle
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD USA
| | - J. R. Lupski
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - R. A. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | | | - W. Salerno
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - A. English
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | | | | | - A. Thorogood
- Centre of Genomics and Policy, McGill University, Montreal, Quebec Canada
| | - B. M. Knoppers
- Centre of Genomics and Policy, McGill University, Montreal, Quebec Canada
| | | | - H. Takahashi
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - K. R. Nitta
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - A. Kozhuharova
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - A. M. Suzuki
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - H. Sharma
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - D. Cotella
- Dipartimento di Scienze della Salute, Universita’ del Piemonte Orientale, Novara, Italy
| | - C. Santoro
- Dipartimento di Scienze della Salute, Universita’ del Piemonte Orientale, Novara, Italy
| | - S. Zucchelli
- Area of Neuroscience, SISSA, International School for Advanced Studies, Trieste, Italy
| | - S. Gustincich
- Area of Neuroscience, SISSA, International School for Advanced Studies, Trieste, Italy
| | - P. Carninci
- Center for Life Science Technologies, Division of Genomic Technologies, RIKEN, Yokohama, Japan
| | - J. J. Mulvihill
- Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, MD USA
| | - G. Baynam
- Office of Population Health, Department of Health, Perth, Australia
| | - W. Gahl
- Undiagnosed Diseases Program, National Human Genome Research Institute, Bethesda, MD USA
| | - S. C. Groft
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD USA
| | - K. Kosaki
- Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan
| | - P. Lasko
- Department of Biology, McGill University, Montreal, Quebec Canada
| | - B. Melegh
- Department of Medical Genetics, University of Pecs, Pecs, Hungary
| | - D. Taruscio
- National Center for Rare Diseases, Istituto Superiore di Sanita, Rome, Italy
| | - R. Ghosh
- Pediatrics-Oncology, Baylor College of Medicine, Houston, TX USA
| | - S. Plon
- Pediatrics-Oncology, Baylor College of Medicine, Houston, TX USA
| | - S. Scherer
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - X. Qin
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Sanghvi
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - K. Walker
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - T. Chiang
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - D. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - L. Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, NY USA
| | - J. Black
- Department of Psychiatry, Mayo Clinic, Rochester, NY USA
| | - E. Boerwinkle
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | | | - R. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | | | | | - K. Wani
- MD Anderson Cancer Center, Houston, USA
| | - X. Yu
- MD Anderson Cancer Center, Houston, USA
| | - C. Creasy
- MD Anderson Cancer Center, Houston, USA
| | | | - M. Forget
- MD Anderson Cancer Center, Houston, USA
| | - V. Nanda
- MD Anderson Cancer Center, Houston, USA
| | - J. Roszik
- MD Anderson Cancer Center, Houston, USA
| | - J. Wargo
- MD Anderson Cancer Center, Houston, USA
| | - L. Haydu
- MD Anderson Cancer Center, Houston, USA
| | - X. Song
- MD Anderson Cancer Center, Houston, USA
| | - A. Lazar
- MD Anderson Cancer Center, Houston, USA
| | | | - M. Davies
- MD Anderson Cancer Center, Houston, USA
| | | | - J. Zhang
- MD Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | | | | - M. Xiong
- University of Texas School of Public Health, Houston, TX USA
| | - L. Ma
- University of Texas School of Public Health, Houston, TX USA
| | - N. Lin
- University of Texas School of Public Health, Houston, TX USA
| | - C. Amos
- Geisel School of Medicine at Dartmouth, Hanover, NH USA
| | - N. Lin
- Biostatistics, University of Texas Health Science Center at Houston, Houston, TX USA
| | - P. Wang
- Biostatistics, University of Texas Health Science Center at Houston, Houston, TX USA
| | - Y. Zhu
- Tulane University, New Orleans, LO USA
| | - J. Zhao
- Tulane University, New Orleans, LO USA
| | - V. Calhoun
- University of New Mexico, Albuquerque, NM USA
| | - M. Xiong
- University of Texas Health Science Center at Houston, Houston, TX USA
| | | | - M. Egger
- EPS Software Corp, Spring, TX USA
| | | | - S. Sadedin
- Bioinformatics, Murdoch Childrens Research Institute, Parkville, Australia
| | - A. Oshlack
- Bioinformatics, Murdoch Childrens Research Institute, Parkville, Australia
| | | | - V. A. A. Antonio
- Computational Systems Biology Laboratory, Nara Institute of Science and Technology, Ikoma-cho, Japan
| | - N. Ono
- Computational Systems Biology Laboratory, Nara Institute of Science and Technology, Ikoma-cho, Japan
| | | | - Z. Ahmed
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - M. Bolisetty
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - S. Zeeshan
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - E. Anguiano
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - D. Ucar
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - A. Sarkar
- Laboratory of Genomics and Profiling Applications, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India
| | - M. R. Nandineni
- Laboratory of Genomics and Profiling Applications, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India
| | - C. Zeng
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - J. Shao
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - H. Cao
- BioNano Genomics, Inc, San Diego, CA USA
| | - A. Hastie
- BioNano Genomics, Inc, San Diego, CA USA
| | - A. W. Pang
- BioNano Genomics, Inc, San Diego, CA USA
| | - E. T. Lam
- BioNano Genomics, Inc, San Diego, CA USA
| | - T. Liang
- BioNano Genomics, Inc, San Diego, CA USA
| | - K. Pham
- BioNano Genomics, Inc, San Diego, CA USA
| | | | - Z. Dzakula
- BioNano Genomics, Inc, San Diego, CA USA
| | - Y. Chee-Wei
- Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - L. Dongsheng
- Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Shanghai, Shanghai, China
| | - W. Lai-Ping
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - D. Lian
- Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Shanghai, Shanghai, China
| | - R. O. Twee Hee
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Y. Yunus
- Institute of Medical Molecular Biotechnology, Universiti Teknologi MARA, Sungai Buloh, ᅟ
| | - F. Aghakhanian
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campus, Petaling Jaya, Malaysia
| | - S. S. Mokhtar
- Institute of Medical Molecular Biotechnology, Universiti Teknologi MARA, Sungai Buloh, ᅟ
| | - C. V. Lok-Yung
- Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - J. Bhak
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic Of Korea
| | - M. Phipps
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campu, Petaling Jaya, Malaysia
| | - X. Shuhua
- Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Shanghai, Shanghai, China
| | - T. Yik-Ying
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - V. Kumar
- Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - H. Boon-Peng
- UCSI University, Kuala Lumpur, Kuala Lumpur, Malaysia
| | - I. Campbell
- Research Division, Peter Maccallum Cancer Centre, East Melbourne, Australia
| | - M. -A. Young
- Familial Cancer Centre, Peter Maccallum Cancer Centre, East Melbourne, Australia
| | - P. James
- Familial Cancer Centre, Peter Maccallum Cancer Centre, East Melbourne, Australia
| | | | - M. Rain
- Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
| | - G. Mohammad
- Department of Medicine, Sonam Norbu Memorial Hospital, Leh, Ladakh India
| | - R. Kukreti
- Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
| | - Q. Pasha
- Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
| | - A. R. Akilzhanova
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - C. Guelly
- Center of Medical Research, Medical University of Graz, Graz, Austria
| | - Z. Abilova
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - S. Rakhimova
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - A. Akhmetova
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - U. Kairov
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - S. Trajanoski
- Center of Medical Research, Medical University of Graz, Graz, Austria
| | - Z. Zhumadilov
- Nazarbayev University, National Laboratory Astana, Center for Life Sciences, Astana, Kazakhstan
| | - M. Bekbossynova
- National Scientific Cardiac Surgery Center, Astana, Kazakhstan
| | | | - S. Sandhu
- Swift Biosciences Inc, Ann Arbor, MI USA
| | - T. Harkins
- Swift Biosciences Inc, Ann Arbor, MI USA
| | - V. Makarov
- Swift Biosciences Inc, Ann Arbor, MI USA
| | - H. Doddapaneni
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Glenn
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Z. Momin
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - B. Dilrukshi
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - H. Chao
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Q. Meng
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - B. Gudenkauf
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Kshitij
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Jayaseelan
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - C. Nessner
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - S. Lee
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - K. Blankenberg
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - L. Lewis
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Hu
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Y. Han
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - H. Dinh
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - S. Jireh
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - K. Walker
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - E. Boerwinkle
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - D. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Hu
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - K. Walker
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - C. Buhay
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - X. Liu
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Q. Wang
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Sanghvi
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - H. Doddapaneni
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Y. Ding
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - N. Veeraraghavan
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - Y. Yang
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - E. Boerwinkle
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
- Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX USA
| | - A. L. Beaudet
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - C. M. Eng
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - D. M. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. A. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - K. C. C. Worley
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Y. Liu
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - D. S. T. Hughes
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - S. C. Murali
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - R. A. Harris
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - A. C. English
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - X. Qin
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - O. A. Hampton
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - P. Larsen
- Department of Biology, Duke University, Durham, NC USA
| | - C. Beck
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Y. Han
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - M. Wang
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - H. Doddapaneni
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - C. L. Kovar
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - W. J. Salerno
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - A. Yoder
- Department of Biology, Duke University, Durham, NC USA
| | - S. Richards
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - J. Rogers
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - J. R. Lupski
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - D. M. Muzny
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - R. A. Gibbs
- Human Genome Sequencing Center, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
| | - Q. Meng
- HGSC, Baylor College of Medicine, Houston, TX USA
| | | | - M. Wang
- HGSC, Baylor College of Medicine, Houston, TX USA
| | | | - Y. Han
- HGSC, Baylor College of Medicine, Houston, TX USA
| | - D. Muzny
- HGSC, Baylor College of Medicine, Houston, TX USA
| | - R. Gibbs
- HGSC, Baylor College of Medicine, Houston, TX USA
| | - R. A. Harris
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - M. Raveenedran
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - C. Xue
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - M. Dahdouli
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - L. Cox
- Genetics, Southwest National Primate Research Center, San Antonio, TX USA
| | - G. Fan
- Human Genetics, Univeristy of California Los Angeles, Los Angeles, CA USA
| | - B. Ferguson
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR USA
| | - J. Hovarth
- Genomics & Microbiology Research Laboratory, NC Museum of Natural Sciences, Raleigh, NC USA
| | - Z. Johnson
- Yerkes Nonhuman Primate Genomics Core, Yerkes National Primate Research Center, Atlanta, GA USA
| | - S. Kanthaswamy
- Environmental Toxicology, California National Primate Research Center, Davis, CA USA
| | - M. Kubisch
- Physiology, Tulane National Primate Research Center, New Orleans, LO USA
| | - M. Platt
- Neuroscience, University of Pennsylvania, Philadelphia, PA USA
| | - D. Smith
- Anthropology, University of California Davis, Davis, CA USA
| | - E. Vallender
- Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS USA
| | - R. Wiseman
- Genetics, Wisconsin National Primate Research Center, Madison, WI USA
| | - X. Liu
- Epidemiology, Human Genetics & Environmental Sciences, ᅟ, ᅟ
| | - J. Below
- Epidemiology and Disease Control Human Genetics Center, University of Texas Health Science Center, Houston, TX USA
| | - D. Muzny
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - R. Gibbs
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - F. Yu
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Rogers
- Molecular and Human Genetics, Baylor College of Medicine, Houston, TX USA
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX USA
| | - J. Lin
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - Y. Zhang
- Department of Statistics, University of Connecticut, Storrs, CT USA
| | - Z. Ouyang
- The Jackson Laboratory for Genomic Medicine, Farmington, CT USA
| | - A. Moore
- National Cancer Institute, Rockville, USA
| | - Z. Wang
- St. Jude Children’s Research Hospital, Memphis, USA
| | - J. Hofmann
- National Cancer Institute, NIH, DHHS, Rockville, USA
| | - M. Purdue
- National Cancer Institute, Rockville, USA
| | | | | | - D. Albanes
- National Cancer Institute, Rockville, USA
| | - C. S. Liu
- Changhua Christian Hospital, Changhua, Taiwan Province of China
| | - W. L. Cheng
- Changhua Christian Hospital, Changhua, Taiwan Province of China
| | - T. T. Lin
- Changhua Christian Hospital, Changhua, Taiwan Province of China
| | - Q. Lan
- National Cancer Institute, Rockville, USA
| | - N. Rothman
- National Cancer Institute, Rockville, USA
| | - S. Berndt
- National Cancer Institute, Rockville, USA
| | - E. S. Chen
- Biochemistry, National University of Singapore, Singapore, Singapore
| | - H. Bahrami
- Proteomics, Faraby Eye Hospital, Tehran, Iran Islamic Republic Of
- R & D, MIB Co., Tehran, Iran Islamic Republic Of
| | | | | | - H. Bahrami
- Proteomics, Faraby Eye Hospital, Tehran, Iran Islamic Republic Of
- R & D, MIB Co., Tehran, Iran Islamic Republic Of
| | | | | | - K. K. R. Alharbi
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
| | - M. Zhalbinova
- Laboratory of Genomic and Personalized Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - A. Akilzhanova
- Laboratory of Genomic and Personalized Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - S. Rakhimova
- Laboratory of Genomic and Personalized Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - M. Bekbosynova
- Cardiology, JSC “National Research Cardiac Surgery Center”, National medical holding, Astana, Kazakhstan
| | - S. Myrzakhmetova
- Cardiology, JSC “National Research Cardiac Surgery Center”, National medical holding, Astana, Kazakhstan
| | - M. Matar
- UAE Genetic Diseases Association, Dubai, United Arab Emirates
| | - N. Mili
- Research Center for Statistics, University of Geneva, Switzerland, Geneva Switzerland
| | - R. Molinari
- Research Center for Statistics, University of Geneva, Switzerland, Geneva Switzerland
| | - Y. Ma
- Department of Statistics, University of South Carolina, Columbia, USA
| | - S. Guerrier
- Department of Statistics, University of Illinois at Urbana Champaign, Champaign, USA
| | - N. Elhawary
- Department of Molecular Genetics, Medical Genetics Center, Ain Shams University, Cairo, Egypt
- Department of Medical Genetics, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - M. Tayeb
- Department of Medical Genetics, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - N. Bogari
- Department of Medical Genetics, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - N. Qotb
- Department of Psychology, Umm Al-Qura University, Faculty of Education, Mecca, Saudi Arabia
| | - S. A. McClymont
- Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
| | - P. W. Hook
- Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
| | - L. A. Goff
- Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
| | - A. McCallion
- Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
| | - Y. Kong
- The Jackson Laboratory, Bar Harbor, USA
- Graduate School of Biomedical Science and Engineering, University of Maine, Orono, USA
| | | | | | | | - L. Zhao
- The Jackson Laboratory, Bar Harbor, USA
| | - P. M. Nishina
- The Jackson Laboratory, Bar Harbor, USA
- Graduate School of Biomedical Science and Engineering, University of Maine, Orono, USA
| | - B. M. Edrees
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - M. Athar
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - F. A. Al-Allaf
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - M. M. Taher
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - W. Khan
- Department of Basic Sciences, College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - A. Bouazzaoui
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - N. A. Harbi
- Department of Pediatric, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
| | - R. Safar
- Department of Pediatric, Madinah Maternity and Children’s Hospital, Madinah, Saudi Arabia
| | - H. Al-Edressi
- Department of Pediatric, Madinah Maternity and Children’s Hospital, Madinah, Saudi Arabia
| | - A. Anazi
- Pediatric, King Fahad Medical City, Riyadh, Saudi Arabia
| | - N. Altayeb
- Molecular Diagnostics Unit, Department of Laboratory and Blood Bank, King Abdullah Medical City, Makkah, Saudi Arabia
| | - M. A. Ahmed
- Medical Genetics, King Salman Armed Forces Hospital, Tabuk, Saudi Arabia
| | - K. Alansary
- Medical Genetics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Z. Abduljaleel
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - A. Kratz
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - P. Beguin
- Brain Science Institute (BSI), Launey Research Unit, RIKEN Wako, Wako, Japan
| | - S. Poulain
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - M. Kaneko
- Brain Science Institute (BSI), Launey Research Unit, RIKEN Wako, Wako, Japan
| | - C. Takahiko
- Brain Science Institute (BSI), Launey Research Unit, RIKEN Wako, Wako, Japan
| | - A. Matsunaga
- Brain Science Institute (BSI), Launey Research Unit, RIKEN Wako, Wako, Japan
| | - S. Kato
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - A. M. Suzuki
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - N. Bertin
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - T. Lassmann
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - R. Vigot
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - P. Carninci
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - C. Plessy
- Center for Life Science Technologies, RIKEN Yokohama, Yokohama City, Kanagawa Japan
| | - T. Launey
- Brain Science Institute (BSI), Launey Research Unit, RIKEN Wako, Wako, Japan
| | - D. Graur
- Biology and Biochemistry, University of Houston, Houston, USA
| | - D. Lee
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
| | - A. Kapoor
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
| | - A. Chakravarti
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J. Friis-Nielsen
- Technical University of Denmark, Center for Biological Sequence Analysis, Lyngby, Denmark
| | - J. M. Izarzugaza
- Technical University of Denmark, Center for Biological Sequence Analysis, Lyngby, Denmark
| | - S. Brunak
- Technical University of Denmark, Center for Biological Sequence Analysis, Lyngby, Denmark
| | - A. Chakraborty
- Molecular Biology, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India
| | - J. Basak
- Molecular Biology, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India
| | - A. Mukhopadhyay
- Medical Oncology, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India
| | | | - D. Das
- National Institute of Biomedical Genomics, Kalyani, India
| | - N. Biswas
- National Institute of Biomedical Genomics, Kalyani, India
| | - S. Das
- National Institute of Biomedical Genomics, Kalyani, India
| | - S. Sarkar
- Chittaranjan National Cancer Institute, Kolkata, India
| | - A. Maitra
- National Institute of Biomedical Genomics, Kalyani, India
| | - C. Panda
- Chittaranjan National Cancer Institute, Kolkata, India
| | - P. Majumder
- National Institute of Biomedical Genomics, Kalyani, India
| | - H. Morsy
- Human Genetics, Faculty of Medicine, Alexandria, Egypt
| | - A. Gaballah
- Microbiology, Faculty of Medicine, Alexandria, Egypt
| | - M. Samir
- Clinical and Experimental Surgery, Faculty of Medicine, Alexandria, Egypt
| | - M. Shamseya
- Clinical and Experimental Internal Medicine, Medical Research Institute, Faculty of Medicine, Alexandria, Egypt
| | - H. Mahrous
- Human Genetics, Faculty of Medicine, Alexandria, Egypt
| | - A. Ghazal
- Microbiology, Faculty of Medicine, Alexandria, Egypt
| | - W. Arafat
- Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria, Egypt
| | - M. Hashish
- Human Genetics, Faculty of Medicine, Alexandria, Egypt
| | | | - N. Jaeger
- Genetics, Stanford University, Palo Alto, USA
| | - M. Snyder
- Genetics, Stanford University, Palo Alto, USA
| | | | | | - T. Davis
- New England Biolabs, Ipswich, USA
| | | | | | | | | | | | - K. Zhang
- Pathology, University of North Dakota, Grand Forks, USA
| | | | | | | | | | - N. Jäger
- Genetics, Stanford University, Palo Alto, USA
| | - J. Chen
- Genetics, Stanford University, Palo Alto, USA
| | - R. Haile
- Stanford Cancer Institute, Stanford University, Palo Alto, USA
| | - M. Hitchins
- Stanford Cancer Institute, Stanford University, Palo Alto, USA
| | | | - M. Snyder
- Genetics, Stanford University, Palo Alto, USA
| | - S. Jiménez-Morales
- Cancer Genomic Laboratory, National Institute of Genomic Medicine (INMEGEN), ᅟ, Mexico
| | - M. Ramírez
- Biología, FES -Iztacala, UNAM, ᅟ, Mexico
| | - J. Nuñez
- Hospital de Pediatría, CMN SXXI, IMSS, ᅟ, Mexico
| | - V. Bekker
- Investigación Médica en Inmunología, CMN La Raza, IMSS, ᅟ, Mexico
| | - Y. Leal
- Diagnóstico Molecular H1N1-Influenza , UMAE-IMSS, Mérida, Yucatán Mexico
| | - E. Jiménez
- Hematología Pediátrica, CMN La Raza, IMSS, ᅟ, Mexico
| | - A. Medina
- Hemato-Oncología, Hospital Infantil de México, ᅟ, Mexico
| | - A. Hidalgo
- Cancer Genomics Laboratory, INMEGEN, ᅟ, Mexico
| | - J. Mejía
- Coordinación de Investigación en Salud, IMSS, ᅟ, Mexico
| | - V. Halytskiy
- Molecular Immunology Department, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, Ukraine
| | | | | | | | | | | | - K. Belhassa
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - K. Belhassan
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - L. Bouguenouch
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - I. Samri
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - H. Sayel
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - FZ. moufid
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - I. El Bouchikhi
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - S. Trhanint
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - H. Hamdaoui
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - I. Elotmani
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - I. Khtiri
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - O. Kettani
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - L. Quibibo
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - M. Ahagoud
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - M. Abbassi
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - K. Ouldim
- Department of Medical Genetics and Oncogene, Morocco; Medical Genetics, CHU Hassan II Fes, Fes, Morocco
| | - A. V. Marusin
- Evolutionary Genetics, Institute of Medical Genetics, ᅟ, Russian Federation
| | - A. N. Kornetov
- Siberian State Medical University, Tomsk, Russian Federation
| | - M. Swarovskaya
- Evolutionary Genetics, Institute of Medical Genetics, ᅟ, Russian Federation
| | - K. Vagaiceva
- Evolutionary Genetics, Institute of Medical Genetics, ᅟ, Russian Federation
| | - V. Stepanov
- Evolutionary Genetics, Institute of Medical Genetics, ᅟ, Russian Federation
| | - E. M. Cutiongco De La Paz
- National Institutes of Health, University of the Philippines, Manila, Philippines
- Philippine Genome Center, University of the Philippines, Quezon City, Philippines
| | - R. Sy
- College of Medicine, University of the Philippines, Manila, Philippines
| | - J. Nevado
- National Institutes of Health, University of the Philippines, Manila, Philippines
| | - P. Reganit
- College of Medicine, University of the Philippines, Manila, Philippines
| | - L. Santos
- College of Medicine, University of the Philippines, Manila, Philippines
| | - J. D. Magno
- College of Medicine, University of the Philippines, Manila, Philippines
| | - F. E. Punzalan
- College of Medicine, University of the Philippines, Manila, Philippines
| | - D. Ona
- College of Medicine, University of the Philippines, Manila, Philippines
| | - E. Llanes
- College of Medicine, University of the Philippines, Manila, Philippines
| | - R. L. Santos-Cortes
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX United States
| | - R. Tiongco
- College of Medicine, University of the Philippines, Manila, Philippines
| | - J. Aherrera
- Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - L. Abrahan
- Philippine General Hospital, University of the Philippines, Manila, Philippines
| | - P. Pagauitan-Alan
- Philippine General Hospital, University of the Philippines, Manila, Philippines
| | | | - K. H. Morelli
- The Jackson Laboratory, Bar Harbor, USA
- Graduate School of Biomedical Sciences & Engineering, The University of Maine, Orono, USA
| | - J. S. Domire
- Center For Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio USA
| | - N. Pyne
- Center For Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio USA
| | - S. Harper
- Center For Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio USA
| | - R. Burgess
- Graduate School of Biomedical Sciences & Engineering, The University of Maine, Orono, USA
| | - M. Zhalbinova
- Laboratory of Genomic and Personalized Medicine, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - A. Akilzhanova
- Laboratory of Genomic and Personalized Medicine, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - S. Rakhimova
- Laboratory of Genomic and Personalized Medicine, National Laboratory Astana, Nazarbayev University, ᅟ, Kazakhstan
| | - M. Bekbosynova
- Cardiology, JSC “National Research Cardiac Surgery Center”, National Medical Holding, Astana, Kazakhstan
| | - S. Myrzakhmetova
- Cardiology, JSC “National Research Cardiac Surgery Center”, National Medical Holding, Astana, Kazakhstan
| | - M. A. Gari
- Medical Laboratory Technology, ᅟ, Saudi Arabia
| | - A. Dallol
- Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - H. Alsehli
- Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - A. Gari
- Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - M. Gari
- Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - A. Abuzenadah
- Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - M. Thomas
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - M. Sukhai
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - S. Garg
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - M. Misyura
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - T. Zhang
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - A. Schuh
- Princess Margaret Cancer Centre, Toronto, Canada
| | - T. Stockley
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | - S. Kamel-Reid
- Advanced Molecular Diagnostics Laboratory, ᅟ, Canada
| | | | | | | | | | | | | | | | | | | | - C. Xiao
- National Institutes of Health, Bethesda, USA
| | | | - S. Sherry
- National Institutes of Health, Bethesda, USA
| | - C. Rangel-Escareño
- Computational Genomics, National Institute of Genomic Medicine, Mexico City, Mexico
| | - H. Rueda-Zarate
- Computational Genomics, National Institute of Genomic Medicine, Mexico City, Mexico
| | - I. A. Tayubi
- Computer Science, Faculty of Computing and Information Technology, King AbdulAziz University, Rabigh, Saudi Arabia
| | - R. Mohammed
- Computer Science, Faculty of Computing and Information Technology, King AbdulAziz University, Rabigh, Saudi Arabia
| | | | - I. Ahmed
- Computer Science, Faculty of Computing and Information Technology, King AbdulAziz University, Rabigh, Saudi Arabia
| | - T. Ahmed
- Computer Science, Faculty of Computing and Information Technology, King AbdulAziz University, Rabigh, Saudi Arabia
| | - S. Seth
- Institute of Applied Cancer Science, ᅟ, USA
| | - S. Amin
- Genomic Medicine, University of Texas, ᅟ, ᅟ
| | - X. Song
- Institute of Applied Cancer Science, ᅟ, USA
| | - X. Mao
- Genomic Medicine, University of Texas, ᅟ, ᅟ
| | - H. Sun
- MD Anderson Cancer Center, Houston, USA
| | | | - A. Futreal
- Genomic Medicine, University of Texas, ᅟ, ᅟ
| | - J. Zhang
- Institute of Applied Cancer Science, ᅟ, USA
| | - S. J. Whiite
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - T. Chiang
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - A. English
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - J. Farek
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - Z. Kahn
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - W. Salerno
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - N. Veeraraghavan
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - E. Boerwinkle
- Human Genetics Center, University of Texas Health Science Center at Houston, Houston, USA
| | - R. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, ᅟ, USA
| | - T. Kasukawa
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - M. Lizio
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - J. Harshbarger
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - S. Hisashi
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
- Preventive Medicine and Diagnosis Innovation Program, RIKEN, Wako, Japan
| | - J. Severin
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - A. Imad
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - S. Sahin
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | - T. C. Freeman
- The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK
| | - K. Baillie
- The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK
| | - A. Sandelin
- Department of Biology & Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
| | - P. Carninci
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
| | | | - H. Kawaji
- Center for Life Science Technologies, RIKEN, Yokohama, Japan
- Preventive Medicine and Diagnosis Innovation Program, RIKEN, Wako, Japan
- Advanced Center for Computing and Communication, RIKEN, Yokohama, Japan
| | | | - W. Salerno
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas USA
| | - A. English
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas USA
| | | | | | | | - E. Boerwinkle
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas USA
- Human Genetics Center and Department of Epidemiology, UT School of Public Health, Houston, Texas USA
| | - R. A. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas USA
| | - A. H. Salem
- Anatomy, Arabian Gulf University, Manama, Bahrain
| | - M. Ali
- Biochemistry, Arabian Gulf University, Manama, Bahrain
| | - A. Ibrahim
- Central Laboratory, Ministry of Science and Technology, ᅟ, Sudan
| | - M. Ibrahim
- College of Animal Production Science and Technology, Sudan University of Science and Technology, Khartoum, Sudan
| | - H. A. Barrera
- Bioquimica y Medicina Molecular, Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | - L. Garza
- Bioquimica y Medicina Molecular, Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | - J. A. Torres
- Bioquimica y Medicina Molecular, Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | - V. Barajas
- Bioquimica y Medicina Molecular, Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | | | - D. Kershenobich
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Shahroj Mortaji
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Pedro Guizar
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Eliezer Loera
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Karen Moreno
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Adriana De León
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Daniela Monsiváis
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Jackeline Gómez
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | - Raquel Cardiel
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Distrito Federal, Mexico
| | | | - V. Bonifaz-Peña
- Computational Genomics, Nacional de Medicina Genomica, Mexico City, Mexico
| | - C. Rangel-Escareño
- Computational Genomics, Nacional de Medicina Genomica, Mexico City, Mexico
| | - A. Hidalgo-Miranda
- Cancer Genomics Laboratory, Nacional de Medicina Genomica, Mexico City, Mexico
| | - A. V. Contreras
- Nutrigenetics and Nutrigenomics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City, Mexico
| | - L. Polfus
- Human Genetics Center, University of Texas Health Science Center, Houston, USA
| | | | - X. Wang
- System Genetics, The Jackson Laboratory, Bar Harbor, USA
| | - V. Philip
- System Genetics, The Jackson Laboratory, Bar Harbor, USA
| | - G. Carter
- System Genetics, The Jackson Laboratory, Bar Harbor, USA
| | - A. A. Abuzenadah
- Center of Innovation in Personalized Medicine, Faculty of Applied Medical Sciences, King Abdulaziz University, ᅟ, Saudi Arabia
| | - M. Gari
- Center of Innovation in Personalized Medicine, Faculty of Applied Medical Sciences, King Abdulaziz University, ᅟ, Saudi Arabia
| | - R. Turki
- Ob/Gyn, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
| | - A. Dallol
- Center of Innovation in Personalized Medicine, Faculty of Applied Medical Sciences, King Abdulaziz University, ᅟ, Saudi Arabia
| | - A. Uyar
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - A. Kaygun
- Department of Mathematical Engineering, Istanbul Technical University, Istanbul, Turkey
| | - S. Zaman
- Department of Biomedical Engineering, University of Connecticut, Storrs, USA
| | - E. Marquez
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - J. George
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - D. Ucar
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | | | | | | | | | | | - T. Davis
- New England Biolabs, Ipswich, USA
| | | | | | - D. B. Starr
- Genetics, Stanford University, Stanford, USA
| | - M. Baird
- DNA Diagnostics Center, Fairfield, USA
| | | | - K. Sheets
- Vibrant Gene Consulting, Cambridge, USA
| | - R. Nitsche
- Agilent Technologies, Agilent Technologies, Waldbronn, Germany
| | - L. Prieto-Lafuente
- Agilent Technologies UK Ltd, Agilent Technologies UK Ltd., Edinburgh, UK
| | | | - J. Lee
- NIH/NLM/NCBI, Bethesda, USA
| | | | | | - P. K. R. Thavanati
- Institute of Human Genetics, Department of Molecular Biology & Genomics, Centre for Health Sciences, ᅟ, Mexico
| | - A. Escoto de Dios
- Institute of Human Genetics, Department of Molecular Biology & Genomics, Centre for Health Sciences, ᅟ, Mexico
| | | | | | - M. R. Ruiz Mejia
- Biochemistry, Centre for Health Sciences, University of Guadalajara, Guadalajara, Mexico
| | - K. R. R. Kanala
- Human Genetics Unit, Department Anthropology, Sri Venkateswara University, Tirupati, India
| | - Z. Abduljaleel
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - W. Khan
- Department of Basic Sciences, College of Science and Health Professions, King Saud Bin Abdul Aziz University for Health Sciences, Riyadh, Saudi Arabia
| | - F. A. Al-Allaf
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - M. Athar
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - M. M. Taher
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - N. Shahzad
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - A. Bouazzaoui
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
- Department of Medical Genetics, Umm Al Qura University, Mecca, Saudi Arabia
- Medical Clinic 3 – Hematology/Oncology, University Hospital Regensburg, Regensburg, Germany
| | - E. Huber
- Department of Pathology, University Hospital Regensburg, Regensburg, Germany
| | - A. Dan
- IgNova GmbH, Oberursel, Germany
| | - F. A. Al-Allaf
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
| | - W. Herr
- Medical Clinic 3 – Hematology/Oncology, University Hospital Regensburg, Regensburg, Germany
| | - G. Sprotte
- Department of Ansethesiologie, University of Würzburg Medical School, Würzburg, Germany
| | - J. Köstler
- Department of microbiology, University Hospital Regensburg, Regensburg, Germany
| | - A. Hiergeist
- Department of microbiology, University Hospital Regensburg, Regensburg, Germany
| | - A. Gessner
- Department of microbiology, University Hospital Regensburg, Regensburg, Germany
| | - R. Andreesen
- Medical Clinic 3 – Hematology/Oncology, University Hospital Regensburg, Regensburg, Germany
| | - E. Holler
- Medical Clinic 3 – Hematology/Oncology, University Hospital Regensburg, Regensburg, Germany
| | - F. Al-Allaf
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, ᅟ, Saudi Arabia
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
- Molecular Diagnostics Unit, Department of Laboratory and Blood Bank, King Abdullah Medical City, Makkah, Saudi Arabia
| | - A. Alashwal
- King Faisal Specialist Hospital and Research Centre, ᅟ, Saudi Arabia
| | - Z. Abduljaleel
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, ᅟ, Saudi Arabia
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - M. Taher
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, ᅟ, Saudi Arabia
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - A. Bouazzaoui
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, ᅟ, Saudi Arabia
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - H. Abalkhail
- King Faisal Specialist Hospital and Research Centre, ᅟ, Saudi Arabia
| | - A. Al-Allaf
- Faculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - R. Bamardadh
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - M. Athar
- Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, ᅟ, Saudi Arabia
- Science and Technology Unit, Umm Al-Qura University, ᅟ, Saudi Arabia
| | - O. Filiptsova
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - M. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - Y. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Burlaka
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Timoshyna
- Human Physiology and Anatomy, National University of Pharmacy, Kharkiv, Ukraine
| | - O. Filiptsova
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - M. N. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - Y. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Burlaka
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Timoshyna
- Human Physiology and Anatomy, National University of Pharmacy, Kharkiv, Ukraine
| | - O. Filiptsova
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - M. N. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - Y. Kobets
- Pharmaceutical Marketing and Management, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Burlaka
- Biology, National University of Pharmacy, Kharkiv, Ukraine
| | - I. Timoshyna
- Human Physiology and Anatomy, National University of Pharmacy, Kharkiv, Ukraine
| | - F. A. Al-allaf
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
- Molecular Diagnostics Unit Department of Laboratory Medicine and Blood Bank, King Abdullah Medical City, ᅟ, Saudi Arabia
| | - M. T. Mohiuddin
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
| | - A. Zainularifeen
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
| | - A. Mohammed
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
| | - H. Abalkhail
- Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - T. Owaidah
- Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - A. Bouazzaoui
- Department of Medical Genetics Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia
- Science and Technology Unit, Umm Al Qura University, Mecca, Saudi Arabia
| |
Collapse
|